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Abstract 
 
The pentraxins, serum amyloid P component (SAP) and C-reactive protein (CRP) are target proteins 
for the development of treatments for amyloidosis and ischaemic injury, respectively, in humans. 
This study reports the first multivalent ligands capable of targeting all five SAP binding sites 
simultaneously. Ligands presenting five or ten D-proline headgroups and composed of five peptide-
glycol linkers emanating from ε-N-substituted lysine residues on a central cyclic peptide core were 
synthesised by solid phase peptide synthesis. The sub-nanomolar, ~250pM, binding affinity 
approximated by Isothermal Titration Calorimetry (ITC) for one decavalent ligand is the strongest 
affinity for an SAP binding ligand currently known and stronger than the affinity of SAP binding to 
amyloid deposits. X-ray crystallography and mass spectrometry shows the decavalent ligands non-
covalently cross-linking two SAP pentamers, in the same manner observed for lead drug candidate 
CPHPC, but with increased affinity. 
 
In addition, the binding of SAP with N-acetyl D-proline has been investigated by x-ray 
crystallography. Using a 1.5Å resolution structure the exact interaction of the headgroup used in 
CPHPC, penta- and decavalent ligands, was investigated. The results show potential for an 
electrostatic interaction between the carbonyl oxygen of acetyl from the ligand and the side chain 
amide of Gln148, which has not previously been considered.  
 
Applications of multivalent binding are still emerging; in this study, bivalent ligand BPC8 was used 
as an additive to crystallise CRP from the Rat (rCRP) in non-covalently cross-linked decameric 
complexes. Previous x-ray crystallography studies have failed due to extreme radiation sensitivity 
of the crystals produced. This problem has been overcome with a complete dataset obtained from a 
single crystal at 3.2Å. No inter-protein contacts are seen between pentamers in the decamer 
complex, therefore the use of bivalent ligands has facilitated the observed crystal packing. 
Multivalent ligands are suggested as tools for overcoming difficult crystallisation issues. 
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Chapter 1. Introduction 
 
Serum Amyloid P component, SAP, is a normal circulating plasma glycoprotein in 
humans (Emsley et al., 1994). As a member of the pentraxin superfamily of proteins 
(Pepys and Baltz, 1983), it has a distinctive structure of five identical protomers 
arranged in a pentameric ring. The name pentraxin is derived from the Greek penta 
(five) and ragos (berries; Osmand et al., 1977). In addition to the radial protomer 
arrangement, the pentraxins are related by a ‘family signature’ amino acid sequence of 
HxCxS/TWxS (where x is any amino acid; Pepys et al., 1997).  
 
The pentraxin family is divided into the classical ‘short’ members and the more recently 
discovered ‘long’ members. The ‘long’ pentraxins share a similar C-terminal domain to 
the ‘short’ pentraxins, but have an unrelated N-terminal domain (Mantovani et al., 
2003). The first ‘long’ pentraxin discovered was TNF-stimulated gene 14, PTX3 (Lee et 
al., 1993). Other ‘long’ pentraxins consist of neuronal proteins NPI, NPII and NPR 
(Dodds et al. 1997) and sperm-egg fusion protein, Apexin (Reid and Blobel, 1994). 
 
The ‘short’ pentraxins have two known members SAP and C-Reactive Protein, CRP. 
CRP and SAP share 51% strict sequence identity in humans and 66% homology when 
conserved residues are taken into account (Pepys et al., 1997). Both ‘short’ pentraxins 
are phylogenically conserved plasma proteins found in most vertebrates and some 
invertebrates with no reported occurrences of deficiency or polymorphism in organisms 
in which it has been found. However, despite stable conservation through evolutionary 
history, the exact roles of SAP and CRP vary between species and in many cases remain 
unclear. The ‘short’ pentraxins have a variety of roles in different species such as 
behaviour as an acute phase protein, specificity of ligand binding and ability to activate 
complement. 
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SAP 10 20 30 40 50 60 
Homo Sapiens HTDLSGKVFV FPRESVTDHV NLITPLEKPL QNFTLCFRAY SDLSRAYSLF SYNTQGRDNE 
Rattus Norveigicus QTDLNQKVFV FPRESETDYV KLIPWLEKPL QNFTLCFRAY SDLSRSQSLF SYSVNSRDNE 
Mus Musculus QTDLKRKVFV FPRESETDHV KLIPHLEKPL QNFTLCFRTY SDLSRSQSLF SYSVKGRDNE 
 70 80 90 100 110 120 
Homo Sapiens LLVYKERVGE YSLYIGRHKV TSKVIEKFPA PVHICVSWES SSGIAEFWIN GTPLVKKGLR 
Rattus Norveigicus LLIYKAKLEQ YSLYIGNSKV TVRGLEEFPS PIHFCTSWES SSGIAEFWVN GKPWVKKGLQ 
Mus Musculus LLIYKEKVGE YSLYIGQSKV TVRGMEEYLS PVHLCTTWES SSGIVEFWVN GKPWVKKSLQ 
 130 140 150 160 170 180 
Homo Sapiens QGYFVEAQPK IVLGQEQDSY GGKFDRSQSF VGEIGDLYMW DSVLPPENIL SAYQGTPLPA 
Rattus Norveigicus KGYTVKSSPS IVLGQEQDTY GGGFDKTQSF VGEIADLYMW DSVLTPENIH SVDRGFPPNP 
Mus Musculus REYTVKAPPS IVLGQEQDNY GGGFQRSQSF VGEFSDLYMW  DYVLTPQDIL FVYRDSPVNP 
 190 200 210 220   
Homo Sapiens NILDWQALNY EIRGYVIIKP LVWV    
Rattus Norveigicus NILDWRALNY EINGYVVIKP RMWDNKSS    
Mus Musculus NILNWQALNY EINGYVVIRP RVWD    
 
CRP 10 20 30 40 50 60 
Homo Sapiens QTDMSRKAFV FPKESDTSYV SLKAPLTKPL KAFTVCLHFY TELSSTRGYS IFSYATKRQD 
Rattus Norveigicus HEDMSKQAFV FPGVSATAYV SLEAESKKPL EAFTVCLYAH ADVS--RSFS IFSYATKTSF 
Mus Musculus HEDMFKKAFV FPKESDTSYV SLEAESKKPL NTFTVCLHFY TALSTVRSFS VFSYATKKNS 
 70 80 90 100 110 120 
Homo Sapiens NEILIFWSKD IGYSFTVGGS EILFEVPEVT VAPVHICTSW ESASGIVEFW VDGKPRVRKS 
Rattus Norveigicus NEILLFWTRG QGFSIAVGGP EILFSASEIP EVPTHICATW ESATGIVELW LDGKPRVRKS 
Mus Musculus NDILIFWNKD KQYTFGVGGA EVRFMVSEIP EAPTHICASW ESATGIVEFW IDGKPKVRKS 
 130 140 150 160 170 180 
Homo Sapiens LKKGYTVGAE ASIILGQEQD SFGGNFEGSQ SLVGDIGNVN MWDFVLSPDE INTIYLGGPF 
Rattus Norveigicus LQKGYIVGTQ ASIILGQEQD SYGGGFDANQ SLVGDIGDVN MWDFVLSPDQ INAVYVGRVF 
Mus Musculus LHKGYTVGPD ASIILGQEQD SYGGDFDAKQ SLVGDIGDVN MWDFVLSPEQ ISTVYVGGTL 
 190 200 210 220   
Homo Sapiens SPNVLNWRAL KYEVQGEVFT KPQLWP     
Rattus Norveigicus SPNVLNWRAL KYETHGDVFI KPQLWPLTDC CES   
Mus Musculus SPNVLNWRAL NYKAQGDVFI KPQLWS    
 
Table 1.1. Sequence alignment for SAP and CRP from humans, the rat and mouse. Residues involved in 
metal binding are highlighted (turquoise) along with residues adjacent to the metal binding site, which are 
often involved in ligand binding (red) such as the hydrophobic pocket formed by Leu62, Tyr64 and Tyr74 
in SAP and glycosylation sites (yellow). 
 
CRP is an acute phase protein in humans. An acute phase response is a physiological 
and biochemical response to forms of tissue injury, inflammation or infection (Pepys 
and Hirschfield, 2003). There are a range of acute phase proteins some of which 
increase in concentration, others decrease in concentration in response to stimuli. For 
CRP, the acute phase response can be dramatic, with the concentration increasing as 
much as 1000-fold from a normal plasma concentrations of less than 10mg L
-1
 (Gabay 
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and Kushner, 1999; Young et al., 1991). CRP is also known to activate complement by 
binding to the C1q recognition protein (Kaplan and Volanakis, 1974; Siegel et al., 
1974). CRP-mediated complement activation has subsequently been implicated as the 
cause of increased inflammation and tissue injury during myocardial infarction and 
stroke (Griselli et al., 1999; Gill et al., 2004). 
 
SAP, as its name suggests, is associated with universal presence in amyloid deposits 
(Bladen et al., 1966; Cathcart et al., 1967). The amyloidoses are a heterogeneous group 
of disorders characterised by extracellular deposition of abnormally folded proteins (Tan 
and Pepys, 1994). A range of proteins and peptides are known to form amyloid fibres 
and the process of asymptomatic amyloid deposition is a consequence of ageing. 
Clinical amyloidosis occurs in a range of diseases, for example the formation of β-
amyloid plaques occurs dramatically in Alzheimer’s disease (Hardy and Higgins, 1992), 
β-2-Microglobulin amyloid deposition is a complication of long-term haemodialysis 
(Gorevic et al., 1986) and formation of islet amyloid is a common feature in patients 
with Type II Diabetes (Jiménez et al., 2002). SAP is universally present in all amyloid 
deposits regardless of the nature of the amyloid protein and constitutes around 15% of 
the dry mass. SAP in amyloid deposits coats and stabilises fibrils against attack from 
phagocytes (Tennent et al., 1995). It is likely that SAP is binding to a common motif 
present on all amyloid proteins, but as yet no motif has been identified.  
 
For the aforementioned reasons, CRP and SAP have emerged as targets for therapeutics 
in the treatment of cardiovascular disease and amyloidosis respectively (Pepys et al., 
2006; Kolstoe and Wood, 2010). Drug discovery programs are currently ongoing for 
both CRP and SAP. This section will focus principally on the SAP, with information 
regarding CRP introduced in Chapter 3 where appropriate. Firstly, the structure of SAP 
with be introduced followed by a discussion of the possible physiological role of SAP 
and its role in amyloid deposits. The Chapter will also review ligand binding by SAP, 
development of ligands for SAP and conclude with an introduction to multivalent 
binding processes and emerging knowledge of their role in biological processes, as well 
as some potential applications in targeted therapeutics. 
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1.1. Structure of SAP 
SAP and CRP have 51% strict sequence identity in man and have very similar tertiary 
and quaternary structures (Ashton et al., 1997). The short Pentraxins are recognisable 
by their homopentameric quaternary structure (Osmand et al., 1977). Their structure 
consists of five identical protomers arranged in a pentameric disc-like configuration 
(Figure 1.1). Pentameric SAP measures approximately 100Å in diameter, 35Å deep with 
a central pore 20Å in diameter.  
 
Figure 1.1. Cartoon representations of the B-face (Left) and A-face (Right) of a single SAP pentamer. 
Drawn using molecular graphics program Pymol (Pymol molecular graphics system, version 1.3. 
Distributed by Schrödinger LLC) using SAP model coordinates 1SAC downloaded from the protein data 
bank (PDB; www.rcsb.org/pdb). The model shows five identical protomers formed from β-sheets 
(yellow) linked by short loop regions (green) arranged in a β-jellyroll topology, the short α-helix (red) on 
the “A-face” of the pentamer and two calcium ions (limon yellow) on the opposing binding, “B-face”. 
 
Each protomer of SAP consists of 204 amino acids folded into a flattened β-jellyroll 
topology formed by two anti-parallel β-sheets linked by short loop regions (Figure 1.2; 
Emsley et al., 1994). The core secondary structure of SAP is remarkably similar to that 
of legume lectins such as Concanavalin A. Both β-sheets are extended by a β-meander 
of three further strands. The hydrophobic core of the protomer forms non-polar 
interactions with neighbouring protomers, burying around 15% of the total surface area 
and resulting in a very strong attraction that requires boiling in sodium dodecyl sulphate 
to dissociate the protomers (Pepys et al. 1997). The β-jellyroll is stabilised by multiple 
hydrogen bonds and a single intramolecular disulphide bond between Cys36-Cys95. 
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The loop regions which link the secondary structure elements are short, which gives the 
protomers a tight compact appearance and makes SAP highly resistant to proteolysis. 
 
Figure 1.2. Cartoon representation of the structural features of single protomer of SAP. The β-jellyroll is 
depicted by the yellow ribbon with the extended β-meander in purple. A short α-helix is visible on the A-
face of the protomer with two calcium ions (limon yellow) shown bound on the opposing B-face. The 
calcium binding loop is highlighted in blue and all other loop regions are represented by green. Image 
generated in Pymol using the structure of SAP was downloaded from the PDB (PDB file: 1SAC). 
 
A short α-helix is found on one face of each subunit, the so-called ‘A-face’. The α-helix 
contains Glu167, which is the residue responsible for calcium-dependent aggregation of 
SAP in the absence of any other ligand. The opposing side of the protomer, commonly 
termed the 'B-face' contains the double-calcium binding site of SAP. The calcium 
binding site is formed by residues from a β-sheet and a flexible loop which undergoes a 
conformational change in the presence of calcium. The loop is composed of residues 
134-152 containing mostly acidic residues capable of coordinating the divalent cations. 
At physiological pH and in the absence of calcium, SAP is detected as a decameric 
complex in which two SAP pentamers interact through their disordered calcium-binding 
loops (Pepys et al., 1977). The disordered loop region is the only site at which 
proteolysis can occur and this is completely inhibited by the binding of calcium ions 
(Kinoshita et al., 1992).  
 
Chapter 1. Introduction 
 
23 
The calcium binding of SAP coordinates two metal ions separated by around 4Å. The 
first calcium ion is bound by the side chains of Asp58, Asn59, Glu136 and Asp138 and 
the main chain carbonyl oxygen of Gln137. The second calcium ion is more loosely 
bound being that it is coordinated by two water molecules with the side chains of 
Glu136, Asp138 and Asn148 providing the only protein ligands (Mikolajek et al., 2011). 
The coordination spheres of both cations are completed by the phosphate or carboxylate 
group of a ligand. A small hydrophobic pocket adjacent to the calcium binding site 
formed by the side chains of Leu62, Tyr64 and Tyr74. Though small, the hydrophobic 
pocket is known to be important for efficient ligand binding to SAP. The side chain 
pyrrolidine ring of N-acetyl D-proline and a methyl group of 4,6-O-(1-
carboxyethylidene)-β-D-galactosepyranoside (MOβDG) are two ligands known to 
interact with the hydrophobic pocket. There is also some evidence that carbohydrate 
based ligands, such as MoβDG, form electrostatic interactions between oxygen atoms in 
their heterocyclic ring and the amide groups of Gln148 and Asn59 (Thompson et al., 
2002).  
 
A single N-glycosylation site exists on the side chain of Asn32 of each protomer 
(Tennent and Pepys, 1994). The single biantennary oligosaccharide is located towards 
the A-face of the protomer at the N-terminal end of a β-sheet that is obscured from 
solvent by the α-helix. Unusually, the oligosaccharide does not exhibit the same extent 
of microheterogeneity common in plasma glycoproteins, particularly during an acute 
phase response (Figure 1.3). Loss of the sialic acids from the terminus of the 
oligosaccharide results in glycosylated pentraxins being rapidly catabolised by 
hepatocytes (Pepys et al., 1994; Yang et al., 1992). 
Figure 1.3. Structure of the biantennary oligosaccharide of SAP. Image generated using Marvin sketch 
(Marvin Sketch, version 5.12.0, Chemaxon Ltd.). 
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1.2. Physiological role of SAP 
The stable conservation of SAP and the lack of any polymorphism in man, strongly 
suggests an important physiological function, but despite many theories, its exact role 
remains unclear. This lack of clarity is due to numerous difficulties in its study, for 
example the lack of any known deficiency or polymorphism means the results of such 
an affliction cannot be directly observed. Furthermore, it is difficult to extrapolate 
results of experiments using animal models because the pentraxins fulfil different roles 
in different species. For example, murine SAP is an acute phase protein (Pepys et al., 
1979), increasing in plasma concentration by up to 50-fold during an acute phase 
response; in humans, only modest increases of SAP concentration are observed and only 
during chronic active diseases (Pepys et al., 1997). SAP binds ligands in a calcium-
dependent manner, but it is also capable of binding to neighbouring pentamers through 
non-covalent interaction between the calcium binding site and Glu167. This presents a 
problem for in vitro study because purified SAP rapidly aggregates at physiological 
calcium concentration and pH and is only inhibited by the presence of a ligand or 
calcium chelating species such as EDTA (Hind et al., 1984).  
 
1.2.1. DNA binding by SAP 
One interesting observation is that SAP is the only normal plasma protein capable of 
binding to DNA and chromatin. The binding displaces H1-type histones, thus 
solubilising the DNA (Pepys and Butler, 1987; Butler et al., 1990). It could be that SAP 
is involved in controlling the degradation of extracellular chromatin during cell death 
(Bickerstaff et al., 1999). This potential role is supported by the tightly folded structure 
of SAP; secondary structures are linked by short loop regions, preventing proteolysis in 
the presence of calcium ions, which suggests SAP operates in a hostile environment 
(Kinoshita et al., 1992). The marshalling of this potentially biologically active cellular 
debris may be important in preventing autoimmunity and stopping incorrect genetic 
information entering neighbouring cells prior to phagocytosis (Breathnach et al., 1989). 
Furthermore, evidence is emerging that SAP's role in mediating DNA clearance could 
be the reason for the poor response to DNA vaccinations observed in Humans (Wang et 
al., 2012). 
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SAP has also been observed binding to the surface of apoptotic cells (Familian et al., 
2001). This may be due to chromatin or phosphoethanolamine fragments exposed on the 
surface of dying cells. It has been suggested that the binding of SAP to apoptotic cells 
facilitates their uptake by macrophages, which could have implications in the treatment 
of systemic lupus erythematosus where clearance of apoptotic cells is hampered (Bijl et 
al., 2003). 
 
1.2.2. Role in Innate Immunity 
SAP's role in innate immunity is slightly paradoxical; the rate of phagocytosis is 
retarded for some bacteria to which SAP binds, but SAP knock out mice are more 
susceptible to lethal infection with E. Coli. O111:B4, which SAP does not bind 
(Noursadeghi et al., 2000). This could be explained by observations that SAP protects 
podocytes in the renal system from Haemolytic Uremic Syndrome by binding to Shiga 
toxin 2 produced by E. Coli. (Dettmar et al., 2014). Therefore SAP may have some 
beneficial host defence function, but it has been suggested that SAP's beneficial 
function in mediating DNA removal has been hijacked by evolution of some bacteria 
using bound SAP as camouflage from the immune system.  
 
1.2.3. Role in Amyloidosis 
Since 1966, SAP has been seen in amyloid deposits as its identical Amyloid P 
component (AP), although originally mistaken for amyloid fibres (Bladen et al., 1966). 
In 1967 AP was identified as the key plasma constituent of amyloid, accounting for 15% 
of the dry mass of deposits (Cathcart et al., 1967; Pepys et al., 1997) and was 
subsequently isolated in its identical serum form (Pepys et al., 1977). SAP binds to all 
forms of amyloid fibril in a calcium-dependent manner regardless of the amyloid 
peptide present (Pepys et al., 1994). Tennent et al. (1995) identified that in binding to 
amyloid deposits, SAP stabilises fibrils, preventing their proteolysis. For this reason, 
SAP's role in amyloidosis has attracted significant interest as a target for therapeutics to 
treat amyloidosis and amyloid-related conditions. 
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1.3. Amyloidosis 
Amyloid deposits were first discovered in 1851 when Virchow initially incorrectly 
suggested cellulose as the principal constituent based on results of staining fibrils with 
iodine (Virchow, 1851). The staining was actually caused by the presence of heparan 
sulfate proteoglycans in amyloid deposits. Friedrich and Kekule subsequently correctly 
identified protein to be the major polymeric constituent of amyloid (Friedrich and 
Kekule, 1859). 
 
Amyloid proteins coalesce to form fibrils, which have a common quaternary structures 
regardless of the protein involved (Sunde et al., 1997). Amyloid fibrils consist of 
twisted fibres of β-strands running parallel to the axis of the fibrils, and with individual 
protein chains perpendicular to the long axis of the fibrils (Figure 1.4). Approximately 
50 different disorders associated with the misfolding of normally soluble peptides and 
proteins (reviewed by Knowles et al., 2014). As the mass of amyloid fibrils grows, they 
associate strongly with plasma and extracellular matrix proteins and proteoglycans 
forming amyloid deposits, which invade the extracellular space of organs destroying 
normal tissue architecture and function (Sipe, 1992). In addition to similar morphology, 
amyloid fibrils are characterised by resistance to proteolytic digestion (Sorenson and 
Shimamura, 1964) and insolubility under physiological conditions (Glenner et al., 
1968). 
 
Figure 1.4. a) Cartoon representation of a fibril of Amyloid β 1-42 derived from solid state NMR. b) Top: 
simulation of fibril of Amyloid β 1-42 formed from four protofilaments. Bottom: cryoelectron 
micrographs of Amyloid β 1-42 fibrils. Figure adapted from Lührs et al., 2005. 
 
Amyloidosis is a clinical disorder which results in extracellular deposition of abnormal 
fibrils derived from aggregation of misfolded, normally soluble protein (Pepys, 2006). 
Chapter 1. Introduction 
 
27 
Amyloidosis is directly responsible for 1 in 1000 deaths in developed countries. The 
clinical disorder can either be systemic or local. Systemic amyloidosis occurs when 
circulating plasma protein precursors are deposited as amyloid in some or all of the 
viscera, blood vessel walls and connective tissue (Sipe, 1992). In local amyloidosis, 
amyloid deposits are restricted to a single organ or tissue.  
 
Amyloidosis may be acquired as a complication of a primary disease that causes 
occurrence of abnormal protein or increased quantities of a normal protein with 
amyloidogenic properties, for example amyloid light-chain (AL) amyloidosis is caused 
by increased production of Ig light chain protein, which commonly accumulates in the 
Kidneys (Pepys, 2006; Gertz et al., 2002). Alternatively, amyloidosis can be hereditary 
and caused by gene mutations that encode a variant protein structure more susceptible to 
amyloidogenesis, such as transthyretin-related hereditary amyloidosis, which is caused 
by inherited mutations of the gene encoding the protein transthyretin (Saraiva, 1995).  
 
Amyloid deposits may form as a result of other conditions, these are distinct from the 
clinical disorder of amyloidosis because they are not the direct cause of the clinical 
condition. For example, β-amyloid plaques form in the brains of patients with 
Alzheimer's disease, but there is a poor correlation between the amount of amyloid 
deposited and cognitive impairment. However, the presence of oligomers of β-amyloid, 
which are a precursor to amyloid fibrils, has been shown to increase cognitive 
impairment (Cleary et al., 2005). The fact that SAP assists amyloidogenesis (Botto et 
al., 1997) and stabilises amyloid fibrils has led to suggestions that SAP may assist 
amyloid fibril formation as a way to remove toxic amyloid oligomers from circulation. 
This may be supported by observations of SAP's activity as a chaperone made by Coker 
et al. (2000). 
 
1.3.1. Detection of amyloid deposits 
The characteristic test for presence of amyloid is staining with Congo Red dye in vitro 
and observing the resulting birefringence (Puchtler et al., 1962). Hawkins and Pepys 
(1995) have developed a method for identifying amyloid deposits in vivo using 
radiolabelled I
123
-SAP. SAP's strong affinity for amyloid means the attached iodine 
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isotope accumulates in deposits, which are then detected by whole body scintigraphy 
(Figure 1.5). 
Figure 1.5. Posterior whole body scintigraph after injection of I
123
 radiolabelled SAP. Abnormal uptake of 
the radioactive tracer is observed in the spleen, liver and bone in a patient with systemic Amyloid Light-
chain (AL) amyloidosis. The left pane shows amyloid deposition prior to treatment. The right pane shows 
the same patient 6 months later after 4 rounds of chemotherapy. Adapted from Hawkins and Pepys 
(1995).  
 
1.3.2. Identifying SAP's amyloid binding motif 
Despite significant interest, no SAP binding motif has been identified for any amyloid 
protein. SAP does not bind to the proteins in their native state, indicating that there may 
be some common motif present in the abnormally folded proteins, which SAP 
recognises as an amyloid protein (Pepys et al., 1997). It has been suggested that SAP 
may be binding to the non-protein constituents common to amyloid deposits such 
glycosaminoglycans, dermatan and heparan sulphate (Hamazaki, 1987; Nelson et al., 
1991). However, SAP has been observed binding to isolated amyloid fibrils in vitro. 
Therefore, it is conceivable that SAP binding may involve a mixture of different ligands 
from the fibrils and proteoglycan components of an amyloid deposit. 
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1.3.3. Removing visceral amyloid deposits by targeting SAP 
Amyloid therapies that target SAP have been under development for the past two 
decades (Pepys et al., 2002; Ho et al., 2005). A promising method for clearing visceral 
amyloid deposits involves a two-stage treatment in which first circulating SAP is 
depleted using small molecule bivalent ligand, CPHPC (Gillmore et al., 2010; Figure 
1.7). Once circulating SAP has been depleted then an anti-SAP antibody can be 
administered, which directs to amyloid deposits containing the only significant 
quantities of remaining SAP (Bodin et al., 2010). This has been shown to be an effective 
method of highlighting the presence of amyloid to the immune system, which results in 
rapid clearance of deposits. 
 
1.4. Ligand binding by SAP 
 
1.4.1. Small molecule binding 
A range of natural and synthetic molecules are known to bind to SAP in a calcium-
dependent manner. All known small molecules bind through either a phosphate or 
carboxylate group coordinating the double-calcium binding site of SAP. Additional 
protein-ligand interactions also involve, to a greater or lesser extent, the hydrophobic 
pocket adjacent to the calcium-binding site and electrostatic interactions between the 
ligand and polar side chain functional groups of the protein.  
 
Phosphoethanolamine (PE) is the archetype synthetic ligand for SAP (Pontet et al., 
1978), with phosphocholine (PC) the corresponding ligand for CRP, although CRP also 
binds to PE (Mikolajek et al., 2011). This binding preference is used in the isolation and 
purification of the pentraxins from human sera (Hawkins et al., 1991). PE- and PC- 
sepharose columns are used sequentially to bind the pentraxins with high specificity in 
the presence of calcium. Prior to the development of immobilised PE columns, SAP was 
purified using agarose gel (Pepys et al., 1977) with the R-enantiomer of the cyclic 
pyruvate of galactose, MOβDG, identified as the SAP binding species.  
 
MOβDG is one of a number of carbohydrate-based ligands for SAP, which also include 
glycosaminoglycans such as heparin (Thompson and Enfield, 1978), in particular 
heparan and dermatan sulphates, glycans terminating in mannose and glycans with pre-
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terminal galactose (Pepys et al., 1997). Binding is not limited to saccharides; nucleotide 
deoxyadenosine monophosphate (dAMP) and a range of amino acids, such as D-proline 
also bind to SAP in a calcium-dependent manner. 
 
SAP binds more strongly to D-amino acids than the analogous L-enantiomer in all 
reported cases. For example, the N-acetyl D-proline binds to SAP with a 15μM 
dissociation constant, Kd, the comparative interaction of N-acetyl L-proline has a Kd of 
only 322μM (Kolstoe thesis, 2005). This difference in binding affinity can be explained 
by the ability of the pyrrolidine ring of NADPro to fit into the hydrophobic pocket of 
SAP. Other amino acids such as D-valine and D-alanine have been observed binding to 
SAP through their C-terminus either by isothermal titration calorimetry or x-ray 
diffraction (Kolstoe thesis, 2005; Purvis thesis, 2002). In contrast, O-phosphothreonine 
binds through the side chain phosphate in preference to the C-terminal carboxyl group 
(Figure 1.6). This interaction also serves to underline the importance of the hydrophobic 
interaction, as the side chain methyl group fits into the hydrophobic pocket. 
Figure 1.6. Cartoon and stick representation of phosphothreonine binding to SAP (Generated with 
Pymol; PDB file: 2W08. Two calcium ions (limon yellow) are coordinated by multiple side chains of the 
protein, with the coordination completed by water molecules (red spheres) and the phosphate group of the 
ligand. The methyl group of the side chain of phosphothreonine can be seen in the hydrophobic pocket 
formed by Leu62, Tyr64 and Tyr74. Cartoon: α-helix (red), β-sheet (yellow), loops (green). Protein stick 
representation: carbon (green), oxygen (red) and nitrogen (blue). Phosphothreonine stick diagram: carbon 
(turquoise), oxygen (red), nitrogen (blue), phosphorus (orange). 
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L-glutamic acid binds to SAP through its side chain carboxylic acid, although this has 
only been observed when Glu167 from the A-face of an SAP pentamer occupies the B-
face of another pentamer during auto-aggregation. The auto-aggregation of SAP is not 
prevented by addition of 100mM free L-glutamic acid. This suggests a multivalent 
interaction where the presence of multiple Glu167 in a single binding entity presented in 
a pentagonal symmetry is stronger than the monomeric interaction. 
 
1.4.2. Development of bivalent ligands for SAP 
The homopentameric symmetry of SAP suggests simultaneous binding of multiple 
ligands. This has been surreptitiously exploited by the development of bivalent ligands 
that non-covalently cross-link SAP forming tightly bound decameric complexes with 
binding affinities indicative of cooperative binding (Figure 1.8).  
 
The D-enantiomer of angiotensin converting enzyme inhibitor, Captopril (Smith and 
Vane, 2003), was an initial hit compound for SAP discovered during a search of the 
Roche compound library (Pepys et al., 2002). It was observed that dimerising D-
Captopril by disulphide bond formation increased the IC50 from 100μM for monomeric 
D-Captopril to 5μM for the dimeric compound (Figure 1.7). Rationalisation of the 
structure yielded R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-
carboxylic acid (CPHPC). CPHPC is simply two D-proline headgroups linked by a 
hexanoyl chain, which binds to SAP with a remarkable 10nM dissociation constant.  
Figure 1.7. SAP binding ligands identified by Pepys et al. (2002). a) D-Captopril. b) D-captopril dimer. 
c) CPHPC. 
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CPHPC has been shown to have significant potential in the treatment of amyloidosis 
and amyloid-related conditions. The cross-linking binding of SAP is preserved in vivo, 
leading to rapid catabolism of decameric protein by the hepatocytes and depletion of 
SAP from circulating plasma (Gillmore et al., 2010). However, despite binding with a 
low nanomolar binding affinity, CPHPC does not strip SAP from amyloid fibres (Wood 
and Kolstoe, 2010). This quirk allows SAP in amyloid deposits to be targeted by an 
anti-SAP antibody after depletion of the protein from plasma. Bodin et al. (2010) have 
shown this methodology to be an effective way of rapidly clearing visceral amyloid 
deposits in vivo. 
 
Ho et al. (2005) have also developed bivalent pyruvate acetal of glycerol-based ligands 
for SAP through rational optimisation of MoβDG's binding to SAP. In both cases, the 
bivalent ligands induce non-covalent decamer formation in SAP leading to a dramatic 
increase in binding affinity.  
Figure 1.8. Cartoon representation of x-ray diffraction crystal structures of non-covalent cross-linking of 
two SAP pentamers by bivalent ligands (stick representation). Left: CPHPC-SAP decameric crystal 
structure (PDB file: 4AVT; Kolstoe et al., 2014). Right: Pyruvate acetal of glycerol bivalent ligands in 
complex with SAP (PDB file: 2A3X; Ho et al., 2005) Model generated in Pymol, cartoon colours: α-helix 
(red), β-sheet (yellow), loops (green), calcium ions (limon yellow). Bivalent ligand colours: carbon 
(turquoise), oxygen (red), nitrogen (blue). 
 
The cooperative mode of binding displayed by bivalent ligands suggests that further 
binding affinity increases might be achieved by increasing the valency of the binding 
species further. The natural conclusion based on the pentameric structure of SAP is the 
synthesis of pentavalent ligands, while the evidence of beneficial pharmacokinetic 
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properties of cross-linking by bivalent ligands provides the motivation for synthesising 
decavalent ligands that maintain the non-covalent cross-linking ability of CPHPC. A 
firm understanding of multivalency is crucial to realising the maximum potential 
affinity of polyvalent ligands for SAP. 
 
1.5. Multivalent ligand binding 
A multivalent interaction is defined as the binding of multiple ligands from a single 
entity, e.g. a surface or molecule, to multiple receptors from another binding entity 
(Mammen et al., 1998). Presentation of monovalent ligands on an appropriate entity can 
turn a moderate monovalent binding affinity into a strong multivalent interaction 
through a range of mechanisms distinct from those of the corresponding monovalent 
interaction (Figure 1.9; reviewed by Gestwicki et al., 2002). However, the effect of 
multivalency is not limited to simply an affinity increase, it can also increase the 
specificity of binding, allowing development of more targeted molecules.  
Figure 1.9. Mechanisms of monovalent and multivalent binding adapted from Gestwicki et al. (2002). 
 
Subsite binding occurs when the interaction of a multivalent ligand with the main 
binding site facilitates a subsequent interaction at a lesser binding site, which may not 
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be possible for a monovalent ligand because the ligand binds more loosely to the subsite 
(Chittasupho, 2012). Chelation effects occur when the simultaneous binding of multiple 
ligands from the same entity decreases the rate of dissociation. Steric stabilisation is a 
benefit derived from the larger size and distribution of a multivalent ligand over the 
monovalent species, which prevents binding of other competitive ligands. Statistical 
binding occurs when the presentation of multiple copies of a ligand in a single binding 
entity simultaneously forms multiple contacts with receptors, reducing the chance of 
complete dissociation of the ligand and increasing the probability of rebinding. 
Receptor clustering brings multiple binding ligands or receptors into close proximity 
allowing a multivalent process to take place.  
 
The synergistic increase in binding affinity achieved by combining a number of 
monovalent ligands into a single multivalent species is classified as either cooperative 
or additive (Boas and Heegaard, 2004; Ercolani and Schiaffino, 2011). Additive binding 
is the result of increased binding efficiency achieved by having a greater number of 
binding entities per mole of ligand. In the additive case, the binding affinity is 
proportional to the monovalent binding affinity and the number of simultaneous 
independent binding interactions formed with a multivalent receptor. Cooperative 
binding can be either positively or negatively cooperative. In a positively cooperativity 
binding process, the observed affinity is stronger than would be expected for a purely 
additive process due to the action of linking monovalent ligands together into a single 
molecule. The converse of this is negative cooperativity, where the observed binding 
affinity is less than the expected additive interaction. Determining the degree of 
cooperativity is notoriously difficult and has led to a number of incorrect assessments of 
multivalent interactions (Ercolani, 2003). It should be noted that even in a negatively 
cooperative process, the binding affinity still exceeds the affinity of the corresponding 
monovalent interaction (Boas and Heegard, 2004). 
 
Biology nomenclature often describes receptors as the species present on the surface of 
a target cell or surface. In this investigation, the nomenclature recommended by 
Mammen et al. (1998) will be used, in which the receptor refers to ligand binding 
pockets on the protein and the ligand is any entity capable of binding to these pockets, 
regardless of whether the species is free in solution or immobilised on a solid phase.  
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1.5.1. Thermodynamics of multivalent binding 
The thermodynamics of a binding reaction determine the stability of the bound products 
relative to the unbound starting components. The relationship of factors affecting the 
stability of a protein ligand complex is given by the change in Gibbs free energy: 
        
∆G =  ∆H − T∆S         Equation 1.1. 
 
ΔG is the change in Gibbs free energy, ΔH is the change in enthalpy, T is the 
temperature of the system and ΔS is the change in entropy, also known as the change in 
the degree of disorder or the degrees of freedom. In thermodynamics, a process is 
spontaneous at a given temperature if it is accompanied by a negative change in the 
Gibbs free energy (Housecroft and Constable, 2006). The enthalpy of a multivalent 
binding reaction is proportional to the enthalpy of a single analogous monovalent 
binding event and the number of binding events occurring during the multivalent 
interaction. Entropy is a measure of the disorder within a system and is an aggregation 
of the translational, rotational and conformational entropy of an entity. A multivalent 
ligand is expected to have the same rotational and translational entropy as the 
comparable monovalent species, but greater conformational entropy due to the 
increased structural complexity of the linker used to combine the monovalent ligands 
into a single entity (Mulder et al., 2004). This also leads to a greater reduction of 
conformational energy upon binding and has led some to suggest that minimising the 
degrees of freedom by introducing greater rigidity into the structure of the linker is 
important in the design of multivalent ligands (Mammen et al., 1998a; Mammen et al., 
1998b; Krishnamurthy et al., 2006). However, more recent evidence has found that 
flexible linkers retain a certain degree of flexibility upon binding, resulting in a smaller 
negative change in entropy and making conformational entropy less influential on the 
stability of multivalent complexes than expected (Krishnamurthy et al., 2007). This is in 
agreement with the strong binding affinities observed for a number of multivalent 
ligands with flexible linkers (Kramer and Karpen, 1998; Mammen et al., 1998; Kitov et 
al., 2000; Choi, 2004). It has been argued subsequently that rigid structures can prevent 
ligands adopting the ideal conformation for binding, reducing the interaction's affinity 
(Deniaud et al., 2011) 
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The conformational entropy is determined by the size of the multivalent scaffold and the 
length and nature of the linkers of which it is composed. The size and nature of the 
multivalent scaffold will often be determined by the physical properties of the targeted 
multivalent receptor, in particular the distance between the binding sites. The effect of 
the linker length and flexibility is explained by the concept of effective concentration. 
Effective concentration is the probability of two inter-linked entities reacting or forming 
a binding interaction (Kuhn, 1934; Jacobsen and Stockmayer, 1950). Mulder et al. 
(2004) give a clear example of effective concentration using a bivalent ligand in which 
one headgroup is already bound to the macromolecule (Figure 1.10).  
 
Figure 1.10. Schematic of effective concentration of a partially bound multivalent ligand as depicted by 
Mulder et al., (2004). [▼]eff is the effective concentration of the ligand experienced by the unoccupied 
binding site of the partially bound receptor molecule. [▼]sol is the real concentration of the ligand in the 
solution. 
 
After the first headgroup has bound, the remaining unbound headgroup is essentially 
tethered close to the surface of the macromolecule. If the tether is of sufficient length 
and flexibility the second headgroup will be able to bind to the macromolecule without 
dissociation of the first. This gives a local concentration of the ligand that is higher than 
the real concentration, when no ligand is bound. In relation to conformational entropy, 
the optimal length of the linker is one that spans the distance between the two binding 
sites. Too short and the effective concentration will not be increased relative to the real 
concentration and a second ligand molecule will be needed to fully saturate the binding 
sites of the macromolecule. If only just long enough, binding of the second headgroup 
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will induce steric strain reducing conformational freedom and favouring dissociation of 
the headgroup. Conversely if too long, the headgroup will occupy a larger radius around 
the first headgroup, lowering the effective concentration and increasing the 
conformational entropy of the molecule. 
 
1.5.2. Kinetics of multivalent binding 
The effective concentration is a concept that falls under the broader subject of reaction 
kinetics. Kinetics describes the rate and extent to which a particular product will be 
produced relative to its reactants. In multivalent binding this can be thought of as the 
extent to which a particular multivalent complex will form. The extent of multivalent 
complex formation of a single ligand interacting with a single protein can be expressed 
as:   
 
Ka =
[ML]
[M][L]
 
           
Where multivalent ligand, L, of concentration [L] interacts with macromolecule, M, 
present in concentration [M] to form complex ML present in concentration [ML] at 
equilibrium. Ka is the equilibrium constant of association for the complex. In a 
multivalent interaction, the equilibrium constant is the product of all the individual 
constants for each binding event between a single headgroup from the ligand and a 
single binding site of the macromolecule. The rate of the first interaction is expected to 
be slower than the rate for the monovalent process due to the greater complexity of the 
multivalent species (Chittasupho, 2012). But the binding of subsequent headgroups is 
expected to be faster due to the greater effective concentration and the increased 
probability of any one individual headgroup rebinding due to being tethered close to 
macromolecule binding site by the remaining bound headgroups of the ligand 
(Krishnamurthy et al., 2007). The influence of the effective concentration on the overall 
binding constant is expressed by the relationship: 
 
𝐾𝑛 = 𝑏𝐾1
𝑛𝐶𝑒𝑓𝑓
𝑛−1
         Equation 1.3. 
         
Equation 1.2. 
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Where the overall association constant for a multivalent process involving n interactions 
is the product of a number of statistical factors related to the length and flexibility of the 
ligand, b, the association constant of a single headgroup attachment K1 and the effective 
concentration of a partially bound ligand, Ceff. The dissociation of the multivalent ligand 
is greatly reduced in comparison to the monovalent interaction because this requires 
dissociation at all points of attachment. Dissociation of headgroups is known to be 
stepwise and the probability of rebinding high (Rao et al., 1998), so the concentration of 
species only attached to the macromolecule by a single point of attachment at any given 
time is a small fraction of total bound concentration. In contrast, the concentration of 
singly bound species in a monovalent interaction is equal to the total concentration of 
ML and once unbound the EC is equal to the real concentration of the ligand.  
 
In addition to the determining the probability of dissociation, kinetics can be used to 
describe the probability of a multivalent event being intermolecular or intramolecular 
(Figure 1.11). When a multivalent ligand interacts with multiple binding sites from a 
single receptor molecule, the binding is classified as intramolecular, and when the single 
multivalent ligand interacts with multiple receptor molecules simultaneously the 
binding is considered to be intermolecular (Chittasupho, 2012; Figure 1.11).  
Figure 1.11. a) Intramolecular and b) Intermolecular multivalent binding. 
 
The preference of a multivalent ligand to form either an intra- or intermolecular species 
can be expressed by the ratio of the dissociation constant for the intermolecular reaction 
over the dissociation constant of the intramolecular reaction, which is commonly known 
as the effective molarity (EM; Equation 1.4).  
 
𝑀𝑒𝑓𝑓 = (
𝐾𝑛
𝑏𝐾1
𝑛)
1/(𝑛−1)
 Equation 1.4. 
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At low concentrations of ligand, intramolecular binding is favoured, but when the 
concentration of free ligand exceeds the effective concentration intermolecular 
interactions become favourable. While effective concentration is a theoretical value 
based on ligand geometry, size and flexibility, EM is quantified using the observed 
binding constants for the multivalent individual processes (Equation 1.4.; Mulder et al., 
2004). In this way, EM can measure the affinity enhancement over a monovalent 
process (Anderson et al. 1995; Rao et al., 1998; Felluga et al., 2000). EM has also been 
used to determine the ease of cyclisation in a multivalent system (Kirby, 1980; Galli and 
Mondolini, 2000), i.e. the ease of complete saturation of a single multivalent receptor by 
a single multivalent ligand. This has direct relevance to SAP, as Ho et al. (2005) have 
conducted investigations of complex formation under different concentrations of 
bivalent ligand and found the same ligand concentration dependence for the formation 
of decameric complexes of SAP using non-covalent, cross-linking, bivalent ligands. 
Furthermore, they found decameric complexes occur over a greater range of ligand 
concentrations for ligands with stronger binding affinities for SAP. Therefore, the design 
of decavalent ligands for SAP needs to consider the concentration of ligand when 
attempting to analyse protein-ligand complexes by methods such as x-ray 
crystallography, as the concentration of ligand will determine whether pentameric or 
decameric complexes are observed.  
 
It is clear that the design of multivalent ligands is shaped by two factors, firstly the 
mode of binding sought, either intramolecular or intermolecular. Secondly, the effort to 
produce the most effective multivalent binding species for target receptor. The second 
factor may not always seek the ligand with the strongest binding affinity, greater 
specificity may also be important. Efficient multivalent binding requires a consideration 
of the individual binding process, the relative positioning of the binding sites and nature 
of the linker used to join multiple monovalent headgroups. The concepts of effective 
concentration, effective molarity and entropy are important in quantifying the influence 
of the multivalent ligand structure; while separate investigations of the monovalent 
binding interaction are required to determine the expected affinity gain and inform 
aspects of multivalent ligand design, such as the correct chemical linkage needed to 
ligate the monovalent headgroups into a single binding entity. 
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1.5.3. Examples of multivalent processes 
There are many examples of multivalent binding processes in biological systems, but 
often they are not fully understood due to the complexity of the process, difficulty in 
identifying the exact constituents involved and cited examples of misinterpretation of 
binding cooperativity (Ecrolani, 2003). 
 
Concanavalin A (ConA) is a carbohydrate binding lectin that is probably one of the best 
characterised multivalent receptors (Goldstein et al., 1965; Edelman et al., 1972). For 
this reason it has been used as a model for numerous studies of multivalent ligand 
design and application (Kanai et al., 1997; Dam et al., 2000; Cairo et al., 2002; Deniaud 
et al., 2011). Similarly, its avid binding to carbohydrate ligands means ConA is widely 
used in the purification of glycoproteins (Iscove et al., 1974). Significant similarities 
have been observed between the tertiary structures of SAP and ConA subunits (Figure 
1.12; Emsley et al., 1994). In particular, both proteins have a flattened β-jellyroll 
topology and double cation binding sites. ConA induces agglutination of various cell 
types by interaction with carbohydrate moieties exposed on the surface of cells 
(Podolsky et al., 1974). This interaction can be taken as an example of an 
intermolecular multivalent binding process in which ligands from multiple cells are 
bound by a single receptor, resulting in agglutination. 
 
Figure 1.12. Cartoon representation of a subunit of Concanavalin A (PDB file: 3CNA). There are 
similarities in the arrangement of the β-sheet (yellow) and the double cation binding site. Loop regions 
are denoted by the green ribbon; calcium ion (limon yellow), manganese ion (violet). 
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A possible, example of multivalent binding relevant to the pentraxins is the proposed 
mechanism of complement activation by CRP during an acute phase response (Kaplan 
and Volanakis, 1974). CRP recognises phosphatidylcholine moieties presented on the 
surface of damaged cells and phosphocholine presented on the surface of some bacterial 
cells (Volanakis and Kaplan, 1971; Volanakis and Wirtz, 1979). The process is likely to 
be multivalent, with the strength of binding of CRP linked to the density of ligands on 
the entities surface. At a certain density, CRP will bind to the surface in sufficient 
density and distribution for the C1q complex of the complement system to bind, 
activating the complement system by the classical pathway (Peisajovich et al., 2008). 
C1q consists of multiple globular headgroups which bind individually to CRP 
pentamers through a cleft on the A-face of the pentraxin (Gaboriaud et al., 2003). 
Therefore, the proposed role of CRP in mediating the removal of nuclear material 
during cell death could be the result of two sequential multivalent binding processes. It 
could be contemplated that the need for two multivalent processes for the activation of 
complement reduces the possibility of improper complement activation. Although the 
exact groups involved and the mode of binding between CRP and C1q have yet to be 
elucidated, this example shows how the Pentraxins characteristic pentavalent structure 
could facilitate multivalent binding interactions as part of a function in the innate 
immune system.  
 
An oft cited example of multivalent binding is the binding of Shiga toxins from E. coli 
to glycolipids on the surface of host cells. Shiga toxins are composed of six components 
in an AB5 structure where the B5 component has a pentameric symmetry (Figure 1.13; 
Ling et al., 1998). Shiga-like toxins are responsible for millions of deaths from bacterial 
infections every year making it a popular drug target (Holmgren and Svennerholm, 
1992). Monovalent therapeutics bind with only modest affinities, but multivalent 
analogues display greatly enhanced affinities capable of inhibiting binding to cell 
surfaces (Kitov et al., 2000). Kitov et al. used a monosaccharide as the central core and 
alkyl chains to link five monovalent trisaccharide ligands into a single binding entity. 
The wide ranging potential applications means that a plethora of scaffolds have been 
developed for multivalent ligands. 
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Figure 1.13. a) The STARFISH Shiga-like toxin inhibitor molecule developed by Kitov et al., 2000. b) 
STARFISH bound to the B5 subunit of Shiga-toxin 1 (SLT1) in an arrangement suggested by the authors. 
Cartoon representation of SLT1 with each subunit denoted by different colour. Figure adapted from Kitov 
et al., 2000. 
 
1.5.4. Design of multivalent ligands 
Multivalent ligands need to present multiple headgroups in an environment and 
orientation that is amenable to simultaneous binding by receptors on the surface of the 
target protein. Typically, this requires a scaffold to which the headgroups can be 
chemically-linked without modification of the key functional groups of the monovalent 
analogue. However, there are examples of self-assembling multivalent scaffolds, which 
maintain their structure by non-covalent interactions between building blocks such as 
peptides, DNA and micelles (Matsuura, 2013). There are also examples that combine 
the two methodologies, such as the use of liposomes to present multiple copies of 
multivalent saccharide ligands developed by Qu et al. (2014).  
 
As discussed in the previous section, the design of a multivalent ligand should allow 
adequate size and flexibility to bridge the distance between multiple binding sites, so as 
to minimise steric strain. The design will also be significantly influenced by whether the 
ligand is intended to bind through an intra- or intermolecular mechanism. For 
intramolecular binding interactions targeting a 1:1 binding ratio, multivalent ligands 
should be designed to maximise the effective concentration, to discourage 
intermolecular binding and increase the probability of rebinding. 
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As a result of the design considerations above, multivalent ligands typically consist of a 
central core with linkers of specified length emanating outwards to a headgroup at their 
extremities capable of interacting with a binding site from the target. The number of 
headgroups is determined by the number of binding sites targeted and the length of the 
linkers dependent on the distance between the binding sites. Flexibility is a 
consideration in the design of a multivalent ligand (Kane, 2010), and the vast majority 
of multivalent scaffolds found in the literature have flexible linkers, although the central 
core may be rigid (Mammen et al., 1998; Boas and Heegaard, 2004). 
 
Covalently-bound chemical architectures are most relevant for SAP, as bivalent forms 
of monovalent ligands linked with hexanoyl chains have already shown significant 
promise as therapeutics. Much of the focus in designing multivalent ligands is on choice 
of the central scaffold (Mammen et al., 1998). It has been reported that rigidification of 
the central scaffold can be detrimental to the ligands function, as it prevents ligands 
adopting the ideal geometry for simultaneous interaction with all binding sites (Deniaud 
et al., 2011). However, rigidity is known to be an advantage if it is used to fix the 
scaffold in the optimal geometry for binding (Vrasidas et al., 2003). For this reason, a 
number of multivalent ligands use rigid central scaffolds or structures known to 
maintain a particular shape. As previously mentioned Kitov et al. (2000) developed 
Shiga-like toxin inhibitors, which have a central saccharide unit to maintain a roughly 
pentameric symmetry. Oligosaccharides, such as cyclodextrins also offer rigid structures 
with controllable substitution (Figure 1.14; Gomez-Garcia et al., 2005).  
 
Rigid architectures are not limited to saccharide-based structures. Fullerene-based 
structures are one interesting application in which the rigid covalent structure can be 
used to fix the arrangement of ligands displayed on the surface (Isobe et al., 2003).  
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Figure 1.14. Examples of rigid central scaffolds utilised for multivalent ligands a) cyclodextrin based 
ligands developed by Gomez-Garcia et al. (2005), b) cyclic decapeptide with rigidity provided by proline 
residues, which induce fixed β-turns, Renaudet and Dumy (2003), c) multivalent ligand using a fullerene 
to maintain the desired pentameric structure developed by Isobe et al. (2003). 
 
Peptides are another class of biomolecule used in rigid scaffolds for multivalent ligands, 
despite the fact that peptides are not typically thought of as having well-defined 
secondary structures. Renaudet and Dumy (2003) showed that careful placement of 
proline residues in the amino acid sequence of a cyclic peptide can produce a rigid 
architecture. In their investigation they synthesised a peptide with rigidity conferred by 
the presence of two β-turns to fix the conformation and ensure the four ligands were 
presented on the same face of the central scaffold. In contrast, Zhang et al. (2004) 
showed that it is not always necessary to specifically include residues known to increase 
rigidity. Zhang et al. synthesised multivalent Cholera toxin inhibitors synthesised cyclic 
peptides with repeating (AAn-K)5 sequences that demonstrated a 100,000-fold affinity 
gain over the corresponding monovalent ligand. They also performed computer 
simulations to show that the molecules maintained an expanded cyclic structure. 
Furthermore, they concluded that it was not important to present ligands on the same 
face of the central scaffold providing the arms used to link the ligands to the central 
scaffold were sufficiently long and flexible.  
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The multivalent examples given so far target a specific number of binding sites. 
However, there are a number of structures, which aim to present the maximum number 
of ligand headgroups to increase the chances of a successful interaction and maximise 
the probability of statistical rebinding. Perhaps one of the most well-known examples 
are the multiple antigen presenting (MAP) peptides reported by Tam (1988) for use in 
synthetic peptide vaccines. MAP peptides are more an example of dendrimers, which 
are a popular basis for presenting a high density of ligands (reviewed by Boas and 
Heegaard, 2004).  
 
The chemical nature of the linker does not generally garner as much attention as the 
scaffold, instead the length is considered the critical feature (Deniaud et al., 2011). 
Polymeric materials such as polyethylene glycol are common constituents of linkers, 
most likely due to their increased solubility over simple alkyl chains (Deniaud et al., 
2011); although, there are also many examples using diamino-based polymeric 
materials, particularly in the synthesis of dendrimer multivalent ligands (Boas and 
Heegaard, 2004). The Starburst
TM
 dendrimers developed by Tomalia et al. (1985) are a 
classic example and also show the combination of diamino compounds and amino acids, 
specifically β-alanine. Therefore, research of the literature supports a flexible linker, 
with suitable solubility properties, which does not engage in specific interactions with 
the target and can be ligated to both the headgroup and a central scaffold. The 
headgroup should provide binding specificity and a moderate affinity, both of which 
will be enhanced in a multivalent ligand. Finally, the central scaffold should be 
relatively rigid that maintains the ideal geometry for multiple simultaneous interactions 
with the target's binding sites. 
 
1.5.5. Multivalency for SAP 
The structure of the Pentraxins look almost as if they are the result of natural receptor 
clustering with multiple identical receptors presented in a pentameric symmetry with 
strong non-covalent interactions between protomers (Emsley et al., 1994). The current 
theory of SAP binding to amyloid deposits also relies on clustering of multiple 
monovalent ligands presented in configuration amenable to multivalent recognition by 
SAP (Pepys et al., 1997). SAP does not bind to amyloid proteins in their native, soluble 
state. This may be due to the fact that the refolding needed for amyloid proteins to form 
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their characteristic cross-β structure exposes a new motif that SAP recognises. 
Alternatively, it may simply be that for SAP recognition, a motif conserved after 
refolding of the amyloid protein needs to cluster with other SAP binding motifs to allow 
binding to occur with sufficient affinity. 
 
Considering the homopentameric structure of SAP, it is difficult to contemplate binding 
to amyloid deposits occurring in anything other than a multivalent manner. However, 
this does not mean that SAP is binding the same ligand in each binding site or even that 
all binding sites are occupied. SAP is known to bind to a range of molecules found in 
amyloid deposits and the exact composition of the binding motifs for SAP may vary 
within the same amyloid deposit, let alone between deposits of different amyloid 
proteins (Pepys et al., 1997). 
 
1.6. Project Aims 
The aim of this investigation was to synthesise a range of multivalent ligands for SAP 
that exploit the expected cooperative binding of the protein's five identical subunits. The 
novel non-covalent cross-linking of SAP by CPHPC has been shown to have a greatly 
increased binding affinity over monovalent N-acetyl D-proline, so linking five CPHPC 
into a single molecule capable of simultaneous interaction with ten subunits from two 
SAP pentamers was also of significant interest as this could further improve the binding 
affinity. Therefore, the ligands would need to present pentameric symmetry, but with a 
flat structure that does not prevent close association of two pentamers with a multivalent 
ligand in the middle. This thesis documents the synthesis and characterisation of 
multivalent ligands for SAP conducted between 2010 to 2014. It also describes x-ray 
crystallographic studies of monovalent ligand N-acetyl D-proline binding to SAP to 
understand the exact interaction of the chosen headgroup for the multivalent ligands. 
Additionally, the x-ray crystal structure of Rat C-Reactive Protein (rCRP) is presented 
in complex with bivalent ligand CPHPC. rCRP is has been the focus of a number of 
previous crystallographic studies due to its unusual structural features compared to other 
pentraxins. However, it has not been possible to obtain satisfactory data until now, and it 
is theorised that the use of novel bivalent ligands was a significant factor in overcoming 
previous difficulties. 
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Chapter 2. X-ray crystal structure of Serum Amyloid P 
component in complex with N-acetyl D-proline 
 
2.1. Introduction 
Over the past two decades significant efforts have been made to discover small 
molecule ligands capable of binding to SAP in a calcium dependent manner. Since the 
protein's discovery, it has been known that SAP is prevalent in amyloid deposits 
(Cathcart et al., 1967). In 1995, Tennant and co-workers identified SAP's role in 
stabilising amyloid fibres and preventing proteolysis. SAP coats amyloid fibres, 
preventing recognition and removal by the immune system. This makes therapeutics 
capable of stripping SAP from amyloid deposits desirable drug targets in the treatment 
of amyloidosis.  
 
No amyloid motif capable of binding to SAP has yet been identified, but numerous 
small molecule ligands for SAP have been identified and there are several crystal 
structures reported in the literature of SAP co-crystallised with a range of ligands 
including acetate, phosphoethanolamine, MOβDG (Emsley et al., 1994), dAMP 
(Hohenester et al., 1997), N-acetyl D-proline (Purvis thesis, 2002), N-acetyl L-proline 
(Kolstoe et al., 2014), CPHPC (Purvis thesis, 2002; Jenvey thesis, 2006; Kolstoe et al., 
2014). 
 
CPHPC is a bivalent ligand capable of non-covalently cross-linking two SAP pentamers 
to form a decamer (Pepys et al., 2002). CPHPC is currently under development as a 
treatment for amyloidosis (Kolstoe and Wood, 2010). Sustained treatment of patients 
with CPHPC results in sustained >95% depletion of circulating SAP by hepatocytes 
(Gillmore et al., 2010). Despite binding to SAP with a low nanomolar dissociation 
constant (Kolstoe thesis, 2005), CPHPC cannot remove SAP bound to amyloid deposits. 
So an anti-SAP antibody can be used to locate directly to the amyloid deposit and 
highlight its presence to the immune system, which rapidly clears the mis-folded protein 
(Bodin et al., 2010). Understanding the mechanics of the binding interaction between 
CPHPC and SAP is essential for intelligent development of treatments for amyloidosis, 
and for the design of multivalent ligands that mimic the action of CPHPC. Crystal 
structures of SAP with CPHPC have been attained (Purvis thesis, 2002; Jenvey thesis, 
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2006), but there is some ambiguity surrounding the nature of the ligand interaction with 
amino acid residues adjacent to the calcium binding site. 
Figure 2.1. a) Bis D-proline compound, CPHPC. b) N-acetyl D-proline, NADPro. 
 
SAP binds to small molecule ligands in a calcium-dependent manner. This interaction is 
further improved when the small molecule has a non-polar functional group capable of 
fitting into the small hydrophobic pocket adjacent to the calcium binding site. The D-
proline headgroups of CPHPC bind with the pyrrolidine ring fitting tightly into the 
hydrophobic pocket formed by Leu62, Tyr64 and Tyr74 from SAP (Purvis thesis, 2002). 
However, it is unclear whether the binding interaction extends beyond the calcium 
binding site and the hydrophobic pocket. The carbonyl group of the hexanoyl chain in 
CPHPC is known to be in close proximity to the phenyl side chain of Tyr64, but there is 
no conclusive evidence in the literature that demonstrates the presence or absence of a 
hydrogen bond between the two functional groups.  
 
N-acetyl D-proline (NADPro) is not restrained by the hexanoyl chain that is present in 
CPHPC (Figure 2.1), therefore the crystal structure of NADPro in complex with SAP 
should show if any preference exists between the cis and trans conformation for the 
carbonyl oxygen of the acetyl group when the ligand is unrestrained by other functional 
groups. A low resolution crystal structure of NADPro has previously been collected but 
as it is limited to a resolution of just 2.4Å (Purvis thesis, 2002), the electron density map 
is not sufficiently detailed to discern if any preference exists between the cis and trans 
isomers of the ligand's acetyl group. For this purpose, a high resolution structure of 
NADPro in complex with SAP was sought. If the acetyl is shown to form a hydrogen 
bond with SAP then it would be beneficial to formulate CPHPC in the cis/cis 
conformation such that any energy barrier to the binding of SAP is minimised, 
alternatively it may be beneficial to design a new compound to exploit this interaction. 
Furthermore, a detailed understanding of the nature of SAP ligand interaction is crucial 
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to design multivalent ligands capable of binding to SAP with the maximum binding 
affinity. 
 
2.2. Methods and Results 
 
2.2.1. Crystallisation of SAP with N-acetyl D-proline 
SAP was purified from human sera in Professor Sir Mark Pepys’s laboratory (London, 
UK) according to the procedure outlined by Hawkins and co-workers (1991). In brief, 
SAP is isolated from sera of healthy donors by calcium-dependent affinity 
chromatography using a phosphoethanolamine (PE) sepharose column. The column is 
equilibrated with TC buffer (10mM Tris, pH 8.0, 140mM NaCl, 2mM CaCl2, 0.1% w/v 
NaN3), followed by elution with TE buffer (10mM Tris, pH 8.0, 140mM NaCl, 10mM 
EDTA, 0.1% w/v NaN3). SAP is then concentrated by ultrafiltration and dialysed 
against TN buffer (10mM Tris, pH 8.0, 140mM NaCl, 0.1% w/v NaN3). 
 
N-acetyl D-proline (NADPro) was purchased from Bachem AG (Bubendorf, 
Switzerland). SAP was co-crystallised with NADPro by hanging drop vapour diffusion 
at 4
o
C. In this method, microlitre drops of protein-ligand solution are mixed with similar 
volumes of a crystallisation cocktail on a siliconised coverslip. The mixed drop of 
protein/cocktail solution is suspended by surface tension above a 1ml well of the 
crystallisation cocktail in a sealed environment (Figure 2.2). Crystallisation cocktails 
are designed to induce slow precipitation of a protein over time. Typically they contain a 
precipitant, such as polyethylene glycol, buffer, salts, additives and cryoprotectants. The 
protein drop contains a lower concentration of precipitant than the well solution, so 
water diffuses through the vapour phase from the drop to the well solution. As the drop 
shrinks, the concentration of protein slowly increases until it reaches a supersaturation 
point and precipitates from solution. If the rate of precipitation is gradual enough, then 
the protein can precipitate in a crystalline form; the protein solubility diagram in Figure 
2.3 illustrates how the protein solubility changes with changing protein and precipitant 
concentration, as a vapour diffusion experiment proceeds, the volume of the solvent 
containing the protein shrinks. As the solvent volume decreases the protein 
concentration increases, ideally to the point that it reaches the nucleation phase of 
Figure 2.3, at this point crystallisation may begin, reducing the concentration of protein 
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in the aqueous phase to the metastable point where crystal growth may continue.  
Figure 2.2. Diagram of hanging drop vapour diffusion crystallisation experiment. 
 
Figure 2.3. Protein solubility diagram. Graph demonstrates how the protein solubility changes with 
increasing concentration of protein and precipitant. During a vapour diffusion experiment, the volume of 
the aqueous solvent decreases in the protein drop, leading to an increase in both protein and precipitant 
concentration, ideally this brings the concentration of protein into the nucleation phase, at which point it 
begins to crystallise (Image taken from http://www-
structmed.cimr.cam.ac.uk/Course/Crystals/Theory/phase_diag_zones.html). 
 
Crystallisation of proteins is not trivial and it is not possible to predict the conditions 
required to produce crystals for x-ray diffraction experiments when dealing with a 
never-before crystallised protein. Typically, an effort to crystallise a protein ab initio 
utilises a sparse matrix screen in which 96 conditions used to successfully grow crystals 
of unrelated proteins are tested with the target protein (Page et al., 2003). Methods for 
crystallising SAP are widely available in the literature, so conditions described by 
Purvis (thesis, 2002) were chosen to co-crystallise SAP with NADPro using a grid 
Chapter 2. X-ray crystal structure of Serum Amyloid P component in complex with N-acetyl D-proline 
 
51 
screen to refine the published parameters. A grid screen typically alters two variables, 
such as precipitant concentration and pH, in a linear fashion centred around previously 
determined conditions (McPherson, 1982). Small differences in the crystallisation 
cocktail can greatly influence the quality of crystals produced. A grid screen is a useful 
way of varying crystallisation conditions in a narrow range to optimise “hits” from a 
sparse matrix screen. Crystals of NADPro-SAP were obtained using 10.1mg ml
-1
 
protein with a 20-fold molar excess of NADPro at 4
o
C with 15% w/v PEG 550 MME, 
60mM Tris buffer, pH 7.5, 84mM NaCl, 10mM CaCl2 and 18% v/v glycerol.  
 
X-ray crystallography experiments are typically performed at 100K. Modern 
synchrotrons produce powerful radiation capable of generating radical species within 
the crystal, which can damage the protein, leading to rapid deterioration of the crystal at 
room temperature (Garman, 1999). Cooling crystals in a stream of cold nitrogen gas 
during data collection reduces the thermal motion of radical species produced by x-ray 
radiation. However, the cryo-cooling process can induce ice formation that destroys the 
protein crystal. It is often necessary to add a cryoprotectant to the crystallisation cocktail 
to prevent ice crystals forming. The cryoprotectant can be added directly to the 
crystallisation cocktail prior to the vapour diffusion experiment, or after crystallisation 
by soaking the protein crystal in a drop of well solution containing the desired 
cryoprotectant. In this experiment, crystals of SAP were obtained using a crystallisation 
cocktail that already contained 18% v/v glycerol and this proved sufficient to prevent 
ice formation upon cryo-cooling. 
 
Crystals of SAP-NADPro were removed from the crystallisation drop in a small amount 
of mother liquor using a nylon loop. The loop was immediately plunged into liquid 
nitrogen and stored at 100K prior to data collection. 
 
2.2.2. X-ray diffraction data collection 
X-rays are electromagnetic radiation with wavelengths between 100Å to 0.1Å first 
identified by Wilhelm Conrad Röntgen in 1895. Henry and Lawrence Bragg were the 
first to realise that x-rays were scattered by the periodic arrangement of atoms in a 
crystal (Rupp, 2010). Furthermore, they discovered that the intensity and angle at which 
x-rays are scattered by a crystal is directly related to the position and identity of the 
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atoms within the crystal. By recording the diffraction pattern produced by a crystal from 
multiple different angles, it is possible to calculate the exact position of the atoms, or 
more specifically, pinpoint areas of electron density within the crystal.  
 
X-rays are absorbed by atoms, causing oscillations in electrons, which then emit 
radiation of the same wavelength as the absorbed radiation. Waves emitted from a single 
atom combine with those emitted from all other atoms in the unit cell. The unit cell of a 
protein crystal is the minimum repeating unit needed to replicate the entire crystal 
structure by repeated lattice translations. As the emitted radiation can be thought of as a 
2-dimensional sine wave, the phase or relative displacement of the wave along the x-
axis is important. Waves with the same displacement are “in-phase” and combine 
constructively, increasing the amplitude of the combined wave, whereas waves with 
opposite phases combine destructively, reducing the combined amplitude. Only 
diffracted x-rays where the partial waves combine in a constructive manner result in a 
reflection that appears as a spot on a diffraction pattern which can be recorded and 
measured by a detector. Placing a photon detector in-line with the x-ray source and the 
crystal allows accurate measurement of the intensity of diffracted waves that can be 
used in subsequent investigations to solve the crystal structure of a protein. 
 
X-ray diffraction data was collected on beamline I03 at Diamond Light Source, DLS, 
(Didcot, UK). DLS is a third generation synchrotron which accelerates electrons in a 
vacuum to >99% the speed of light using electromagnets. Powerful electromagnets 
maintain the electron's speed and synchronous path (Figure 2.4; Rupp, 2010). As the 
path of the electron changes, it emits energy in the form of electromagnetic radiation. 
Insertion devices, such as wigglers and undulators, can be inserted into a synchrotron to 
produce an even more intense beam of radiation by causing rapid oscillation in the 
electron's path. The beam of radiation is passed through a series of mirrors and slits to 
produce a finely collimated beam of monochromatic x-rays, which are used by a 
beamline in diffraction experiments (Figure 2.5). 
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Figure 2.4. Diagram of Diamond Light Source Synchrotron (Didcot, UK). 1. Electron gun. 2. Booster 
ring. 3. Storage ring with bending magnets to maintain synchronous path. 4. Monochromator for selecting 
single wavelength of radiation. 5. Experimental hutch containing crystal mounting and data collection 
apparatus. 6. Beamline control room. Image adapted from: 
http://www.diamond.ac.uk/PressOffice/MediaResources.html on 27/04/2014 
Figure 2.5. Diagram of a typical synchrotron beamline. Shows the undulator which stimulates emission 
of intense x-ray radiation by electrons as they pass through the insertion device. A series of mirrors and 
slits selects a single wavelength used in the diffraction experiment. Image taken from 
hhttp://www.diamond.ac.uk/Beamlines/Mx/I03/Beamline-Schematic.html on 27/04/2014 
 
Upon exposure of the crystal to the x-ray beam, a diffraction pattern is produced, which 
can be recorded by a detector. In recent years, synchrotrons have replaced their charge-
coupled device (CCD) detectors with Pilatus Hybrid Pixel detectors leading to a 
significant change in data collection methodologies (Brönnimann et al., 2003). The x-
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ray diffraction data for the SAP-NADPro crystals were recorded on a CCD detector, but 
subsequent chapters will present data collected using Pilatus detectors. CCD detectors 
consist of a thin fluorescent film that absorbs x-ray radiation and emits visible light, 
which is carried along a fiber glass taper leading to a CCD semiconductor array where 
free electrons are generated. This produces an electrical signal proportional to the 
number of photons detected, so the exact photon count can be stored digitally as a 
measure of the diffraction spot intensity.  
 
 
Figure 2.6. Charge-coupled device x-ray detector. An x-ray strikes the fluorescent surface of the detector 
causing emission of visible light proportional to the number of electrons responsible for producing the 
detected x-ray, which travels down a fibre optic taper to a charge coupled device which measures the 
intensity of the visible light and stores the photon count for later analysis (Image taken from: 
proteincrystallography.org Date: 8/5/2014) 
 
Monochromatic radiation of known wavelength is essential for crystallographic studies 
to facilitate the determination of atom spacing using Bragg's equation. 
 
 
 
nλ = 2d sin θ 
 
 
Figure 2.7. Left: Bragg's law where n is an integer, d is the spacing between diffraction scattering planes 
and θ is the diffraction angle of the wave relative to the lattice plane. Right: representation of incoming x-
ray being diffracted by two parallel planes of atoms within a crystal.  
Chapter 2. X-ray crystal structure of Serum Amyloid P component in complex with N-acetyl D-proline 
 
55 
Bragg's law visualises reflections as occurring on sets of parallel lattice planes within a 
crystal. As previously discussed, diffracted waves emanating from the crystal must be 
in-phase for them to combine constructively and result in a signal at the detector for a 
particular reflection. Bragg's law defines the interplanar spacing necessary for two 
waves of wavelength, λ, and diffraction angle, θ, to produce maximum constructive 
interference. Each spot recorded by the detector is the combined wave produced by the 
diffraction contribution of every atom in the unit cell. The structure factor, Fhkl, is a 
complex function that can be calculated by Fourier summation of the diffraction from 
all atoms in the unit cell with a magnitude proportional to the square root of the 
intensity of a diffraction spot (Rupp, 2010).      
 
𝐹ℎ𝑘𝑙 =∑𝑓𝑗𝑒
2𝜋𝑖(ℎ𝑥𝑗+𝑘𝑦𝑗+𝑙𝑧𝑗)
𝑛
𝑗=1
 
 
The structure factor equation sums the diffraction contributions of all atoms, where fj is 
the scattering contribution of atom j. i is the imaginary number (-1)
1/2
, x, y, z are the 
fractional coordinates of the atom in the unit cell and h, k, l are the coordinates of a 
reflection in the reciprocal lattice produced by a set of parallel planes within the crystal. 
The atomic scattering factor, fj, treats atoms as spherical regions of electron density 
where the magnitude of the contribution to the overall structure factor is related to the 
number of electrons it possesses. Therefore, the amplitude of the diffracted wave from 
one atom is determined by the number of electrons. The exponential part of the equation 
shows the fractional displacement of atom j along each unit cell axis, indicating that the 
phase is related to the position of the atom within the unit cell. The amplitude of the 
waves that produced a particular reflection on the diffraction pattern can be obtained 
from the data because it can be shown that the square root of the intensity recorded for a 
spot on the diffraction pattern is proportional to amplitude. However, the phase is not 
recorded by the diffraction experiment and therefore must be determined separately. 
 
 
 
 
 
Equation 2.1 
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2.2.3. Data quality assessment 
Once the crystal had been loaded onto the synchrotron beamline, two diffraction images 
separated by a 90
o
 rotation of the crystal were collected to determine the spacegroup of 
the crystal and whether the crystal could produce diffraction data of sufficient quality 
for data collection. The diffraction pattern of the first x-ray exposure is pictured below. 
 
Figure 2.8. Diffraction image of NADPro-SAP crystal NAD3. 
 
Manual inspection of the diffraction pattern indicated that the crystal diffracted to a 
resolution of at least 1.5Å with the indexing program Mosflm determining the mosaicity 
to be 0.77
o
 (Powell, 1999). The maximum resolution is the minimum interplanar 
spacing for which reflections can be recorded and mosaicity refers to the relative 
displacement of repeating units within the crystal. The crystal can be thought of as a 3-
dimensional mosaic of unit cell blocks, which when well aligned produce sharp, narrow 
peaks on the diffraction pattern. If however the unit cells are not well aligned and the 
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mosaic spread is high then a single reflection may persist over a number of sequential 
diffraction images. The peak profiles in a crystal with high mosaicity appear smeared 
making it difficult to accurately determine the maximum peak height and index the 
reflection. The mosaicity of the NAD3 crystal was less than 1.00
o
 so was considered 
usable for x-ray diffraction. Processing of the two images with Mosflm indicated a 0.5
o
 
oscillation angle was required for each frame to prevent reflections overlapping onto 
multiple frames. In total 360 images were collected using 25% transmission of the 
synchrotron beam and a 0.5
o
 oscillation angle to record 180
o
 of diffraction data with a 
maximum resolution of 1.4Å. 
 
2.2.4. Data processing 
The raw diffraction data collected from DLS was processed using Mosflm. The first 
stage of data processing is to index reflections from the diffraction pattern and assign 
the unit cell of the crystal. A unit cell's dimensions are given by axes a, b and c and 
angles α, β, and γ. Each unit cell can be assigned to 1 of 14 Bravais lattices based on 
their dimensions and translational symmetry (Rupp, 2010). Symmetry operations such 
as rotations and screw axes allow identical motifs within the unit cell to be 
superimposed upon each other. The asymmetric unit is the smallest motif in the unit cell 
that can be used to replicate the entire unit cell contents through its symmetry 
operations. Combining all possible symmetry operations with the 14 Bravais lattices 
gives rise to 65 spacegroups in which a protein can crystallise. Mosflm and other data 
processing programs are used to determine the spacegroup in which the protein 
crystallised. 
 
Each set of planes within the unit cell that act as sources of diffraction, as defined by 
Bragg's law, produce a reflection at a particular angle. The concept of the reciprocal 
lattice can be used to determine the position at which a particular reflection will be 
detected. Each real-space lattice point is related to a corresponding point in the 
reciprocal lattice. If a vector from an arbitrary origin with coordinates (0, 0, 0) to the 
real-space lattice point has a magnitude of dhkl, then magnitude of the corresponding 
reciprocal lattice point will be 1/dhkl. Reciprocal lattice points are produced by 
diffraction from a set of parallel planes within the real-space lattice. Miller indices, hkl, 
indicate the frequency with which a set of planes intersect a particular axis, for example 
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a set of planes with miller indices (5, 3, 4) intersects the a-axis 5 times, the b-axis 3 
times and the c-axis 4 times. Each set of parallel planes produces one spot which can be 
assigned coordinates hkl in the reciprocal lattice. Mosflm can calculate the unit cell 
dimensions by treating reciprocal lattice points as vectors between the origin and each 
reflection (Powell, 1999). To determine the spacegroup, Mosflm selects approximately 
200 reflections from 1 or more diffraction images using a peak search routine that 
includes choosing reflections with suitable signal-to-noise, I/σ(I), ratio. The selected 
peaks are then used to compute the smallest triclinic cell with minimal symmetry. The 
basic cell is then compared to the 64 other possible space groups by distorting the unit 
cell dimensions and comparing the expected position of reflections for a given space 
group against those observed in the diffraction pattern. A penalty score is applied to 
each unit cell based on the results, with the space group of the highest symmetry, but 
lowest penalty generally selected. Table 2.1 shows the results of the spacegroup 
determination routine in Mosflm. The solution before the first big increase in penalty 
scores is generally selected as the correct cell symmetry, in this case the monoclinic 
primitive spacegroup from solution 3. 
 
   Unit cell dimensions 
Solution Lattice Penalty a (Å) b (Å) c (Å) α (o) β (o) γ (o) 
1 aP 0 71.1 94.9 99.7 96.9 89.9 90.1 
2 aP 0 71.1 94.9 99.7 83.1 89.9 89.9 
3 mP 1 94.9 71.0 99.7 90.0 96.9 90.0 
4 mC 41 146.0 129.1 71.1 90.0 90.2 90.0 
5 oC 42 129.0 145.6 71.2 90.0 90.0 90.0 
6 mC 42 128.9 145.6 71.1 90.0 90.2 90.0 
 
Table 2.1. Mosflm unit cell determination results for SAP-NADPro crystal prior to full data collection. 
Chosen solution highlighted in blue. 
 
P21 was indicated as the correct spacegroup based on the results of the indexing 
procedure, with unit cell dimensions of a = 94.42Å, b = 70.56Å , c = 99.06Å α = γ = 
90.00
o
 β = 96.90o after cell refinement. The data was integrated in Mosflm to estimate 
the intensity of each reflection with an associated error after subtracting the background 
noise. Integration is achieved by drawing a box around the area of a diffraction image 
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where a reflection is predicted by the spacegroup and measuring the intensity of the 
peak while subtracting the background signal recorded by pixels neighbouring the 
reflection spot. This process reduces the data from many individual image files into a 
single reflection, MTZ, file.  
 
The program ViewHKL (Evans, 2006) reads MTZ files and can be used to view the 
recorded reflections along different planes in the reciprocal lattice. Symmetry elements 
in the unit cell cause some reflections to be absent from the diffraction pattern. In the 
case of spacegroup P21 the two-fold screw axis dictates that certain reflections have 
symmetry mates with exactly opposite phases, which leads to perfect annihilation of the 
signal and the absence of a reflection in the diffraction pattern. Each spacegroup has 
specific conditions for systematically absent reflections, for spacegroup P21, each 
reflection along reciprocal axis, k, where k = 2n will be absent (Kopský and Litvin, 
2010). ViewHKL can be used to see if systematic absences are observed on the expected 
planes and thereby validate the choice of spacegroup. Figure 2.9 shows the hk0 plane of 
the NADPro-SAP data and Figure 2.10 is an enhanced image showing the 0k0 plane 
with the expected position of the absent reflections circled. These figures show absent 
reflections in the expected positions, therefore it is highly likely that P21 is the correct 
spacegroup for the NADPro-SAP crystal. 
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Figure 2.9. Precession image of NADPro-SAP diffraction intensities of the hk0 plane. 
 
 
Figure 2.10. Enhanced precession image viewing the 0k0 plane. Red circles show the systematic 
absences at intervals of k = 2n caused by symmetry elements of the P21. 
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2.2.5. Merging and Scaling 
The integrated data were scaled and merged in SCALA (Kabsch, 1988) from the CCP4 
suite of programs (Collaborative Computer Project 4; Winn et al., 2011). During data 
collection a number of factors can cause the measured intensities to vary and as such 
they are not on the same scale (Evans, 2006). Factors affecting the recorded intensity 
include variation of incident x-ray beam intensity and radiation damage. Scaling 
compares symmetry related reflections to calculate and apply appropriate correction 
factors to minimise the difference between their measured intensities. Once scaled, it is 
possible to identify the resolution limit and any bad regions in the data. Internal 
consistency in the data can be measured with R-factors such as R-merge, R-rim and R-
pim. R-merge, also known as R-sym, is the most inferior of the R-factors as it does not 
adjust for multiplicity, which is multiple measurements of the same symmetry-related 
reflection. Having multiple observations of the same reflection should result in 
increased precision of the measurement, but R-merge increases with increasing 
multiplicity (Weiss et al., 1997). R-rim (a.k.a. R-meas) and R-pim correct for increased 
multiplicity and are therefore more instructive (Diederichs and Karplus, 1997).  
 
The merging R-factors are defined as: 
 
𝑅𝑚𝑒𝑟𝑔𝑒 =
∑ ∑ |𝐼(ℎ)𝑖 −
𝑁
𝑖=1ℎ 𝐼ℎ̅|
∑ ∑ 𝐼(ℎ)𝑖
𝑁
𝑖=1ℎ
 
 
𝑅𝑟𝑖𝑚 =∑(
𝑁
𝑁 − 1
)
1/2∑ ∑ |𝐼(ℎ)𝑖 −
𝑁
𝑖=1ℎ 𝐼ℎ̅|
∑ ∑ 𝐼(ℎ)𝑖
𝑁
𝑖=1ℎ
 
 
𝑅𝑟𝑖𝑚 =∑(
1
𝑁 − 1
)
1/2∑ ∑ |𝐼(ℎ)𝑖 −
𝑁
𝑖=1ℎ 𝐼ℎ̅|
∑ ∑ 𝐼(ℎ)𝑖
𝑁
𝑖=1ℎ
 
 
The merging R-factors take N number of observations of the intensity I of reflection h 
and calculate the difference between each observation and the average recorded 
intensity for the reflection. A high R-merge value can also be an indication of incorrect 
indexing, an R-merge covering all reflections in excess of 60% could be an indication 
Equation 2.2. 
Equation 2.3. 
Equation 2.4. 
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that the wrong spacegroup has been selected. In this scenario, the reflections on the 
diffraction pattern would deviate from their expected location causing a high variability 
in the observed intensities. For NADPro-SAP, the R-pim averaged over all reflections 
was 3.6% further supporting the assignment of P21 as the correct spacegroup. 
 
SCALA outputs merging statistics for each resolution shell of the data, Table 2.2 
provides a summary of the statistics for SAP-NADPro crystal NAD3. There is little 
agreement within the crystallographic community about the correct way to determine 
the resolution limit of diffraction data. But, a signal-to-noise ratio, I/σ(I) > 2.0 in the 
highest resolution shell is good indicator of the strength of recorded reflections. R-
factors can be calculated for reflections within different resolution ranges to give an 
indication of the internal consistency for particular parts of the diffraction pattern. 
Weaker, high resolution reflections invariably have higher merging R-values due to the 
low signal-to-noise ratio and this can be used to judge a potential resolution cut-off to 
prevent noise being included in the dataset. The NAD3 dataset shows an R-pim of 
38.5% in the highest resolution shell with an I/σ(I) of 2.6 indicating that diffraction may 
have been detectable beyond 1.5Å, however this was not apparent during data collection 
and therefore, no attempt was made to collect reflections of higher resolution. An 
analysis of the resolution of crystallographic data for structures deposited in the protein 
data bank reveals (www.rcsb.org/pdb) that the resolution of the NAD3 data is in the 90
th
 
percentile of all deposited structures, so it is not too concerning that the resolution limit 
is conservative. Overall completeness was acceptable, >95%, and the multiplicity is 
high at 7.0 considering the relatively low symmetry of spacegroup P21. 
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Parameter Crystal NAD3 
Space Group P21 
Unit Cell Dimensions a = 94.42, b = 70.56, c = 99.06 Å β = 96.90o 
Resolution Range 28.66 – 1.50 Å 
No. of Reflections 1 392 596 
No. of Unique Reflections 198 644 
Multiplicity 7.0 (6.9) 
Completeness (%) 96.5 (91.0) 
Rpim 0.036 (0.385) 
(I)/σ(I) 14.1 (2.6) 
Wilson B-factor 14.6 
Refinement  
Molecular Replacement Model 1SAC 
No. of Residues 1020 
No. of Solvent Molecules 962 (Water), 5 (GOL) 
No. of Ligand Molecules 5 (NAD), 10 (Ca), 5 (NAG) 
Rmsd Bonds 0.007Å 
Rmsd Angles  1.26
o
 
Residues in Favoured Regions (%) 98.17 
Residues in Disallowed Regions (%) 0 
Average B-factor  
Protein 14.72 
Ligand 24.77 
Solvent 28.87 
R-factor (%) 15.47 
R-free (%) 16.76 
 
Table 2.2. Processing and refinement statistics for SAP-NADPro crystal, NAD3. Figures in parenthesis 
denote results for the highest resolution shell (1.58-1.50 Å). 
 
2.2.6. Molecular replacement and the Phase Problem 
Equation 2.1 demonstrates how all atoms within the unit cell contribute to every spot on 
the diffraction pattern. A structure factor for each reflection observed on the diffraction 
pattern can be calculated by Fourier summation of the diffractive contribution of all 
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atoms in the unit cell. As each reflection can be viewed as diffraction of x-rays by a 
particular set of parallel planes in the crystal, only the atoms that lie on that set of planes 
with contribute constructively to the signal recorded by the detector. Viewing each 
structure factor as a complex wave, the structure factors from all reflections can be 
combined and Fourier transform used to construct a map of the electron density that 
produced the observed diffraction pattern. Performing the Fourier transform is 
analogous to a lens focusing visible light in a standard microscope.  
 
𝜌(𝑥, 𝑦, 𝑧) =
1
𝑉
∑∑∑𝐹ℎ𝑘𝑙𝑒
−2𝜋𝑖(ℎ𝑥+𝑘𝑦+𝑙𝑧−𝛼′ℎ𝑘𝑙)
𝑙𝑘ℎ
 
 
The Fourier transform in Equation 2.5 shows the method for calculating the electron 
density, ρ(x, y, z) at coordinates x, y, z, where V is the volume of the electron density, 
|Fhkl| is the amplitude of a structure factor with Miller indices h, k, l and phase α'hkl. As 
previously mentioned the amplitude can be calculated from the intensity measured by 
the detector, but the phase must be obtained by other means. 
 
There are a variety of methods for solving the phase problem. Molecular replacement is 
one such method, applicable to proteins whose structures have already been solved by 
x-ray crystallography and can be downloaded from the Protein Data Bank. In molecular 
replacement, the coordinates of a previously determined structure are used to calculate 
new initial phases for the new experimental data. The coordinates of the model structure 
are translated into the new asymmetric unit and new phases calculated based on the 
position and orientation of the protein. The calculated phases are then input with the 
observed amplitudes into calculated structure factors, Fcalc, and the results compared to 
the values for the experimentally observed structure factors, Fobs. Phases are calculated 
for many different orientations of the protein in the asymmetric unit; the result that 
gives the smallest difference between the calculated and observed data is selected as the 
best solution and used as the initial phase estimates for structure refinement. In the case 
of human SAP, the structure has already been solved by protein crystallography (Emsley 
et al., 1994). Coordinates for the SAP crystal structure 1SAC were downloaded from 
the PDB. The coordinate file was edited to remove all cations and ligands; leaving only 
the SAP pentamer as the search model. Firstly, the number of molecules in the 
Equation 2.5. 
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asymmetric unit was estimated based on the cell volume and the molecular weight of 
the protein, the CCP4 program Matthews determined that one SAP pentamer was 
present with a probability of 99% (Matthews, 1968). Based on this estimation the 
molecular replacement program, Phaser (McCoy et al., 2007) was used to search for a 
single copy of SAP in the asymmetric unit.  
 
Phaser utilises Maximum Likelihood (ML) algorithms to determine new coordinates for 
the search model within the unit cell. ML is a branch of statistics that calculates the 
likelihood of a model given the data defined as the probability of the data given the 
model (McCoy et al., 2007). For molecular replacement this means calculating phases 
based on the coordinates of the model within the asymmetric unit and determining the 
probability of observing those phases based on the data. This is achieved by first 
periodic rotations of the search model within the asymmetric unit and then translating 
the correctly orientated model to give a set of coordinates most likely to produce the 
observed data. The rotation and translation searches are performed separately because it 
dramatically reduces the computational load of molecular replacement to a level that 
can be handled by desktop computers in a reasonable period of time.  
 
The most probable molecular replacement solution for the NADPro-SAP data was 
written into a PDB file containing the new coordinates and a new MTZ file containing 
the initial phase estimates. Phaser calculates log-likelihood gain (LLG) values to 
determine how much better the new coordinates for the search model represent the 
observed data compared to a random placement of atoms in the asymmetric unit 
(McCoy et al., 2007). A Z-score is then computed to show by how many standard 
deviations the LLG exceeds the average LLG of a set of randomly arranged atoms. A 
translation function Z-score (TFZ) of greater than 8.0 indicates a certain molecular 
replacement solution. For NADPro-SAP the molecular replacement solution output by 
Phaser had a LLG of 14690.3 and this corresponded to a TFZ of 72.9. 
 
The initial phases contain significant errors as they mostly represent the model structure 
used for molecular replacement. Repeating rounds of refinement of atomic coordinates 
and calculation of improved phases are employed to construct a model that best 
represents the electron density that produced the observed diffraction pattern.  
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2.2.7. Refinement 
The output molecular replacement solution is a PDB file with the coordinates of the 
search model placed in the new unit cell. The coordinates from the model allow 
calculation of phases, which when input into the structure factor equation allow 
generation of an electron density map. Errors between the calculated phases and the true 
phases of the experimental data are minimised through refinement. Refinement is 
performed through ‘reciprocal-space’ phase improvements and ‘real-space’ coordinate 
refinement. Refinement was performed using Refmac, CCP4 (Murshudov, 1997), while 
model building was performed using Coot (Emsley and Cowtan, 2004). Refmac utilises 
log-likelihood calculations to achieve a structure solution with the highest probability 
given the data. Log-likelihood uses Bayesian statistics that weigh experimental 
observations against prior information. Prior information includes biochemical 
knowledge about bond lengths, angles and non-crystallographic symmetry (NCS). 
Inclusion of prior knowledge is essential for protein crystallography because the data-
to-parameter ratio is low.  
 
Model parameters, such as x, y, z coordinates, can be refined based on experimental 
data, while the prior knowledge restraints, aims to prevent the model containing 
unrealistic chemical or geometric properties. SAP is a pentameric protein composed of 5 
identical subunits arranged radially, which means a 5-fold rotation axis runs through the 
centre of the pentamer. No crystal system has a 5-fold symmetry element, therefore the 
axis is non-crystallographic and can be used as a restraint in refinement. The subunits 
must have identical folds, but may differ in small elements such as the conformation of 
side chains and flexible loop regions. At the beginning of refinement tight NCS 
restraints were applied to improve the data-to-parameter ratio of the data when the 
phase error was at its highest, as refinement proceeded the NCS restraints were loosened 
to allow local deviations in the structure to be borne out. 
 
The output PDB file from MR was input into Refmac with the reflection MTZ file and 
refined as a rigid body to improve the initial placement of the pentamer in the 
asymmetric unit; this gave a starting R-work value of 33.64% and a R-free of 33.25%. 
The R-work is a measure of the agreement between the observed diffraction data and 
the diffraction data that would be expected based on the model (Brünger, 1992). 
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Brünger introduced the R-free value as a cross-validation statistic to highlight potential 
bias in the R-work caused by over-refinement. Prior to refinement, a small proportion of 
the experimental data (5% or 2500 reflections, whichever is lower) is selected as the R-
free set and omitted from use in refinement. As the R-free data is not used to calculate 
the phases for the electron density map it can be used as a less biased judge of the 
model's quality.  
 
The pentamer model and electron density maps were then observed as σA weighted 
2Fo-Fc and Fo-Fc maps (Read, 1986) using the molecular graphics program Coot 
(Emsley, 2004). Fo (Fobs) are the observed structure factors from the reflection, MTZ, 
file, while Fc (Fcalc) are the calculated structure factors based on the model. Molecular 
graphics programs, such as Coot, can display maps that highlight the differences and 
similarities between Fo and Fc to aid model building. The map showed 2 large spheres 
of difference density around Asp-138 for each protomer, this region is known to be the 
calcium binding pocket of SAP (Emsley et al., 1994). Therefore, 2 calcium ions were 
built into the spheres of difference density for each protomer, 10 in total.  
 
The subsequent rounds of alternating reciprocal-space restrained refinement and real-
space model building involved placing N-acetylglucosamine at Asn-32 of each subunit 
as previously reported (Tennent and Pepys, 1994), rebuilding flexible loop regions to 
trace electron density and the placement of solvent, water and glycerol molecules. The 
final R-work value for the refined model was 15.47% and 16.76% for the R-free. Root-
mean-square (RMS) values for bond lengths and angles are a simple method for 
determining deviation of the model from biochemical ideal bond geometry; for the 
NADPro-SAP structure, the final root-mean-square RMS Bond value was 0.007Å and 
the RMS Angle was 1.26
o
. 
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2.3. Discussion 
 
2.3.1. Crystal Packing 
The molecular graphics program PyMol (PyMol molecular graphics system, Version 1.3 
Schrödinger LLC) was used to demonstrate the packing of SAP pentamers in the crystal 
(Figure 2.11). The pentamers are stacked A-face to B-face in layers that are staggered by 
displacement of half a pentamer's width from the layer beneath both along and 
perpendicular to the plane of the paper. There are no large gaps between the pentamers 
indicating that molecular replacement found all the copies of SAP in the asymmetric 
unit. 
Figure 2.11. Crystal packing of SAP in crystal NAD3 with B-face of pentamer uppermost in all cases. 
Pentamers are coloured to clarify the different layers of protein molecules within the crystal. The unit cell 
is depicted by the blue outline. 
 
2.3.2. Protein Structure 
The refined SAP structure in this investigation conforms to those previously reported 
(Emsley et al., 1994; Srinivasan et al., 1994). The refined structure shows 5 identical 
protein chains arranged radially (Figure 2.12). Each protomer chain is folded into a 
flattened β-jellyroll topology. The β-jellyroll is formed by two anti-parallel β-sheets 
each 7 strands in length (Figure 2.13). In addition there is a short α-helix on the A-face 
of each pentamer and a calcium binding loop on the opposing B-face. These 
observations provide certainty that the desired protein was crystallised and that the 
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molecular replacement solution is correct. In order to validate this observation, a 
number of tools and calculations were employed to assess the model geometry and the 
consistency of the model with the observed electron density. 
 
Figure 2.12. A and B faces of NADPro-SAP structure in crystal NAD3. α-helix (red), β-sheet (yellow) 
and loops/flexible regions (green). 
 
Figure 2.13. Example of 2Fo-Fc electron density map (grey mesh, 1.8σ) generated from the NADPro-
SAP dataset and the protein model built within it as a ball and stick and cartoon representation. Pictured is 
part of two neighbouring β-strands containing cysteines that form the single disulphide bond in each SAP 
subunit. Model colours: β-sheet cartoon (green ribbon); ball and stick diagram: carbon (green), oxygen 
(red), nitrogen (blue) and sulphur (yellow).  
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2.3.3. Structure Validation 
 
2.3.3.1. Protein Geometry  
The bond lengths and angles are restrained during refinement, but some deviations from 
ideal geometry are expected due to steric strain imposed on bonds, protein folding and 
electrostatic interactions with neighbouring functional groups. Conversely, the low data-
to-parameter ratio of x-ray crystallographic data can lead to over-refined structures 
where unrealistic or impossible geometry is imposed upon the model by phase errors 
that manifest themselves as erroneous peaks in the electron density map. It is important 
to strike a balance between restraining and over-refining a structure and this can be 
achieved through monitoring R-factors and the aggregate RMS deviations from ideal 
bond lengths and angles. 
 
The difference between the R-work and the R-free is used to assess model bias. A 
general rule is that the R-free should be no greater than 5% higher than the R-work. In 
the case of the NADPro-SAP structure the final R-work value was 15.47% with an R-
free of 16.76%, this provides confidence that the model is not significantly biased due 
to over-refinement. 
 
RMS values for bond lengths and angles aggregated across the whole structure can be 
compared with other solved structures in the PDB. The acceptable upper limit of RMS 
values for bond lengths and angles is generally considered to be 0.02Å and 2.00
o
 
respectively, although there is no definite agreement on these values amongst 
crystallographers. The NADPro-SAP structure presented here is of reasonably high 
resolution, so there is more crystallographic data to influence the model by providing 
experimental observations for deviations from ideal geometry. Therefore with RMS 
bond length and angles of 0.007Å and 1.26
o 
respectively, the overall bond geometry of 
the NADPro-SAP structure can be considered reliable. 
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2.3.3.2. Ramachandran Plot 
The Ramachandran plot is a useful tool for assessing the geometry of the protein 
backbone (Ramachandran et al., 1963). The Ramachandran plot is a graph of the φ-ψ 
torsion angles between the N-Cα and the Cα-C' bonds of a peptide (see Figure 2.13). 
Ramachandran calculations are not used for refinement in Refmac so can be applied to 
unbiased validation of model geometry.  
Figure 2.14. Backbone torsion angles of a polypeptide chain. 
 
Ramachandran et al. (1963) observed that combinations of backbone torsion φ and ψ 
angles coalesced around a range of allowed values depending on the identity of the 
amino acid residue and its position within a polypeptide sequence. Plotting backbone 
torsion angles on a contour map reveals a number of forbidden regions which would 
bring atoms into too close contact. For ideal geometry all backbone torsion angles 
should be within the favoured regions of the plot. The Ramachandran plot for the 
general case of NADPro-SAP structure is pictured in Figure 2.15. The plot shows all 
residues in the allowed region of the plot and the vast majority within the favoured 
region. This shows that the protein backbone does not contain unrealistic geometry and 
is therefore not over-refined, nor does it contain areas where the main protein chain is 
under excessive strain. 
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Figure 2.15. Ramachandran plot for the general case of NADPro-SAP protein backbone torsion angles 
generated using the Molprobity server for all subunits (Chen et al., 2010). Light blue contour indicates 
favoured regions, dark blue contour indicates allowed regions. The Phi and Psi angles shown on each axis 
relate to the backbone torsion angles depicted in Figure 2.14. 
 
2.3.3.3. B-factor analysis 
The atomic displacement parameter or B-factor is an atomic scattering factor modifier 
that is used to account for displacement of electron density from its mean position due 
to factors such as greater thermal motion. Higher thermal motion is expected in flexible 
regions of a protein such as loops or disordered side chains. The average B-factor for a 
protein model tends to be proportional to the resolution of the data. Reciprocal space 
refinement programs, such as Refmac, increase the B-factor to compensate for areas of 
poor electron density in the map. This reduces the contribution from inaccurate phases 
and is crucial in minimising the error in the overall calculated phase.  
 
B-factors for particular residues or groups of residues can be compared to the average 
B-factor to identify problematic regions where the data is poorly described by the 
model. The cause of poor electron density can be high flexibility of residues or it could 
be a sign that parts of the model are built incorrectly. The average B-factor for the 
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protein atoms in the NADPro-SAP structure was 14.72. Figure 2.16 demonstrates the B-
factor per residue for each chain of the refined protein structure. Although the B-factors 
fluctuate significantly throughout each chain, there is no region that is systematically 
worse than the rest of the chain. The biggest deviations from the average B-factor are 
observed for residues 25-28, 55-57 and 122-130, which all correspond to flexible loop 
regions of SAP. 
 
Figure 2.16. B-factor per residue of each chain for NADPro-SAP structure. There is clear difference in 
the B-factors between Glu27, which is part of flexible loop region and Glu136, which is a crucial residue 
for metal binding. 
 
2.3.3.4. Binding site analysis 
The refined NADPro-SAP structure shows, each calcium ion is bound by a loop region 
on the B-face of SAP. The first calcium ion is bound by the side chain functional groups 
of Asp58, Asn59, Glu136 and Asp138, the main chain carbonyl of Gln137 with the 
carboxyl group of NADPro completing the coordination sphere of the metal ion (Figure 
2.17). The second calcium ion is more loosely bound with the protein coordinating the 
metal through the side chains of Glu136, Asp138 and Gln148. The rest of the 
coordination sphere is completed by two water molecules and the carboxyl group of the 
ligand. These observations are consistent with those made by Emsley et al. (1994). 
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Figure 2.17. Ball and stick representation of NADPro bound into the double calcium binding site of SAP. 
Left: 2Fo-Fc electron density map (grey mesh) of NADPro-SAP data drawn at 1.8σ). Clear density is seen 
for NADPro within the binding site with a T-shaped protrusion pointing towards the two calcium ions 
(limon yellow spheres) and the pyrrolidine ring fitting into the adjacent hydrophobic pocket. Right: image 
with red dotted lines show coordination of calcium ions. Black dotted lines show distances between 
carbonyl oxygen of acetyl of NADPro and Gln148 and Tyr64. SAP atom colours: carbon (turquoise), 
oxygen (red) and nitrogen (blue), red spheres (water). SAP Cartoon: β-sheet (yellow), α-helix (red) and 
loop (green); NADPro colours: carbon (green), oxygen (red) and nitrogen (blue). 
 
Prior to adding the ligand to the model there was a clear area of difference density for 
NADPro around the calcium binding site of each protomer that showed a ring structure 
and two T-shaped protrusions that were attributed to the acetyl and carboxylate of the 
ligand (Figure 2.17). Coordinates and restraints for the NADPro ligand were built using 
the Prodrg server (Schüttelkopf and van Aalten, 2004). NADPro coordinates the 
calcium ions through its carboxylate with the pyrrolidine ring fitting into the 
hydrophobic pocket (Figure 2.17). This arrangement is in agreement with previously 
reported binding of ligands with SAP (Purvis Thesis, 2002; Pepys et al., 2002). 
 
Despite the high resolution of the structure, the peaks in the electron density map for the 
ligand did not provide conclusive evidence over the proper orientation of the acetyl 
group of NADPro. Comparing the nature of the atoms in the acetyl group, oxygen has 8 
electrons and an electronegativity of 3.44 on the Pauling Scale (Housecroft and 
Constable, 2006), carbon has 6 electrons and an electronegativity of 2.55. Therefore, we 
would expect the carbonyl oxygen of the acetyl group to demonstrate a slightly higher 
peak in the electron density map than the carbon of the methyl group if there is a fixed 
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conformation. The calcium binding site of each subunit was observed separately and the 
electron density map redrawn at different standard deviation (σ) values to find the 
strongest areas of electron density for the acetyl group of NADPro. This method proved 
problematic as the differences between the intensity of the electron density map for each 
part of the acetyl group were minimal. For this reason, the process was repeated after 
calculation of an NCS difference map in Coot to show the average electron density 
distribution across the ligand (Figure 2.18). This showed unequivocally a larger peak for 
density trans to the Cα of NADPro, which supports the notion that the acetyl group 
favours the cis conformation when averaged across all subunits. 
 
 
Figure 2.18. Omit map of N-acetyl D-proline electron density calculated at sigma values between 2.5-4.0. 
A central ring with two T-shaped protrusions is clearly discernible when σ = 2.5. While most electron 
density has been lost by σ = 3.5, there is still clear electron density for the half of the acetyl group that is 
trans to the carboxyl group. SAP atom colours: carbon (turquoise), oxygen (red) and nitrogen (blue), 
calcium ions (lemon green spheres) water (red spheres). SAP Cartoon: β-sheet (yellow), α-helix (red) and 
loop (green). 
 
Beyond direct observation of the electron density map of the ligand, the refined 
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structure shows a number of amino acid residues in close proximity to the NADPro 
binding site that could influence the conformation of the ligand through electrostatic 
interactions. Prior to this investigation the phenyl side chain of Tyr64 was identified as a 
potential hydrogen bond partner for the carbonyl groups of NADPro and CPHPC.  
 
Hydrogen bonds form between a donor, which is an electronegative species with an 
attached partially-positively charged hydrogen that it can “donate”, and a species with a 
free lone pair of electrons capable of accepting the hydrogen. For hydrogen bond 
formation, the acceptor and donor species must be separated by a distance of between 
2.2-4.0 Å (Jeffrey, 1997). The strength of the interaction diminishes rapidly as the 
distance between the acceptor and donor increases. Using Coot, the average distance 
between the phenyl oxygen of Tyr64 and the carbonyl oxygen of the NADPro was 
measured to be 4.72 Å. Therefore, no hydrogen bond can exist between these two 
functional groups (Figure 2.17). However, it was observed that the side chain amide of 
Gln148 is an average distance of 3.85Å from the acetyl group of the ligand, which is 
close enough for a weak electrostatic interaction. 
 
2.3.5. N-acetyl D-proline as a headgroup for multivalent binding 
The crystal structure presented here demonstrates how N-acetyl D-proline binds to SAP 
when unencumbered by any other functional groups that could induce strain into 
protein-ligand interaction preventing the ligand from binding in the ideal conformation. 
These results also provide valuable information for designing multivalent ligands for 
SAP, in particular the choice of headgroup and the design of the linker used to ligate it 
to the rest of the molecule. The ideal multivalent ligand should preserve the binding 
geometry of the univalent headgroup, so it is important that the linker used to combine 
the 5 monomeric D-prolines into a single multivalent ligand is simple and does not 
contain bulky functional groups that could sterically hinder binding. Some weak 
hydrogen bonding character may be present between Gln148 and the acetyl group of 
NADPro. This may be retained in a multivalent ligand if the D-proline is attached to the 
rest of the construct through a peptide bond. However, the bond, if it does exist, is likely 
to make only a minor contribution to the binding affinity compared to the contribution 
from the di-metal coordination of NADPro's carboxyl group. Therefore, it is not 
imperative to make special considerations for a Gln148 hydrogen bonding group in a 
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multivalent ligand for SAP. The design need only ensure that the terminal residue is a 
D-proline presented with a free carboxyl group and the freedom to bind in its preferred 
conformation.  
 
All known ligands for SAP bind in calcium-dependent manner through either a carboxyl 
or phosphate group and N-acetyl D-proline is no exception (Emsley et al., 1994; 
Hohenester et al., 1997; Pepys et al., 2002; Purvis thesis, 2002; Mikolajek et al., 2011; 
Kolstoe et al., 2014). But the importance of the hydrophobic interaction between the 
pyrrolidine ring of NADPro and the side chains of Leu62, Tyr64 and Tyr74 should not 
be overlooked. Kolstoe measured the binding affinity for both D and L proline with SAP 
by Isothermal Titration Calorimetry, which showed D-proline to have a dissociation 
constant of 18.6μM, almost 20-fold stronger than the 322μM dissociation constant for 
L-proline (Kolstoe thesis, 2005). The high resolution crystal structure of NADPro-SAP 
presented here shows the key reason for this difference, the pyrrolidine ring interaction 
with the hydrophobic pocket of SAP. The structure of SAP in complex with N-acetyl L-
Proline (NALPro) downloaded from the PDB (PDB code: 4AVS) shows the pyrrolidine 
ring pointing away from the hydrophobic pocket (Figure 2.19), which is no doubt the 
cause of the reduced binding affinity. The tight fit of D-proline into the binding site of 
SAP provides encouragement that D-proline is the ideal headgroup to present to SAP as 
part of a multivalent ligand and for this reason it was used in the synthesis of 
multivalent ligands that will be presented in Chapters 4 and 5. 
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Figure 2.19. Calcium-dependent binding of D-proline (turquoise carbon atoms; PDB file: 4AYU) and L-
proline (magenta carbon atoms; PDB file: 4AVS) with SAP. 
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Chapter 3. X-ray crystallographic structure of rat C-reactive 
Protein in complex with bivalent ligand BPC8 
 
3.1. Introduction 
The exact function of the Pentraxins' in humans is not known, but SAP and C-reactive 
Protein (CRP) have become key targets in the development of therapeutics for 
amyloidosis (Pepys et al., 2002) and cardiovascular disease (Pepys et al., 2006), 
respectively. Elucidating the functions of the Pentraxins in humans is hampered by the 
fact that no deficiency or polymorphism of either protein has been reported, preventing 
an 'experiment of nature' to decipher their function (Pepys et al., 1997). However, 
investigations of structural differences in related proteins from other organisms can 
improve understanding of human pentraxins, particularly with regard to ligand binding 
specificity. 
Figure 3.1. The structure of phosphoethanolamine (PE; left) and phosphocholine (PC; right). 
 
The archetype ligand for human SAP (hSAP) is phosphoethanolamine, for CRP it is 
phosphocholine (Figure 3.1; Mikolajek et al., 2011). hCRP also binds to 
phosphoethanolamine, but hSAP shows no interaction with phosphocholine. In contrast, 
rat SAP (rSAP) has been observed in complex with phosphocholine by x-ray 
crystallography (Mikolajek thesis, 2008). The structure of the calcium-binding site is 
conserved between human and rat SAP, except for a single conservative substitution of 
Glu66 to Asp66 in rats. This single change moves a hydrogen bonded water molecule 
further from the calcium-binding site of SAP. This has been identified as a key residue 
in preventing phosphocholine binding by human SAP, thus demonstrating the value of 
investigating related proteins from animals. 
 
The other rat pentraxin, rat CRP also has a number of structural features that make its 
crystal structure worthy of investigation. rCRP is glycosylated by a single biantennary 
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oligosaccharide, which is common amongst SAP, but highly unusual for mammalian 
CRP (De Beer et al., 1982; Sambasivam et al., 1993). rCRP also has an extended C-
terminal amino acid sequence of LTDCCES (Rassouli et al., 1992). It has also been 
observed that two subunits per pentamer form an intermolecular disulphide bond 
between their extended C-termini, with the intramolecular disulphide bonds forming 
between the neighbouring cysteines on the remaining subunits. Intramolecular 
disulphide bonds formed between neighbouring cysteines are rare, but is known to 
occur in methanol dehydrogenase from Methylococcus capsulatus (Culpepper and 
Rosenzweig, 2014) 
 
As a result, numerous attempts have been made to crystallise rat CRP (rCRP; Hopkins 
et al., 1994; Mikolajek thesis, 2008). Despite the fact that claims of solving the x-ray 
crystal structure of rCRP have been made, the results remain unpublished (Shrive et al., 
1996). Difficulties in crystallising rCRP both ligand-free and in complex centre around 
a high degree of radiation sensitivity of crystals produced (Hopkins et al., 1994; 
Mikolajek thesis, 2008); to the point that diffraction is completely lost after just a few 
frames of data have been collected. Radiation damage from the x-ray beam afflicts all 
protein crystals, particularly when conducting diffraction experiments on modern 
synchrotrons which produce high energy x-rays (Ravelli et al., 2006).  
 
Radiation damage in crystallography is caused by absorption of photons by either the 
photoelectric effect (total absorption of the incident radiation leading to ejection of an 
inner shell electron) or Compton scattering (inelastic scattering of a photon, which can 
also cause emission of an electron; Garman, 2010). Inner shell electrons liberated by x-
ray absorption are able to travel along the protein backbone by quantum tunnelling and 
will localise at sites of high electron affinity. The mobility of liberated electrons means 
some amino acids show greater susceptibility to radiation damage and leads to local 
damage occurring in a reasonably predictable order. Local damage affects individual 
regions and bonds of a protein and occurs first through elongation and then breakage of 
disulphide bonds followed by decarboxylation of aspartate and glutamate residues and 
then breakage of C-S bonds of methionine side chains (Weik et al., 2000; Burmeister, 
2000). In contrast, global damage is a reduction of crystalline order caused by formation 
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of hydrogen bubbles in the crystal and with increasing x-ray exposure it manifests itself 
through changes in unit cell volume and mosaicity and loss of diffraction intensity 
(Teng and Moffat, 2000; Ravelli et al., 2002; Burmeister, 2000; Ravelli and 
McSweeney, 2000; Weik et al., 2000; Müller et al., 2002; Meents, 2009; Meents, 2010). 
The loss of periodicity is graphically demonstrated by images of crystals of bovine 
enterovirus 2 disintegrating during room temperature diffraction experiments reported 
by Axford et al. (2012; Figure 3.2) 
 
Figure 3.2. Crystal of bovine enterovirus 2. a) prior to exposure, b) after 0.5s exposure to upper right 
quadrant, c) after 0.5s exposure to upper left quadrant, d) after 0.5s exposure to lower left quadrant. Red 
cross-hair denotes position of x-ray beam for next exposure. Adapted from Axford et al. (2012). 
 
The extent of radiation damage is greatly mitigated by cryo-cooling crystals and 
performing diffraction experiments at 100K (Garman, 1999), but damage will still occur 
and some crystals will show greater susceptibility depending on a number of factors, 
Chapter 3. X-ray crystallographic structure of rat C-reactive protein in complex with bivalent ligand 
BPC8 
 
82 
 
such as the nature and packing of the protein. It has been shown that global loss of 
diffraction intensity is caused principally by formation of hydrogen bubbles within the 
unit cell, rather than through damage to residues involved in intermolecular contacts 
between proteins that facilitate the crystal packing (Meents, 2009; Meents, 2010). 
However, the exact crystal packing is still important and it is likely that increasing the 
number or strength of intermolecular contacts could produce crystals with longer 
diffraction lifetimes. Therefore, if cryo-conditions cannot sufficiently extend the 
diffraction lifetime of a crystal, then alternative crystallisation conditions should be 
employed to attempt to crystallise the protein in an alternative spacegroup with different 
crystal packing. This may require the addition of agents to crystallisation cocktails that 
are known to improve crystal resilience; divalent cations such as cadmium have been 
reported to be particularly effective additives (Trakhanov et al., 1998). However, 
producing diffraction quality crystals may still prove intractable and it may be necessary 
to return to sparse matrix screens to begin a de novo search for new crystallisation 
conditions. Ultimately, even successfully growing crystals in different crystallisation 
conditions may not improve diffraction lifetime if the crystal packing of the protein is 
inherently unstable. 
 
Co-crystallisation of bivalent ligands, CPHPC and dAMP with SAP produces crystals 
with unique packing arrangements that have not been observed in crystals of SAP in 
complex with univalent ligands. In theory, bivalent ligand, BPC8, which binds to human 
CRP through the same non-covalent cross-linking mechanism as CPHPC binding to 
SAP, should produce crystals of rCRP with unique crystal packing. A new crystal 
packing arrangement could result in different inter-protein contacts that overcome the 
radiation sensitivity observed by Hopkins et al. (1994) and Mikolajek (thesis, 2008). 
BPC8 should bridge strong non-covalent interactions between pentamers adding new 
intermolecular contacts that could increase stability of the crystal structure. This section 
describes the results of the crystallisation and the potential to use multivalency to solve 
crystallographic problems.  
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3.2. Materials and Methods 
 
3.2.1. Protein purification 
Rat CRP was isolated from normal rat serum by calcium dependent affinity 
chromatography with phosphoethanolamine covalently immobilized to carbohexyl 
Sepharose. After extensive washing with calcium-containing TC buffer 
(10mMTris/HCl, 140mMNaCl, 5mM CaCl2, pH 8.0) rCRP was eluted with 1mM 
phosphocholine in the same buffer. A second cycle of calcium-dependent binding to PC-
Sepharose was employed to concentrate the protein, which was finally eluted in TE 
buffer. rCRP was dialysed against TC buffer. Purity was checked by 8-18% SDS 
polyacrylamide gradient gel electrophoresis (purity > 99%). 
 
Bis-phosphocholine ligand, BPC8, was a gift from Prof. Pepys laboratory (London, 
UK). BPC8 is a bivalent molecule where two phosphocholine molecules are cross-
linked through a phosphate oxygen by an 8 carbon alkyl chain (Figure 3.3). 
 
Figure 3.3. bis-Phosphocholine ligand for CRP, BPC8. 
 
3.2.2. X-ray Crystallography 
Crystals of rCRP were grown by hanging drop vapour diffusion (McPherson, 1982) 
following extensive screening with different crystallisation cocktails containing varying 
excesses of BPC8. Harvested crystals were flash-cooled to 100K by plunging into liquid 
nitrogen using a nylon loop with the crystal suspended in a small quantity of mother 
liquor without additional cryoprotectant. rCRP diffraction data was collected on 
beamline I04 at Diamond Light Source (Didcot, UK). Data was processed using 
Mosflm (Powell, 2006) and programs from the Collaborative Computer Project 4 suite 
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(CCP4, 1994). Molecular replacement was performed using Phaser (McCoy et al., 
2007) with PDB coordinates 1B09 (Thompson et al., 1999). The rCRP-BPC8 complex 
was refined using Phenix (Adams et al., 2010). Model building was performed with 
Coot (Emsley and Cowtan, 2004). Coordinates for BPC8 were generated using the 
Prodrg server (Schüttelkopf and van Aalten, 2004), geometry restraints for the ligand 
were generated using Phenix.elbow. 
 
3.3. Results 
 
3.3.1. Protein crystallisation 
Crystals of rCRP were obtained from a stock solution of 6.1mg ml
-1
 protein in TC buffer 
by cocrystallisation with a 10-fold molar excess of BPC8 at 4
o
C. The protein-ligand 
solution was mixed with an equal volume of reservoir solution containing 150mM 
acetate buffer pH 5.0, 45% w/v 2-methane-2,4-pentanediol (MPD) and 50mM calcium 
chloride. Crystals appeared after 4 weeks, growing to maximum dimension of 0.3 x 0.1 
x 0.1 mm after 9 weeks. The concentration of MPD was sufficiently high for it to act as 
a cryoprotectant, so crystals were flash-cooled without addition of further 
cryoprotectant. 
 
3.3.2. Diffraction data collection and processing 
rCRP crystals were flash cooled in liquid nitrogen at 100K in a small quantity of solvent 
from the mother liquor prior to data collection. In view of previous reports of extreme 
radiation sensitivity, data was collected in two passes with low and then high beam 
attenuation. The two data sets were later merged into a single Mtz file during data 
processing. The methodology employed for collecting multiple datasets from a single 
crystal is controversial in the crystallographic community. It is often asserted that the 
high resolution pass should be performed first as these reflections are the first to be lost 
due to radiation damage. In light of previous investigations, radiation sensitivity was 
expected to be the limiting factor for all reflections. Therefore, the low resolution pass 
was performed first to acquire a complete dataset using just 20% transmission of the x-
ray beam. At the end of the first data collection, diffraction spots were still visible 
towards the edge of the detector, so a second pass was initiated to capture higher 
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resolution reflections using 100% transmission of the x-ray beam. Autoindexing in 
Mosflm recommended hexagonal space group P622 with unit cell dimensions of 
a=b=111.50Å, c=424.74Å and γ=120o at a maximum resolution of 3.2Å and mosaicity 
of 0.45
o
. Full dataset statistics are provided in Table 2. 
 
Figure 3.4. X-ray diffraction pattern of rCRP-BPC8 crystal during second data collection pass, using 
100% transmission of the beam collecting reflections extending to a maximum of 2.9Å using a CCD 
detector.  Bottom right: enlarged image of part of the centre diffraction pane showing the beamstop 
(lighter grey portion) with the centre of the beam within this space. The closely packed diffraction spots 
indicate at least one long unit cell axis. 
 
The high symmetry spacegroup was considered particularly beneficial as the rCRP 
crystals were expected to be highly radiation sensitive; the higher the spacegroup 
symmetry, the more reflections that are symmetry-related. Therefore, a smaller portion 
of reciprocal space needs to be sampled to obtain a full dataset of all measurable 
reflections, so x-ray exposure time can be kept to a minimum. In the first pass 120
o
 of 
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data were collected with a 1
o
 oscillation angle. In the second x-ray exposure of the same 
crystal, 180
o
 of data were collected using a 1
o
 oscillation angle as a safeguard against 
incorrect spacegroup determination by Mosflm. The merging and scaling of the two 
datasets was performed in Scala. The high symmetry of the spacegroup and the 
combination of two data collection runs gave a multiplicity of 34.5 overall and 35.9 in 
the highest resolution shell (3.37-3.20Å) and outer shell completeness of 99.6% with an 
I/σ(I) of 2.7. 
 
3.3.3. Molecular replacement 
The sequence homology between rat pentraxins and their human homologue is high, 
65% for rCRP (Lei et al., 1985; Woo et al., 1985; Table 3.1). Therefore, a previously 
solved structure for hCRP was used as the search model for molecular replacement of 
the rCRP data. Coordinate file 1B09 was downloaded from the Protein Data Bank 
(PDB) and edited to leave only amino acid residues from a single pentamer (Thompson 
et al., 1999). The Matthews coefficient (Matthews, 1968) for the structures indicated 
one pentamer per asymmetric unit with a solvent content of 58%. A molecular 
replacement solution was obtained using Phaser with an LLG of 493 and a TFZ of 11.8. 
A subsequent round of rigid-body refinement in Refmac gave an initial R-work of 
50.5% and an R-free of 52.55%. The R-factor for a collection of atoms placed randomly 
within the unit cell is 59% (Rupp, 2010), so the starting R-factors were high and this 
can be mostly likely attributed to the limited resolution of the data and the increased 
phase error from using the human homologue of the rCRP as the search model. 
However, the TFZ score of 11.8 indicates a certain molecular replacement solution and 
provides confidence that the pentamer was placed correctly within the unit cell and that 
1B09 was an appropriate search model. 
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CRP 10 20 30 40 50 
Homo Sapiens QTDMSRKAFV FPKESDTSYV SLKAPLTKPL KAFTVCLHFY TELSSTRGYS 
Rattus 
Norveigicus 
HEDMSKQAFV FPGVSATAYV SLEAESKKPL EAFTVCLYAH ADVS--RSFS 
 60 70 80 90 100 
Homo Sapiens IFSYATKRQD NEILIFWSKD IGYSFTVGGS EILFEVPEVT VAPVHICTSW 
Rattus 
Norveigicus 
IFSYATKTSF NEILLFWTRG QGFSIAVGGP EILFSASEIP EVPTHICATW 
 110 120 130 140 150 
Homo Sapiens ESASGIVEFW VDGKPRVRKS LKKGYTVGAE ASIILGQEQD SFGGNFEGSQ 
Rattus 
Norveigicus 
ESATGIVELW LDGKPRVRKS LQKGYIVGTQ ASIILGQEQD SYGGGFDANQ 
 160 170 180 190 200 
Homo Sapiens SLVGDIGNVN MWDFVLSPDE INTIYLGGPF SPNVLNWRAL KYEVQGEVFT 
Rattus 
Norveigicus 
SLVGDIGDVN MWDFVLSPDQ INAVYVGRVF SPNVLNWRAL KYETHGDVFI 
 210 220    
Homo Sapiens KPQLWP      
Rattus 
Norveigicus 
KPQLWPLTDC CES    
 
Table 3.1. Aligned amino acid sequences of human CRP and rat CRP. Highlighted residues show areas 
where sequences diverge, with blue representing a conserved change and red a non-conserved sequence 
difference. 
 
3.3.4. Refinement and model building 
A resolution of less than 3.0Å is considered to be a low resolution data set (Headd et al., 
2012). Low resolution structure refinement and model building is akin to looking at an 
out of focus photograph, although the general scene may be deciphered, the fine detail is 
lost. At 3.2Å, it is frequently impossible to determine the exact orientation of peptide 
bonds, side chain rotamers and in many cases there is no clear electron density for the 
side chains, particularly for Lys, Arg and Glu residues. The solution to this problem is to 
build the protein backbone with idealised geometry based on prior knowledge of 
biochemistry. Poorly resolved side chain rotamers are placed in their most common 
conformation, but with increased B-factors or reduced occupancy to account for the lack 
of electron density. Such steps can make the results represent more a study of ideal 
geometry with limited crystallographic observations added. However, there is little 
option when presented with limited experimental data. The main chain of the protein 
can often still be built with reasonable confidence, particularly for a short pentraxin, 
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whose subunits are characterised by a well-defined tertiary structure and short flexible 
loop regions.  
 
When refining low resolution data sets extra steps must be taken to prevent over-
refinement. As mentioned in Chapter 2, the data-to-parameter ratio in crystallography is 
poor, even for high resolution data sets (<1.5Å). At 3.2Å resolution this issue is even 
more acute, so special tools and parameter modifications must be utilised. Reciprocal 
space refinement of rCRP was performed using Phenix applying group B-factor 
refinement with NCS and TLS restraints. TLS (translation, libration, screw) restraints 
treat whole domains or regions of a protein structure as groups whose motion is 
correlated by the fact that they are bonded to one another, therefore their motion is 
restricted within a range of possible translations, libration and screw axes (Winn et al., 
2001; Rupp, 2010). This can greatly reduce the number of parameters needed to refine a 
protein structure, making it particularly effective for low resolution refinement. Using 
group B-factors is another way of reducing the number of parameters needed to refine a 
structure with limited x-ray data. Group B-factors treat neighbouring atoms, such as 
side chain atoms in Lys, as likely to exhibit similar freedom of movement, instead of 
each atom's B-factor being adjusted individually, they are adjusted by the same value 
regardless of the differences in their individual starting temperature factor values. 
 
The sequence of the protein model output from the molecular replacement was 
converted from human to rat in Coot using the mutate function to manually edit the 
amino acids based on the sequence of rCRP determined by Rassouli et al. (1992). The 
conversion of the amino acid sequence also required manual rebuilding of regions 
where the model deviated from the path plotted by the electron density map. The 
clearest example of this was the short loop between residues 44-50 (Figure 3.5). hCRP 
contains two extra residues Ser and Thr not present in the sequence of rCRP (Table 3.1). 
Ser45 and Thr46 were deleted from each pentamer using Coot, the chains were then 
renumbered using PDBSet and real space refinement of Ser44 and Arg45 performed to 
bring the two residues within bonding distance. Ten calcium ions were added to the 
structure in the cation binding pocket identified for CRP and metal coordination 
Chapter 3. X-ray crystallographic structure of rat C-reactive protein in complex with bivalent ligand 
BPC8 
 
89 
 
restraints were generated using phenix.readyset to assist positional refinement of the 
ions (Thompson et al., 1999).  
 
Figure 3.5. Stick representation of residues 42-46 of rCRP and the corresponding residues of hCRP. A 
key sequence difference in rCRP is the shorter loop between residues 42-46, hCRP has an extra Ser and 
Thr residue that are absent in rCRP. The original path followed by the hCRP search model (PDB: file 
1B09; magenta chain; atom colours: carbon (magenta), oxygen (red), nitrogen (blue)) deviates from the 
path of the electron density map (grey mesh; 1.5σ). The green ribbon shows the model tracing the 
electron density after manual rebuilding of the rCRP amino acid sequence in Coot (green chain; atom 
colours: carbon (green), oxygen (red), nitrogen (blue)). Image generated with Pymol. 
 
Five BPC8 ligands were built into the structure, but as the asymmetric unit contained 
only one pentamer, the ligand was built on a symmetry axis and therefore the occupancy 
was set to 0.5 to account for the symmetry-related ligand generated in each subunit as a 
result of the spacegroup (Figure 3.6). 
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Figure 3.6. Cartoon depiction of the x-ray crystal structure of rCRP-BPC8 complex. Left: Top-down 
view, right: side-on view showing BPC8 non-covalently cross-linking two pentamers. The cartoon 
depiction shows a β-jellyroll topology composed of two anti-parallel β-sheets (yellow) linked by short 
loops (green), with a short α-helix (red) on the A-face of each protomer. The asymmetric unit of the rCRP 
crystal contains only a single pentamer in spacegroup P6122. This means that a single decameric complex 
is placed either side of a two-fold rotation axis, the symmetry-related copy (red pentamer) was generated 
using the symmetry mate function in Pymol. BPC8 interacts with both pentamers either side of the 
symmetry axis, building the ligand into both binding sites generates a symmetry-related copy, resulting in 
two ligands per binding site in the model. As only one ligand can occupy a binding site at once, the 
occupancy is set to 0.5 and the symmetry copies treated as alternative conformers. Calcium ions are 
shown in magenta. 
 
Continuous rounds of real-space model building in Coot and refinement in Phenix gave 
a final R-free of 27.74% and an R-work of 22.95%. The rms angle value of 1.02
o
 and 
rms bond length of 0.01Å are half the upper limit outlined in Chapter 2, providing 
confidence that the geometry of the model has not be excessively influenced by the low 
resolution electron density, but equally the model shows some deviation from ideal 
geometry suggesting that the crystallographic data has influenced the model. The final 
model was analysed using the Molprobity structure validation server (Chen et al., 
2010). Molprobity analyses inter-atomic steric clashes, rotamers, Ramachandran angles 
and searches for unlikely bond geometry. As well as outputting data for each parameter, 
Molprobity aggregates the results of each parameter into a Molprobity score, which can 
be compared against all other structures of similar resolution deposited in the PDB to 
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give an indication of the model's relative quality. The rCRP-BPC8 model refined with 
riding hydrogens added had a clashscore of 12.3, which is in the 95% percentile, while 
the Molprobity score of 2.0 is in the 100
th
 percentile, in both cases a lower score 
indicates a better result. The results from Molprobity are listed in Table 3.3. 
 
Space Group P6122 
Unit Cell Dimensions a = 111.50, b = 111.50, c = 424.74 Å γ=120.00o 
Resolution Range 96.54 – 3.20 Å 
No. of Reflections 924 260 
No. of Unique Reflections 26 789 
Multiplicity 34.5 (35.9) 
Completeness (%) 99.7 (99.6) 
Rpim 0.05 (0.29) 
(I)/σ(I) 14.3 (2.7) 
Wilson B-factor 51.8 
Refinement  
Molecular Replacement Model 1B09 
No. of Residues 1020 
No. of Solvent Molecules 0 
No. of Ligand Molecules 5 (BPC8), 10 (Ca), 5 (NAG) 
Rmsd Bonds (Å) 0.01 
Rmsd Angles (
o
) 1.02 
Residues in Favoured Regions (%) 93.57 
Residues in Disallowed Regions (%) 0.20 
Average B-factor  
Protein 70.90 
Ligand 93.72 
Solvent N/A 
R-factor (%) 22.95 
R-free (%) 27.74 
 
Table 3.2. Processing and refinement statistics for rCRP-BPC8 crystal x-ray diffraction data. Figures in 
parentheses denote results for the highest resolution (3.37-3.20Å). 
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Clashscore 12.3 
Poor Rotamers (%) 0.82 (7 residues) 
Ramachandran Outliers (%) 0.20 (2 residues) 
Ramachandran Favoured (%) 93.57 (946 residues) 
Molprobity Score 2.02 
Cβ-deviations 0 
Bad backbone bonds (%) 0 
Bad backbone angles (%) 0 
 
Table 3.3. Results of Molprobity analysis of final rCRP-BPC8 model. The percentiles indicated for the 
clash and Molprobity scores are relative to all structures deposited in the PDB with resolution between 
2.94-3.44Å (N=1543). The Molprobity score is a combination of the clash score, Ramachandran and 
rotamer results normalised for the structures resolution, a detailed explanation of the criteria can be found 
in Chen et al., 2010.  
 
The Molprobity result, which causes the greatest concern is the low percentage of 
Ramachandran angles in the favoured region of the plot. Typically >98% is the targeted 
percentage of residues in the favoured region, but for the rCRP-BPC8 structure it is only 
94.57%. Furthermore, 0.2% of residues are outliers in the forbidden region of the plot. 
The lower Ramachandran favoured percentage is likely a by-product of the low 
resolution and the refinement program's attempts to closely match the poorly resolved 
electron density. Residues in loop regions are particularly prevalent in the allowed area 
of the Ramachandran plots, for example Ala84 from the loop region formed by residues 
83-90 is found in the allowed region for all subunits. This is expected as pentraxins are 
characterised by tightly associated secondary structure elements, which can impose 
strained geometry on the short loop regions linking the β-strands. The electron density 
map for residues 83-88 is shown in Figure 3.7 accompanied by the Ramachandran plot 
for the general case of residues in the rCRP-BPC8 structure, the position of each Ala84 
is highlighted occupying the allowed region of the plot for all subunits. The low 
resolution means the electron density is somewhat amorphous, looking more like a tube 
in which the protein backbone is contained (Figure 3.5), rather than the detailed contour 
map seen for NADPro-SAP in Chapter 2 (Figure 2.13). The poor definition in the 
electron density map makes it difficult to build the protein backbone with certainty. The 
refinement programs will refine the position of the backbone to give an acceptable fit 
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with the best geometry. Ramachandran angles are not used in refinement, so can act as a 
less biased judge of final model. It seems that efforts to accommodate the model within 
the amorphous electron density has led to compromises on ideal geometry, giving more 
regions that are “allowed”, but not necessarily “favoured” as Ala84 in Figure 3.7 
appears to show. It may be that these residues have strained backbone torsion angles by 
virtue of their position within the protein chain, but it cannot be known for certain from 
the rCRP-BPC8 data set due to the lack of definition in the electron density map. This 
limits the certainty of conclusions and means the electron density map and model built 
within should be viewed as a guide to the structure and side chains conformations 
viewed as the most likely result given the data. 
 
Figure 3.7. Left: 2Fo-Fc electron density map (grey mesh; contoured at 1.5σ) of residues 83-88 of chain 
B in rCRP-BPC8 generated in Pymol. Right: part of the Ramachandran plot for the general case of 
residues in the rCRP-BPC8 structure, the red arrow indicates the position of Ala84 from each subunit. 
The residues are seen within the allowed region (dark blue contour), but outside the favoured (light blue) 
portion of the plot. The low resolution of the data makes it difficult to determine the correct orientation of 
peptide bonds in the protein backbone, which may explain the lower % of backbone torsion angles falling 
into the favoured region of the Ramachandran plot as determined by Molprobity (Chen et al., 2010). 
Model colours: carbon (green), oxygen (red), nitrogen (blue), green ribbon is cartoon representation of 
protein structure. 
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3.4. Discussion 
 
3.4.1. Radiation damage 
The rCRP-BPC8 crystals still produced visible diffraction after a full dataset had been 
collected, overcoming the issue that plagued previous diffraction experiments. Special 
attention was paid to the extent of radiation damage during downstream processing of 
the diffraction data. If radiation damage was still an issue then it would be expected that 
the quality of diffraction would be impaired in the later diffraction images. Comparison 
of merging R-values for symmetry-related reflections on different diffraction images 
can be used to determine if crystals have been severely degraded by radiation damage. 
Radiation damage will diminish the intensity of previously recorded diffraction spots. A 
graph of merging R-values by image for a crystal affected by severe radiation damage 
will show an asymmetric, positive parabolic curve with values increasingly rapidly for 
later images. A graph of merging R-values against the image (batch) was plotted in 
Scala for the first data collection pass of the rCRP-BPC8 crystal (Figure 3.8). 
Figure 3.8. Graph of merging R-values for each image (batch) for rCRP-BPC8. Comparison of 
differences in intensity of symmetry-related diffraction spots can be used to assess the extent of radiation 
damage. Radiation damage does not appear to have significantly impaired the quality of recorded data as 
the R-merge at the end of data collection does not exceed that of the first few images. Image generated by 
Scala. 
 
The graph of merging R-value against batch shows that the crystal has not suffered 
significant radiation damage. Larger R-merge values are seen for the first batches 
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because the population of data points is smaller, so outlying values are more influential 
on the average intensity. After reaching a minimum value, the R-merge increases as a 
result of progressive radiation damage. If the radiation damage is significant then the 
values will ramp up significantly and greatly exceed the values for the initial batches. In 
the case of the rCRP-BPC8 data, the later values were less than those recorded for the 
initial diffraction images, therefore radiation damage was not a limiting factor during 
data collection. 
 
The electron density maps were also investigated for signs of radiation damage. 
Scission of disulphide bonds and side chain degradation of glutamate and aspartate 
residues are commonly observed as a result of local radiation damage (Weik et al., 
2000; Burmeister, 2000). The limited resolution of the data means that many of the side 
chains of Glu and Asp are poorly resolved, so they are not reliable indicators of 
radiation damage. However, the electron density of the intramolecular disulphide bond 
formed between Cys36-Cys95 on each subunit were analysed for evidence of radiation 
damage. If radiation damage has caused scission of the disulphide bond then a negative 
electron density peak would be observed in the Fo-Fc difference map indicating that the 
electron density predicted by the model exceed the electron density observed in the data. 
Figure 3.9 shows the typical electron density map observed for the disulphide bond.  
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Figure 3.9. Electron density map of Cys36-Cys95 disulphide bond. 2mFo-DFc electron density map is 
represented by the grey mesh, Fo-Fc electron density “difference” map (red mesh indicating areas of the 
model where the expected electron density of the model differs from the observed data. Model atom 
colours: carbon (green), oxygen (red), nitrogen (blue), sulphur (yellow). There is no difference density 
around the disulphide bonds indicating that no significant bond scission was detected, suggesting 
radiation damage was not a significant issue for the rCRP-BPC8 x-ray diffraction data. There is a small 
region of negative difference density underneath the sheet, this was most likely caused by phase error in 
the structure factor calculations as there are no atoms are built into this region of the map. 
 
Red electron density in Figure 3.9 indicates an area where the electron density of the 
model differs from the electron density observed in the diffraction experiment. No red 
electron density is observed in the area occupied by the disulphide bond, indicating that 
they have not been significantly disrupted by exposure to ionising radiation. The 
importance of this observation should not be underplayed, as some disulphide bond 
scission is commonly detected in data collected for the pentraxins. The absence of any 
detectable disulphide bond scission shows that the rCRP-BPC8 crystals are relatively 
resistant to radiation damage, which is in contrast to previous observations of rCRP 
crystals. 
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3.4.2. Structure analysis  
The overall structure of rCRP remains consistent with the observations for the hCRP 
(Thompson et al., 1999). The protein consists of five identical subunits arranged in a 
pentagonal radial symmetry (Figure 3.6). The subunits have two anti-parallel β-sheets 
folded into a flattened β-jellyroll topology. A short α-helix is present on the so-called 'A-
face' of the subunit, while on the opposite 'B-face', there is a double calcium binding site 
in a shallow gutter formed by the curvature of one β-sheet. The protomers of rCRP 
show a slight rotation compared to those of hCRP with calcium binding site tipped 
approximately 2
o
 towards the central pore of the pentamer and a centre of rotation at the 
α-helix (Figure 3.10).  
Figure 3.10. Single protomer of rCRP (red) and hCRP (turquoise; PDB file: 1B09) viewed along the axis 
of the β-jellyroll. The protomer of rCRP is rotated by around 2o moving the calcium binding site at the top 
of the figure towards the central pore of the pentamer, with the centre of rotation at the α-helix at the 
bottom of the image.  
 
Two calcium ions, separated by 4Å are coordinated by an amino acid side chains from 
nearby loops (Figure 3.11). The phosphocholine ligands interact with the protein by two 
oxygens of the phosphate coordinating the calcium ions. The calcium binding 
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environment is slightly different to that of human CRP. The coordination of the first 
calcium ion is reduced by the substitution of Asp58 in hCRP by Phe58 in rCRP. 
Similarly, coordination of the second calcium ion is reduced from four amino acid side 
chains in hCRP to three in rCRP by replacement of Glu147 with Asp145. These 
differences are highlighted when Asp58 and Glu147 from hCRP (PDB file: 3L2Y; 
Mikolajek et al., 2011) are superimposed on the calcium binding site shown for rCRP in 
Figure 3.11a. Figure 3.11b shows clearly that the electron density for Asp145 points 
away from the metal binding pocket in the same way observed for SAP. Based on the 
fact that larger metal ions have been observed binding in the second calcium binding 
site for hSAP (Emsley et al., 1994), it is conceivable that because the coordination of 
both calcium ions are reduced in rCRP that both sites may be capable of binding larger 
metal ions. 
 
 
Figure 3.11. (a) The calcium binding site of rCRP in complex with BPC8 (green chain). Turquoise 
residues, Glu147 and Asp60, have been superimposed from hCRP (PDB: 3L2Y) (turquoise chain) to 
highlight the reduced coordination of both calcium ions (yellow) in rCRP compared with its human 
homologue. (b) 2Fo-Fc (Adams et al., 2010) electron density contoured at 1.5σ (grey) fitted with the 
double calcium binding site and surrounding residues. 
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3.4.3. Surface charge 
Diagrams of the surface charge of the A- and B-faces of rCRP and hCRP were generated 
using Pymol (Pymol Molecular Graphics System, Schrödinger LLC). The extent and 
nature of inter-protein contacts will influence packing and stability of crystals produced. 
Observing the differences between the surface charge distribution of rCRP and related 
pentraxins may highlight the cause of the radiation sensitivity observed in previous 
studies. Figure 3.12 depicts the surface charge on the B-faces of rCRP and hCRP, with 
Figure 3.13 depicting the charge on the A-faces. rCRP could be compared to other 
pentraxins as hCRP is not a simple protein to crystallise, crystals of hSAP that diffract 
to high resolution (<1.5Å) have been obtained. The highest resolution structure of hCRP 
deposited in the protein data bank is 2.5Å (PDB code: 1B09; www.rcsb.org/pdb). 
However, hCRP crystals do not typically suffer from the hyper radiation sensitivity 
observed for rCRP, so it seems an appropriate choice for comparison as it is most 
closely related human protein.  
Figure 3.12. Surface charge map of the B-faces of left: rCRP and right: hCRP. Red areas of the map 
indicate acidic residues, with blue the basic residues and white signifying non-polar residues. 
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Figure 3.13. Surface charge map of A-faces of left: rCRP and right: hCRP. Red areas of the map indicate 
acidic residues, with blue the basic residues and white signifying non-polar residues. 
 
There is a clear reduction in both positive and negative charges on the B-face of rCRP 
compared to its human homologue. This is clearest around the calcium-binding site of 
the protein, where fewer acidic residues at the surface make the site appear smaller. 
However, it is also clear that there are fewer basic surface residues and that the strength 
of the positive charge is less for rCRP than hCRP. This is most apparent towards the 
outer edge of the pentamer (Figure 3.12). In hCRP, a clear region of positively charged 
residues between the binding sites of neighbouring protomers make up a significant 
portion of the outer edge of the pentamer. In rCRP, the same area of the pentamer is a 
mix of mildly basic, mildly acidic and non-polar residues that cannot be clearly defined 
as an either positively or negatively charged region. 
 
The A-faces of both proteins depicted in Figure 3.13 shows a more complex patchwork 
of small areas of alternating positive and negative charge. It is difficult to make clear 
inferences from the maps, but it appears that rCRP shows more areas of strongly acidic 
residues than hCRP. This is particularly pronounced at the outer edge of the pentamer 
where two small areas of negative charge are discernible either side of the small 
positively charged region at each vertex of the pentamer. Analysis of the crystal packing 
shows how the surface charge distribution has influenced inter-protein contacts. 
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3.4.4. Crystal packing 
The packing of rCRP in the crystal is greatly influenced by the presence of the bivalent 
ligand. BPC8 induces decamer formation through non-covalent cross-linking rCRP in a 
B-face to B-face configuration (Figure 3.6). There are no significant interactions 
between surface residues on the opposing B-faces of the decamers. It is difficult to 
conclude whether this is because it is energetically unfavourable or because the length 
of the central alkyl chain of the ligand prevents closer contact between pentamers in the 
decameric complex. Although, it would be expected that if there were a number of 
favourable B-face to B-face interactions then the flexibility of the alkyl chain would 
allow it to fold, bringing the pentamers into closer contact. Therefore, it seems 
reasonable that no favourable contacts exist between opposing rCRP B-faces when 
decamerised by BPC8. 
 
The use of BPC8 means that any inter-protein contacts between neighbouring decamer 
complexes are limited to the A-faces and outer edges of the protomers. Using molecular 
graphics program, Pymol, it is possible to generate the crystal packing of rCRP-BPC8 
pentamers (Figure 3.14). The decamers appear as if arranged in long twisting non-
covalent chains, with each decamer rotated by 45
o
 from the previous pentamer. This 
requires multiple inter-decamer contacts at the outer edge of the complex. Four 
protomers from each decamer are involved in inter-protein interaction with a 
neighbouring complex. The rotation of one complex relative to its neighbour means that 
two of the four protomers form two areas of interactions, with the other two forms only 
a single inter-protein interaction. The fact that the complex is a pentagonal prism means 
the chains of decamers pack into a twisted arrangement of decamers. 
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Figure 3.14. Crystal packing of rCRP decamers. Decamers appear as if formed into long twisted non-
covalent chains by interactions at the edges of protomers in neighbouring complexes. The rCRP 
pentamers are coloured depending on the chain to which they belong, BPC8 has been omitted for clarity. 
There is little interaction between red and green chains, but some interaction between the A-faces of two 
pentamers from different chains can be seen. 
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Figure 3.15. Example of the potential interprotein contacts formed between neighbouring decameric 
complexes. Left: surface charge map of a single rCRP pentamer generated in Pymol with close contacts to 
a neighbouring pentamer (magenta cartoon) highlighted by the blue box. Right: enhanced image of close 
inter-protein contacts between one pentamer (green ribbon, green carbons, red oxygens and blue 
nitrogens) and the neighbouring pentamer (magenta cartoon, magenta carbons, red oxygens, blue 
nitrogens). Red dashed lines show potential inter-protein contact bridged by a coordinated calcium ion 
(limon yellow; calcium ion may be present but electron density not of sufficient resolution to be built into 
model with certainty), blue dashed lines show potential hydrogen bonding.  
 
There seems to be little interaction between different decamer chains pictured in Figure 
3.14. Figure 3.14 depicts two separate arrangements of rCRP-BPC8 decamers. There 
appears to be only one point at which the red and green chains come into close enough 
contact for an inter-protein interaction. This interaction involves the A-faces of two 
pentamers, with close association of residues from two protomers of each pentamer 
(Figure 3.16). Generating a surface charge map shows that this interaction involves the 
mostly non-polar region (residues of one pentamer) interacting with the mostly basic 
region in the middle of the A-face of rCRP (Figure 3.13). It is expected that this 
interaction is mediated by solvent or small molecules from the crystallisation cocktail, 
which cannot be discerned in the electron density map due to its limited resolution. 
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Figure 3.16. rCRP A-face charge map interaction. Left: surface charge map of the A-face of one rCRP 
pentamer generated in Pymol, blue box shows area of close contact with the A-face of a pentamer from a 
separate decamer strand (turquoise cartoon). Right: enhanced image of potential inter-protein contacts 
(red dashed lines) between residues on the loop region of one pentamer (green cartoon, green carbons, red 
oxygens and blue nitrogens) and a loop region from another pentamer (turquoise cartoon, turquoise 
carbons, red oxygens and blue nitrogens). 
 
It is clear that the observed crystal packing would not be possible without the use of 
BPC8 because of the lack of interaction between the B-faces of rCRP pentamers 
involved in the complex. It would not be possible to form the rCRP decamers that are 
the basis of the crystalline structure. The A-face to A-face interactions would be 
possible in a crystal not containing decamers of rCRP, but it seems highly unlikely that 
this alone would stabilise crystal formation. From the successful data collection, it is 
possible to conclude that the use of cross-linking agent has produced crystals of rCRP 
with unique, stable inter-protein contacts. The ligand itself mediates stable inter-protein 
interactions and facilitates others by providing otherwise unobtainable decameric 
architecture. 
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3.4.5. Extended C-terminus 
Both rat pentraxins have a short extended C-terminal region compared with pentraxins 
from other species (Rassouli et al., 1992; Dowton and McGrew, 1990). rSAP is 
extended by the sequence NKSS, similar to the NKIS sequence present on Armenian 
Hamster SAP (Dowton and Waggoner, 1989). In contrast, the seven-residue C-terminal 
fragment of rCRP, LTDCCES, is highly unusual amongst mammalian pentraxins. The 
extended C-terminus of rCRP is reported to form three intra-molecular disulphide bonds 
per pentamer with the termini of the other two subunits forming intermolecular 
disulphide bonds. Non-reducing SDS PAGE gives two bands one around 25kDa 
corresponding to a single subunit and a 50kDA band corresponding to two subunits 
(Rassouli et al., 1992). The electron density at the C-terminus of the rCRP 
crystallographic data presented here is sparse and uninterpretable suggesting the region 
is highly flexible. Furthermore, no evidence was observed for an intermolecular 
disulphide bond, but this could be because the pentameric symmetry of the protein 
means there are five possible orientations for the single intermolecular disulphide so 
averaging over all orientations means none are visible at the limited resolution of the 
data. For this reason neither an extended C-terminus nor an intermolecular disulphide 
bond have been built in the rCRP model presented here. 
 
3.4.6. Complement activation 
hCRP activates the complement system by the classical pathway by binding C1q of the 
C1 complex through clefts on the A-face of each CRP protomer (Kaplan and Volanakis, 
1974; Agrawal and Volanakis, 1994). Complement activation occurs when the B-face of 
CRP binds to one of its ligands, such as chromatin, histones and nucleosome core 
particles. This strongly implies a role for CRP in coordinating the removal of nuclear 
material from dead or dying cells by phagocytes. Similarly, CRP is known to activate 
complement by binding to the C-polysaccharide of streptococcus pneumoniae 
potentially demonstrating its role in innate immunity (Abernathy and Avery, 1941). 
Oddly, it has been reported that rCRP does not activate complement when binding to C-
polysaccharide of streptococcus pneumoniae (de Beer et al., 1982). However, binding 
of rCRP to other ligands such as phosphocholine has been shown to activate 
complement (Padilla et al., 2003). These findings suggest that differences in the 
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structure of rCRP from hCRP prevent or reduce complement activation when binding to 
particular ligands. It could be that the ability to bind to foreign pathogens is lost, but the 
ability to bind nuclear material is retained.  
 
The cleft on the A-face for C1q binding contains a number of residues identified by 
mutagenesis as being important for complement activation by hCRP (Agrawal and 
Volanakis, 1994; Gaboriaud et al., 2003); in particular, residues Glu88, Asp112, Lys114 
and Tyr175. The analogous residues in rCRP are Glu86, Asp110, Lys112 and Tyr173. 
The rCRP-BPC8 structure was investigated to find any clear deviations with a structure 
of hCRP downloaded from the protein data bank (PDB code: 3KQR). Figure 3.17 shows 
the cleft on the A-face of rCRP with the residues of interest highlighted; superimposed 
are the key residues of hCRP with some surrounding residues included for clarity. It is 
apparent that the only noticeable difference in the position of these residues is between 
Glu86 of rCRP and Glu88 of hCRP. In hCRP, the loop of which Glu88 is a part bends 
towards the central pore of the pentamer. In contrast, the loop of rCRP stays closer to 
the surface of the protomer. This best displayed by the distance of the Cα of Trp65, 
which is part of a β-sheet, and Glu86, both of which are conserved in hCRP as Trp67 
and Glu88. In hCRP, the distance between the Cα is around 13Å, while in rCRP the 
distance is closer to 10Å. The shift in position appears to be caused by Pro88 on rCRP 
which causes the loop to fold towards the protomer. However, it must be considered that 
in both proteins this region is a loop and likely to show greater than average flexibility. 
The loops may be able to fold in different conformations, but x-ray diffraction recorded 
only a single conformation because the low temperature at which the data is collected 
reduces the thermal motion of the loop. It is therefore possible to suggest that this 
difference could affect the affinity of binding to C1q as it is the only key complement 
binding residue showing deviation in position from its homologous residue in hCRP. 
However, the suggestion is tempered by the limited resolution of the data and the 
position of Glu86 on a potentially flexible loop region of the protein. 
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Figure 3.17. Complement binding cleft of hCRP (magenta; PDB file: 1B09) and rCRP (green) with 
residues identified as important for complement binding, as identified by Gaboriaud et al., 2003, 
annotated. The grey mesh 2Fo-Fc electron density map shows how the position of the Glu86 loop in rCRP 
differs from the corresponding position determined for the crystal structure of hCRP in PDB file 1B09. 
 
Another structural difference that may influence the affinity of complement binding is 
the extended C-terminal LTDCCES region. As discussed in the previous section, there 
was no clear electron density in which to build the extended C-terminus of rCRP. It was 
concluded that this indicated high flexibility in the six residues. The final residue that 
could be built into the structure was Pro204, whose Cα is just 10Å from the Cα of 
Tyr173. It must therefore be considered that this highly flexible portion of the protein 
could obstruct binding in the complement binding cleft. Based on a backbone length of 
3.8Å per residue, the extended C-terminus could have an effective length of 22.8Å. In 
the case of LTDCCES, there is reportedly an intramolecular disulphide bond between 
the two cysteine residues causing a fold in the chain that would reduce the effective 
length, perhaps to between 11.4 and 15.2Å, which would still be long enough to reach 
Chapter 3. X-ray crystallographic structure of rat C-reactive protein in complex with bivalent ligand 
BPC8 
 
108 
 
the complement binding cleft. Cleavage of the extended C-terminus or removal by 
mutagenesis would show definitively whether the extended C-terminus does influence 
complement binding, but the crystal structure shows that it is in close enough proximity. 
 
There is significant variation between homologous pentraxins of different species in 
terms of behaviour as an acute phase protein, plasma concentration, glycobiology, 
ligand binding specificity and secondary ligand binding effects such as autoaggregation 
and complement activation (Baltz et al., 1982; Pepys and Baltz, 1983). X-ray 
crystallographic analysis of the rat pentraxins reveals how the subtle structural 
differences between pentraxins from different species can result in significant shifts in 
ligand binding specificity.  
 
The structure of rCRP described constitutes the first reported structure of the pentraxin 
from the rat. Previous observations of the high radiation sensitivity of crystals have 
been overcome. Further investigation is required to determine whether the use of 
bivalent ligands to non-covalently cross-link protein complexes has potential to solve 
similar crystallisation problems for other proteins. 
 
The structure of rCRP shows that the coordination of both calcium ions is reduced 
relative to its human homologue. Similar observations for SAP have been shown to 
allow larger metal ions to fit into the more loosely bound metal site (Emsley et al., 
1994). It is therefore possible to speculate that both metal binding sites rCRP may be 
capable of incorporating cations larger than calcium, although this would need to be 
confirmed experimentally. It might be suggested that for a calcium binding protein that 
circulates with a normal plasma concentration of around 450μg ml-1 the ability to 
incorporate a variety of metal ions would be of significant benefit to an organism such 
as the rat which has a highly varied diet and the constant bioavailability of calcium 
cannot be relied upon. 
 
Some of the other previously reported unusual structural features are not well resolved 
by the x-ray diffraction data; in particular, the glycosylation and the extended C-
terminus. Small amorphous different density is visible near glycosylation site Gln128 on 
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each subunit on the pentamer, but it is not possible to definitively place even a single 
saccharide unit. A similar situation is often seen in hSAP at lower resolution so this is 
not considered particularly unusual; a single saccharide unit at each glycosylation site 
has been built in the model for illustrative purposes, but with occupancy set to 0 in the 
PDB file. No evidence is present in the electron density maps for the extended C-
terminal amino acid sequence LTDCCES or the reported intermolecular disulphide 
bridge between two of the subunits' extended C-termini. It could be that this region is 
highly flexible, something supported by the similar situation seen for the NKSS 
segment at the C-terminus of rSAP, where the B-factors are substantially higher than 
elsewhere in the structure (Mikolajek thesis, 2008). Proline-204 is the final residue 
before the extended C-terminal section of rCRP. Pro-204 is 24Å from the nearest Pro-
204 on neighbouring subunits, so it may be possible for two seven residue fragments on 
neighbouring subunits to come into contact with sufficient overlap for disulphide bond 
formation, but there would not be much slack in the chain. We might expect this to 
cause visible distortion in the bond angles of Pro-204 to allow this overlap, but this has 
not been observed. More effort is required to determine whether there is a natural 
intermolecular disulphide bridge present in rCRP or whether it forms as an artefact 
during sample preparation for non-reducing SDS PAGE. 
 
3.4.7. Multivalent ligands as tools for crystallography 
It is expected that in previous studies the crystals of rCRP obtained involved pentameric 
protein complexes, seemingly as a result the crystals were highly sensitive to radiation 
damage. By forming decameric complexes radiation sensitivity has been overcome and 
while it is not possible to say that this is exclusive due to the use of bivalent cross-
linking agents, it is clear that their use has made different inter-protein contacts possible 
and provided strong non-covalent interactions that stabilise the decameric assembly. 
 
Further consideration should be given to the use of multivalent compounds to overcome 
crystallisation problems in x-ray crystallography. Multivalent ligands have been a 
feature of x-ray diffraction experiments involving the pentraxins for the past decade, 
with decameric structures of both SAP and CRP now known (Pepys et al., 2002; Ho et 
al., 2005; Kolstoe et al., 2014; CRP unpublished structure). These structures have 
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markedly different crystal packing and inter-protein contacts compared to structures in 
complex with univalent ligands. Comparison of the crystal packing between the crystal 
structure of SAP in complex with CPHPC (PDB file: 4AVT) and the pentameric SAP-
N-acetyl D-proline structure presented in Chapter 2 confirms that different inter-protein 
contacts exist when a bivalent ligand is used to non-covalently cross-link two SAP 
pentamers. 4AVT is a more representative comparison of structures because the 
crystallisation conditions used were similar to those used to crystallise the SAP-
NADPro structure, ruling out the possibility that different crystallisation conditions 
were responsible for the difference in inter-protein contacts. In NADPro-SAP, the 
crystal packing involves close contact between parts of the A-face and the B-face of 
SAP (Chapter 2, Figure 2.11). This is impossible in a decameric SAP complex because 
the B-faces of the protein are buried in the centre of the decamer.  
 
There is potential for the synthesis of multivalent molecules for a range of proteins 
whose structure remains undetermined or for which crystal structures are only available 
at limited resolution. Although, the resolution of the rCRP structure presented here is 
limited to 3.2Å, a decameric structure of SAP in complex with bivalent ligand CPHPC 
is deposited in the protein data bank with a resolution of 1.6Å (PDB code: 4AVV; 
www.rcsb.org/pdb). This shows that forming a larger decameric protein-ligand complex 
does not hamper the achievable resolution, but in the case of rCRP it does allow for 
successful diffraction experiments. 
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Chapter 4. Synthesis of multivalent ligands for SAP 
 
4.1 Introduction 
 
4.1.1. The design of multivalent ligands for SAP 
In addition to the design requirements determined in Chapter 2, there are a number of 
other key considerations for the synthesis of multivalent ligands for SAP. Firstly, the 
ligand needs to be water soluble for isothermal titration calorimetry and protein 
crystallisation studies. The designed molecule must be large enough to present 
headgroups to all five of SAP's binding sites simultaneously. Using the molecular 
graphics program, Coot (Emsley and Cowtan, 2004) it is possible to measure the 
distances between binding sites in SAP using crystallographic structure presented in 
Chapter 2. The double calcium binding site of each protomer is separated from the 
binding site on the neighbouring protomer by 20Å (Figure 4.1). The maximum distance 
between two binding sites is 68Å for the protomers on opposite sides of the pentamer. 
Drawing a circle whose circumference intersects all five binding sites it is possible to 
determine that a multivalent ligand would need a diameter of at least 56Å to target all 
five binding sites simultaneously. Finally, it is worth considering that many different 
ligands are known for SAP, so the multivalent scaffold and the synthetic strategy should 
be designed to allow ligation of different headgroups, if necessary. 
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Figure 4.1. Cartoon representation of SAP pentamer demonstrating distances between ligand binding 
sites. Image drawn with Pymol (Schrödinger LLC.) 
 
A multivalent ligand consists of three main parts. Firstly, the headgroup, which should 
be a univalent ligand that can easily be linked to other similar univalent ligands through 
a scaffold without compromising the mode of binding. Secondly, the scaffold, which is 
defined as the central component to which the headgroups are attached. Finally, the 
linker or arms used to link the headgroup to the central scaffold and provide sufficient 
separation between the headgroups and the central scaffold for simultaneous 
interactions with all binding sites of the target. The design choices made for each 
component will be briefly discussed.  
 
4.1.1.1. Headgroup design 
Chapter 2 demonstrated that D-proline was a suitable headgroup for a multivalent 
ligand targeting SAP. Furthermore, evidence from Pepys et al. (2002) shows D-proline 
to have moderate univalent binding affinity, which is greatly improved by creating a 
bivalent analogue. This investigation seeks both pentavalent and decavalent ligands for 
SAP using univalent ligand, D-proline and bivalent ligand, CPHPC developed by Pepys 
et al. (2002). CPHPC contains no functional groups that could conceivably be used to 
attach to a multivalent structure without affecting the efficacy of binding, so a slight 
modification is needed. Replacing the hexanoyl chain of CPHPC with aminoadipic acid 
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(hGlu) introduces an amino group which can be used for ligation to a multivalent ligand 
(Figure 4.2). Although the modification does introduces a chiral centre into the 
molecule, the addition of an amino group was considered to be an appropriate 
modification that minimised structural differences between the new amino-CPHPC 
structure and the original bivalent compound upon which it was based.  
 
Figure 4.2. Modified CPHPC headgroup amino-CPHPC, designed to allow ligation through the amino 
group while leaving the C-termini free to interact with SAP. 
 
4.1.1.2. Linker design 
The design of the linker was influenced by a number of factors. The NADPro crystal 
structure presented in Chapter 2 showed some evidence that the acetyl group of 
NADPro favoured a cis conformation with a weak hydrogen bond between the carbonyl 
oxygen of the acetyl group and the amide side chain of Gln148. Therefore, the design of 
the linker for SAP should use an amide bond to ligate the headgroup to the rest of 
molecule and allow maximum flexibility for the headgroup to orientate and bind to SAP 
in its preferred conformation. As discussed in section 4.1.1.1, hGlu was chosen as an 
amino-containing analogue for the hexanoyl linker of CPHPC, this allows it to be 
attached to the linker through an amide bond. Glycine was chosen as the residue 
through which the headgroups would be attached to the linker because its structure is 
achiral and it lacks a side chain functional group, both of which may have interfered 
with binding of the headgroup to SAP.  
 
The binding affinity of any multivalent ligand will be affected by the length of the 
linker; too long and the increased degrees of freedom will reduce the strength of 
binding; too short and a single ligand molecule will not be able to occupy all binding 
sites simultaneously. However, the ideal length for the linker is not immediately obvious 
because interaction between the linker and the surface residues of SAP will affect how 
the flexible chain folds. Therefore, it is best to produce a range of ligands that sample 
various lengths close to but in excess of the minimum required radius of 28Å. For this 
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reason polyethylene glycol (PEG) oligomers were chosen as a key constituent of the 
linkers. PEG-containing amino acids are commercially available in a variety of lengths; 
with a C-terminal carboxylic acid and Fmoc-protected N-terminal amino group they can 
be easily incorporated into a peptide-based structure. The added advantage of PEG is 
that it increases the water solubility of peptides, thus serving to fulfil another 
requirement of the multivalent ligands. However, experience with PEG-containing 
peptides has shown that they are often oily in nature, which makes them more difficult 
to handle. For this reason two gamma-aminobutyric acid (GABA) residues were 
introduced into the linker structure either side of the PEG group to balance the 
hydrophilicity of the compounds. The final design consideration was the functional 
group used to ligate the linker to the central scaffold, this could only be determined by 
first deciding upon the scaffold structure. 
 
4.1.1.3. Scaffold design 
Many different scaffolds have been employed in previous multivalent ligands studies. 
Kitov et al. (2000) utilised a monosaccharide as a scaffold in their synthesis of 
STARFISH multivalent binder of Shiga-like toxins and a plethora of examples of 
peptide and cyclodextrin-based multivalent ligands abound in the literature (reviewed 
by Niederhafner et al., 2008; Deniaud et al., 2011; Qu et al., 2014). However, many of 
the cyclodextrin-based ligands are hexavalent and pentameric cyclodextrins are not 
widely commercially available. Scaffolds of dendrimers formed from polymers such as 
commercially available PEG and peptides like the multiple antigen peptide system 
developed by Tam (1988) were also considered. However, dendrimers were rejected for 
this study as it was thought a more rigid central scaffold would reduce the entropy 
penalty from binding, which should give an increased binding affinity. Research of the 
literature found that cyclic peptides with pentameric symmetry have been developed as 
the basis for multivalent ligands by Zhang et al. (2004). In their investigation, a central 
cyclic peptide scaffold was used, with multiple branches attached through the amino 
side chains of five lysines and a Galactose-based headgroup presented at the end of each 
branch. The group found the binding affinities of their peptide-based multivalent ligands 
to be as much as 100,000 fold stronger than univalent galactose. Zhang et al. also 
conducted computer simulations showing that the cyclic peptide maintained an 
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expanded cyclic shape and did not collapse into a folded secondary structure. For these 
reasons, the lysine-based cyclic peptide developed by Zhang et al. was determined to be 
an appropriate starting point for the design of multivalent ligands for SAP as it was 
likely to offer a rigid core of adequate size to counterbalance the flexibility of the PEG-
based linkers. 
 
However, the method of ligating the linkers to the central scaffold was modified from 
that of Zhang et al. Their method forms attachments between the cyclobutenyl groups 
on the linker and the lysine side chains of the scaffold. As the cyclobutenyl group was 
not readily available, the side chain lysine functional groups were modified using 
chloroacetic anhydride to facilitate thioether formation with a side chain thiol group on 
the linker. This necessitated the presence of a free thiol group on the ligand, therefore 
cysteine was chosen as the N-terminal amino acid of the linker. Conceivably, another 
thiol such as mercpatopropanoic acid would have been less complicated because it does 
not have the amino group found in cysteine, but from an analytical perspective it is 
preferable to have the free amino group present as it more readily takes on a positive 
charge, which makes it easier to monitor synthesis of the compound by mass 
spectrometry.  
 
A second modification to the Zhang et al. strategy was using an alternative method to 
cyclise the scaffold. Zhang's method uses on-resin cyclisation with an Alloc group to 
protect the C-terminus during synthesis (Figure 4.3). Previous experience of on-resin 
cyclisation reactions has shown that the degree of success is sequence specific, some 
peptides, such as β-amyloid 1-42 aggregate with neighbouring peptide chains during 
synthesis preventing further peptide synthesis, let alone on-resin cyclisation; this is in 
spite of the presence of large bulky protecting groups on the side chains of some amino 
acids in the resin-bound peptide and often the aggregation manifests itself as a visible 
reduction in the volume of the peptidyl-resin. Furthermore, on-resin cyclisation requires 
low resin substitution and the high cost of resin means that large scale syntheses are 
prohibitively expensive.  
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Figure 4.3. On-resin cyclisation using Allyl protecting group (Alloc) as used by Zhang et al., 2004. 
 
A number of possible ligation reactions were contemplated. The simplest way to 
replicate the work of Zhang et al., without an on-resin cyclisation, would be to 
synthesise the peptide on a hyper acid-labile resin, cleave it as a protected peptide and 
attempt the head-to-tail cyclisation reaction in solution. It is often possible to achieve 
solution phase cyclisations because the higher probability of intramolecular collisions 
favours cyclisation over intermolecular polymerisation, particularly if a high dilution 
factor is used. However, the presence of protecting groups on the peptide make the 
chain less flexible and often polymerisation occurs anyway. Therefore, the solution-
phase cyclisation method was discounted as an appropriate method. Often in peptide 
synthesis alternative methods of cyclisation cannot be contemplated because achieving a 
specific peptide sequence is a key part of the synthesis. However, in this case it was the 
architecture that was the overall aim and the building blocks used to achieve it were 
interchangeable. 
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A second methodology used to cyclise peptides is native chemical ligation. In this 
method, an active thioester is formed at the C-terminus of a peptide that has an N-
terminal cysteine. The thioester is formed after cleavage, from a suitable resin such as 2-
Chlorotrityl resin, on a protected peptide using benzyl mercaptan (Dawson et al. 1997). 
The thioester species is rapidly displaced by the thiol side chain of cysteine, which 
subsequently rearranges to yield a peptide bond between the C-terminus and the N-
terminal cysteine, which also regenerates the free thiol on the N-terminal cysteine. The 
disadvantage of thioester formation is the use of benzyl mercaptan which is highly 
malodorous. Due to this considerable drawback, thioester formation was discounted as a 
viable method, but it influenced the final decision to use cysteine as a key component of 
the cyclisation reaction. Literature research found previous use of thioether bonds to 
form cyclic peptides for multivalent ligands demonstrating that an intramolecular 
thioether cyclisation would be a realistic methodology (Jones et al., 1998; Jones et al., 
1999). Therefore, it was decided that the thioether method used attach the linker to the 
central scaffold would also be applied to the intramolecular reaction.  
 
Figure 4.3. General reaction scheme of thioether bond formation by thiol alkylation with an alkyl halide 
performed in aqueous solvent under mildly basic conditions. 
 
The detailed design points discussed above led to the final chemical structure of the 
ligands pictured in Figure 4.4. The lengths of the linkers were estimated to be of 
sufficient length by generating the molecules using the Prodrg server (Schuettelkopf and 
Van Aalten, 2004) and measuring the molecule length in Coot (Emsley and Cowtan, 
2004), while the size of the central scaffold was approximated based on the values from 
Zhang et al. (2004). 
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Figure 4.4. Chemical structure of each component for the proposed multivalent ligands for SAP and the 
combined structure. a) Central scaffold with thioether cyclisation. b) linkers with Cys-Gly-GABA-PEGn-
GABA-Gly structure. c) headgroups, left: D-proline, right: amino-CPHPC. 
 
4.1.2. Solid Phase Peptide Synthesis 
Solid Phase Peptide Synthesis (SPPS) is a widely used technique for synthesising 
peptides. In SPPS, a solid phase support, generally consisting of 1% cross-linked 
divinyl benzene, is functionalised with a linker, which is a functional group capable of 
forming a covalent attachment between the solid phase and an amino acid (Merrifield, 
1963). Amino acids are attached to the solid phase through their C-terminal carboxyl 
group, leaving the N-terminal amino group free for covalent attachment of the next 
amino acid. The concentration (substitution) of linkers on the solid phase is varied to 
obtain a balance between yield and reaction efficiency. High concentrations of linker 
produce a higher peptide yield, but when peptide chains reach a length greater than 9 
amino acids they can start to sterically hinder reactions on neighbouring peptide chains, 
leading to incomplete reactions that lower the purity and yield of the final product. 
Typically, a substitution of 0.4 mmol g
-1
 achieves the appropriate balance. 
 
Amino acids have the general structure shown in Figure 4.5. In SPPS, amide (peptide) 
bonds are formed between the amine of the resin-bound nascent peptide chain and the 
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carboxyl group of a solution phase amino acid. There are a vast number of 
commercially available amino acids many with R-groups that would engage in 
undesirable side reactions in the reaction conditions used for peptide bond formation. 
SPPS employs a range of both side chain and N-terminal protecting groups to minimise 
side reactions and direct bond formation to the desired site. The two most common 
protecting group strategies in SPPS are 'Boc' and 'Fmoc', named after the structure of 
the N-terminal protecting group. Fmoc, Fluorenylmethoxycarbonyl, SPPS is more 
widely used because it does not require the use of dangerous hydrofluoric acid (HF) to 
liberate the peptide from the solid phase (Carpino and Han, 1972). Furthermore, Fmoc 
SPPS allows for 'orthogonal protection' in which the side chain protecting groups are 
fully stable to the conditions used to remove the N-terminal protecting group and vice 
versa (Barany and Merrifield, 1977). 
Figure 4.5. Generic structure of an α-amino acid with a primary amine. 
 
The scheme in Figure 4.6 outlines the general processes of SPPS, a more substantial 
explanation can be found in Solid Phase Synthesis: A Practical Approach (Atherton et 
al., 1989). In Fmoc SPPS, the C-terminus of a solution-phase amino acid is reacted with 
the N-terminus of a solid phase-bound amino acid, in the presence of a non-nucleophilic 
base, to form an amide (peptide) bond. Peptide bond formation does not happen 
spontaneously, so a coupling agent, such as Benzotriazole-1-yl-oxy-tris-
(dimethylamino)-phosphonium hexafluorophosphate (BOP), is used to convert the C-
terminus of the incoming amino acid to an active ester that readily reacts with the free 
amino group of the nascent peptide. A high excess of solution phase reagents relative to 
the solid phase amino acid ensures greater than 99% reaction completeness in 40 
minutes. The excess reagents are then easily removed by repeated washing of the resin 
with an aprotic solvent such as dimethylformamide (DMF). The Fmoc group of the 
newly coupled amino acid is then removed by a 20 minute treatment with 20% 
Piperidine/DMF. After the resin is thoroughly washed with DMF, the process of amino 
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acid addition and deprotection is repeated until the desired peptide has been synthesised. 
Subsequent treatment of the resin-bound peptide with 95% trifluoroacetic acid and 5% 
cation scavengers (e.g. triisopropylsilane) liberates the peptide from the solid phase and 
removes any acid-labile side chain protecting groups. Purification by High Performance 
Liquid Chromatography (HPLC) yields a high purity peptide of the desired sequence.  
Figure 4.6. Example scheme of the standard reaction steps of Fmoc solid phase peptide synthesis using 
preloaded Fmoc-Asp(OtBu) resin and coupling of Fmoc-Ala-OH. Step 1: Deprotection with 20% 
piperidine in DMF for 20 minutes. Step 2: Coupling of amino acid using Fmoc-protection on the N-
terminus of the incoming amino acid, a coupling agent, such as BOP, to expedite the reaction and 
diisopropylethylamine (DIPEA) as the non-nucleophilic base. Steps 1 and 2 are repeated with the relevant 
Fmoc-protected amino acid until the desired sequence has been synthesised. Cleavage of the peptide from 
the resin and side chain deprotection is achieved simultaneously using 95% TFA, 5% cationic scavengers. 
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4.1.2.2. Synthesis of non-standard peptides 
Peptide chemistry is a highly malleable medium in which to design molecules with 
specific properties. The amide bonds provide an unreactive backbone, while the wide 
variety of available side chain R-groups gives almost limitless customisation of a 
peptide sequence and its properties. Addition of unnatural amino acids, such as γ-
aminobutyric acid (GABA) or selenomethionine, is no more complicated than the 
inclusion of any standard amino acid. C-terminal amide formation can be achieved 
through the use of dedicated solid phase linkers such as Rink amide. N-terminal 
modifications can be performed both on-resin or in solution post-cleavage. The presence 
of side chain amino and thiol groups in amino acids, such as lysine and cysteine, allow 
for facile ligation of peptides to a host of other molecules. For these reasons, Fmoc 
SPPS is the ideal choice for the synthesis of multivalent ligands for SAP. 
 
4.2. Materials and Methods 
Fmoc-γ-aminobutyric acid (Fmoc-GABA-OH), chloroacetic anhydride, trifluoroacetic 
acid, triisopropylsilane, anisole, thioanisole and ammonium bicarbonate were purchased 
from Sigma Aldrich (Dorset, UK). 2-Chlorotrityl chloride resin was purchased from Iris 
Biotech (Marktredwitz, Germany). Fmoc-protected amino acids, coupling agents, H-D-
Pro-OtBu, Rink Amide MBHA low loaded resin and various length Fmoc-PEGn-OH 
were purchased from Novabiochem (Merck KgaA; Darmstadt, Germany). Dimethyl 
sulfoxide (DMSO) and Diisopropylethylamine (DIPEA) were acquired from Alfa Aesar 
(Ward Hill, MA). Dimethylformamide (DMF) and dichloromethane (DCM) were 
purchased from AGTC Bioproducts (National Diagnostics; Hessle, UK). 
 
Mass spectrometry (MS) was performed on a Micromass ZMD4000 Mass Spectrometer. 
Liquid chromatography mass spectrometry (LCMS) was performed on an Agilent 1100 
series LCMS. Peptides were purified by reverse-phase high-performance liquid 
chromatography (HPLC) on a Gilson HPLC system with two 306 pumps, 118 UV/Vis 
detector, 806 manometric module and 811B dynamic mixer. Peptides were successfully 
purified to between 80-97% purity using an acetonitrile/water (0.1% v/v TFA) mobile 
phase and a Phenomenex Gemini 5μ C18 110Å column as the solid phase.  
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MS was used extensively in this chapter and the next for qualitative structure 
determination. Therefore, the basic theory of the technique will be briefly introduced. 
MS is widely used in organic chemistry and the principal technique for analysis during 
peptide synthesis. MS involves applying either a positive or negative charge to 
molecules in the sample of interest and passing the sample through a mass analyser, 
which separates ions based on their mass/charge (m/z) ratio. Once separated ions arrive 
at the detector, which measures the abundance of different ions in a given mass range 
(Ho et al., 2003).  
 
There are a variety of methods used for ionising the sample, which can be classified as 
either “hard” or “soft”. Hard ionisation techniques, such as electron bombardment, tend 
to cause fragmentation of molecules and therefore are not typically applied to 
polypeptide analysis. Soft ionisation uses gentler methods to apply charge to sample 
molecules. Electrospray ionisation (ESI) is an example of soft ionisation MS and was 
used in this study for both assessing peptide synthesis reactions and multivalent ligand 
interactions with SAP. Electrospray ionisation uses a nebuliser needle with an electrified 
tip to apply charge to solvent droplets containing the molecule of interest (Figure 4.7). 
The sample is injected onto the apparatus in a small quantity of solvent, such as 1:1 
acetonitrile:water solution. For positive ionisation, an acid such as 0.1% v/v 
trifluoroacetic acid is added to improve sample ionisation. The sample enters the cone 
of the spectrometer and is mixed with a drying gas, which forms an aerosol with the 
sample solvent. The droplets of the sample become charged as they leave the cone and 
are dried further by a second stream of drying gas flowing counter to the direction of the 
solvent. Coulombic explosions reduce the size still further until the molecules 
themselves are charged. The charged species is propelled into the mass analyser by 
repulsion from a cylindrical electrode surrounding the nebuliser needle. 
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Figure 4.7. Diagram of the sample nebuliser needle and mass analyser of a typical electrospray mass 
spectrometer (ESI-MS). Adapted from Fenn et al., 1989. 
 
The mass analyser generally consists of either 4 or 6 parallel rods (quadrupole or 
hexapole) arranged radially to which alternating charges are applied with a specific 
frequency. As the ions pass through the centre of the analyser the ions are attracted and 
repelled by the alternating charges of the poles, resulting in a unique undulating 
trajectory (Figure 4.8). Ions with a high m/z ratio change direction rapidly and 
eventually spin out of the analyser or collide with the poles. Heavier ions with low m/z 
ratios change direction more slowly and as a result collide with the poles. Only ions of 
the correct m/z for a particular frequency will pass through the analyser and reach the 
detector. Ions that collide with the detector result in an emission of electrons, which are 
liberated from the surface of the detector and enter the electron multiplier horn. The 
electron multiplier horn amplifies the electrical signal such that it can be recorded as a 
peak on a mass spectrum. The frequency at which the charge is flipped in the mass 
analyser poles determines which ions will reach the detector; varying this through the 
lifetime of a MS analysis gives a full spectrum for the desired mass range. 
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Figure 4.8. Diagram of the Quadrupole and the path of ions through the mass analyser. Adapted from Ho 
et al., 2003. 
 
4.2.1. Synthesis of peptides 
All peptides were synthesised by Fmoc SPPS as described by Atherton et al. (1989), 
non-standard modifications are detailed in the following sections. The multivalent 
ligands were synthesised in several fractions, the central cyclic scaffold 5, the 
pentameric linker-headgroups (6, 7, 8), the decameric linkers (9, 10, 11) and the 
decameric headgroup (14). The fractions were then combined into the desired 
multivalent product by a series of solution phase reactions. 
 
4.2.2. Small scale cleavage of peptides for mass spectrum monitoring during 
synthesis 
The progress of SPPS can be monitored between reaction steps by placing a small 
number of solid phase beads (typically 5-10) in a small test tube adding 100μl of TFA 
and 1μl of triisopropylsilane and heating the sample in a heating block at 100oC until all 
the TFA has evaporated. This method liberates sufficient peptide from the resin for MS 
analysis, which is prepared for injection by dissolving in 200μl of 1:1 water and 
acetonitrile solution. The sample is transferred to a microcentrifuge tube, briefly spun 
down and 10μl of the supernatant injected onto the mass spectrometer. 
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4.2.3. Synthesis of central scaffold 5 
 
4.2.3.1. SPPS of uncyclised central scaffold 1 
Linear peptide 1 (Figure 4.9) was synthesised on low-loaded (0.45mmol g
-1
) Rink 
amide MHBA resin. Rink resin yields a peptide with a C-terminal amide upon cleavage 
with 95% TFA; this can be a useful way of reducing the reactivity of a carboxylic acid 
and preventing undesirable side reactions during post-cleavage modifications. MS 
analysis was performed to confirm the identity of the desired product and assess 
reaction completeness before every Fmoc-deprotection and prior to coupling of the next 
Fmoc-protected amino acid. The mass spectrum of the crude resin-bound product 1 
showed the following peaks: M+2H ion: 751.0 m/z, relative abundance (r.a.): 75%, 
M+2H ion + C-terminal phenol: 803.7 m/z, M+3H ion: 501.2 m/z, r.a.: 100%, M+3H 
ion + C-terminal phenol: 536.5 m/z, r.a.: 70%. +106 peaks were observed, indicating a 
portion of the Rink amide linker had cleaved off the resin attached to the peptide, this is 
commonly known to be an issue with this linker. It only presented itself in this mass 
spectrum because of the elevated temperature of the cleavage conditions used to analyse 
peptides during SPPS (section 4.2.3); no +106 was observed for the final room 
temperature cleavage. 
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Figure 4.9. Synthesis of central cyclic scaffold 5. 
  
4.2.3.2. Formation of 2 by addition of chloroacetyl group to the N-terminus of 1 
Resin-bound peptide 1 was reacted with 3 molar equivalents (equiv.) chloroacetic 
anhydride dissolved in 2ml DMF with 9 equiv. DIPEA over 30 minutes. The unreacted 
material was then removed from the peptidyl resin by filtering and the resin washed 
three times with DMF. The extent of the reaction was determined by MS and Kaiser 
test. The Kaiser test uses 2,2-dihydroxyindane-1,3-dione (ninhydrin) to test for the 
presence of primary amines, making it a simple, but crude, method of testing for 
reaction completeness during SPPS (Figure 4.10). A small sample of peptidyl-resin is 
placed in a small test tube containing 20μl ninhydrin/methanol solution and 40μl water 
containing potassium cyanide and phenol. The mixture is then heated for 3 minutes and 
the colour of the mixture observed. If a free primary amine is present then a “positive” 
dark blue/purple colour is observed, otherwise a negative yellow/straw colour is 
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observed. A Kaiser test of the chloroacetylated peptidyl resin gave a negative result and 
MS confirmed that the coupling reaction was complete. The resin was washed 
thoroughly with DCM to remove any remaining DMF prior to cleaving the peptide from 
the solid phase. For example: 0.6g of 1 reacted with 0.023g (0.135mmol) chloroacetic 
anhydride in 2ml DMF with 125μl (0.73mmol) DIPEA produced a crude mass spectrum 
of product 2: M+2H ion: 788.9 m/z, r.a.: 20%, M+3H ion: 526.5 m/z, r.a.: 55%, M+4H 
ion: 395.2 m/z, r.a.: 100%, M+5H ion: 316.5 m/z, r.a.: 40% (product not isolated prior 
to next reaction, thus not quantified). 
 
Figure 4.10. Reaction of ninhydrin with N-terminus of a nascent peptide chain, followed by reaction of 
the intermediate with ninhydrin to produce the chromophore responsible for the observed purple colour in 
a 'positive' result. 
 
4.2.3.3. Cleavage of 2 from the solid phase and purification of product 3 
To break linkages between the peptide and the solid phase and to remove all acid labile 
protecting groups, dry peptidyl-resin was gently stirred for 3 hours in a solution of 90-
95% TFA, 5-10% cationic scavengers. The cationic scavengers consisted of equal 
volumes of triisopropylsilane, water, anisole and thioanisole. After 3 hours, the cleavage 
solution was separated from the resin by gravity filtration assisted by a small application 
of positive pressure and the resin washed thrice with 2ml 100% TFA. The 6ml TFA used 
to wash the resin was pooled with the rest of the cleavage cocktail. Typical reaction 
quantities: 0.6g 2 was mixed with 6ml TFA and 600μl scavenger for 3 hours. 
 
 
 
Chapter 4. Synthesis of multivalent ligands for SAP 
 
128 
 
4.2.3.4. Removal of TFA from crude 3 
Ether precipitation was used to separate peptides from the concentrated TFA if their 
sequence did not contain PEG. In this method, the cleavage cocktail is pooled in a 40ml 
centrifuge tube. 20ml diethyl ether (ether) is then added, causing a thick white 
precipitate to form. After thorough mixing, the solution is placed in a centrifuge at 3200 
rpm for two minutes. The supernatant is removed, another 20ml ether added and the 
precipitate agitated with a metal spatula to liberate TFA trapped within the precipitate. 
The sample is returned to the centrifuge for a further two minutes. The supernatant is 
removed once more and 5ml water added to the precipitate. The solid is agitated before 
freeze-drying. After freeze-drying the crude peptide material was purified by HPLC 
utilising a 1-21% acetonitrile gradient over 40mins. The product eluted after 11mins, 
MS revealed the product to be free from peptidyl impurities. Purified mass spectrum of 
product 3: M+2H ion: 788.9 m/z, r.a.: 25%, M+3H ion: 526.5 m/z, r.a.: 100%, M+4H 
ion: 395.2 m/z, r.a.: 75%. Product not isolated before next reaction. 
 
4.2.3.5. Formation of 4 by thioether alkylation 
The cyclisation of 3 was achieved immediately after HPLC purification. The pH of the 
aqueous sample eluted from the HPLC was raised to between 7.5-8.0 using ammonium 
bicarbonate and stirred for 3 hours open to the atmosphere. Under basic conditions the 
chloride in the chloroacetyl group undergoes nucleophilic substitution with the thiol of 
the C-terminal cysteine resulting in cyclic peptide 4. After 3 hours, a 10μl sample was 
acidified with formic acid and analysed by MS, which showed the reaction to be 
complete. The reaction mixture was freeze-dried and purified by HPLC. Typical results 
of cyclisation of peptide synthesised on 2x 600mg Rink resin: Yield: 61mg (43.9%). 
Mass spectrum of 4: M+2H ion: 771.1 m/z, r.a.: 10%, M+2H ion + trifluoroacetate: 
828.1 m/z, r.a.: 10%, M+3H ion: 514.4 m/z, r.a.: 100%, M+3H ion + trifluoroacetate: 
552.5 m/z, r.a.: 20%. 
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4.2.3.6. Formation of 5 by reaction of chloroacetic anhydride with the lysine side 
chains of 4 
The five lysine side chains of purified 4 were acetylated with chloroacetic anhydride in 
DMSO under basic conditions. The reaction was determined complete by MS after 
20mins and immediately purified by HPLC. For example 50mg (0.032mmol) 4 was 
dissolved in 2ml DMSO with 78mg chloroacetic anhydride and 125μl (0.72mmol) 
DIPEA added and the mixture stirred for 20mins. After 20mins no 4 was detectable by 
MS, the product was treated with 100μl formic acid and immediately purified by HPLC 
running a gradient of 5-95% acetonitrile over 40mins, the product eluted after 20mins. 
MS of purified 5: M+2H ion: 961.4 m/z r.a.: 100%, unrelated peaks contaminating 
spectrum: 373.6 m/z r.a.: 80%, 295.5 m/z r.a.: 40%. Product not isolated before next 
reaction. 
 
4.2.4. SPPS of 6, 7 and 8 
 
4.2.4.1. Coupling of first amino acid to 2-chlorotrityl chloride resin 
Coupling the first amino acid to 2-Ctr resin involves formation of a stable ester bond by 
nucleophilic substitution of the chloro group on the trityl linker of the resin by the C-
terminal carboxyl group of an Fmoc-protected amino acid. 2-Ctr resin is often used in 
the synthesis of peptides with a C-terminal proline because of their propensity to 
undergo diketopiperazine formation during SPPS. Diketopiperazine formation occurs 
after addition of the second amino acid (Gisin and Merrifield, 1972). Once deprotected, 
some dipeptides have a tendency to arch back towards the resin and attack the ester 
linkage between the peptide and the solid phase. The peptide is liberated from the solid 
phase as a stable 6-member heterocycle and a free hydroxyl group forms on the linker 
(Figure 4.16). Upon addition of the next amino acid, a new ester linkage forms between 
the incoming amino acid and the hydroxyl group on the resin. As the synthesis 
continues it becomes apparent by MS that a proportion of the peptide is missing the first 
two amino acids. Quite often it is not possible to remove the impurity by HPLC, but the 
extent of the side reaction can be suppressed by using a solid phase linker, such as 2-Ctr, 
that has large bulky groups to sterically hinder attack of the peptide ester linkage. 
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The desired product peptides, 6, 7 and 8, (Figure 4.11) were short enough that highly 
substituted resin could be used without the risk of detrimentally affecting the quality of 
the synthesis. Therefore in a typical synthesis, 0.6g 2-Ctr resin was reacted with 
0.3mmol Fmoc-protected amino acid in 50:50 DMF:DCM with 375μl DIPEA for 1 
hour, on the assumption that 1/3 of the amino acid would successfully couple to the 
solid phase. After 1 hour the liquid was removed by filtering the resin and flushing with 
3ml DMF. The resin was then treated with 1ml methanol in 3ml DMF with 375μl 
DIPEA to cap any unreacted linkers. After capping and washing the resin, peptide 
elongation was performed by standard SPPS and the peptide subsequently cleaved by 
the same procedure as for 3 (section 4.2.4.3). However, due to the presence of PEG in 
the sequence of peptides 6, 7 and 8, a different method was used to remove the TFA 
from the crude peptide after cleavage. 
 
Figure 4.11. Structure of linker-headgroups 6, 7, 8, 18, 19 and 20. 
 
4.2.4.2. Separation of peptides containing polyethylene glycol from TFA 
PEG can increase the solubility of peptides in ether, preventing effective precipitation. 
Therefore, the TFA is removed by rotary evaporation. The sample is placed on the rotary 
evaporator until reduced to a viscous oil. 5ml water is then added to the sample and 
freeze-dried. 
 
4.2.4.3. Purification of 6, 7 and 8 
HPLC purification was performed on crude peptides 6, 7, 8 using a 1-51% acetonitrile 
gradient over 40mins the following retention times were recorded: 6 eluted after 
18mins, 7 after 21mins, 8 after 23mins. The purified mass spectra for each component 
were as follows: 6: M+1H ion: 648.6 m/z, r.a.: 100%. 7: M+1H ion: 750.4 m/z, r.a.: 
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100%, M+2H ion: 376.1 m/z, r.a.: 40%. 8: M+1H ion: 848.5 m/z, r.a.: 100%, M+2H 
ion: 420.0 m/z, r.a.: 40%. Yield (2x 600mg syntheses of each product): 6: 181mg 
(23.3%), 7: 107mg, (11.9%), 8: 140mg (13.7%). Percentage yields based on 1/3 of first 
amino acid coupling to solid phase. 
 
4.2.5. Synthesis of 18, 19 and 20 
 
4.2.5.1. SPPS of 9, 10 and 11 
Unlike the pentavalent linker-headgroups, the linkers and the headgroups for the 
decavalent compounds were synthesised separately and then combined by solution 
phase reaction (Figure 4.12). Linkers 9, 10 and 11 were synthesised on 2-Ctr resin 
because the triphenyl structure of the 2-Ctr linker allows the ester bond to be broken 
under weakly acidic conditions, so peptides can be cleaved from the resin without 
removing protecting groups. Protected peptides can then be modified further in solution 
post-cleavage. The N-terminal cysteine was coupled as Boc-Cys(Trt)-OH because it 
negates the need for a final deprotection step and, in the case of 9, 10 and 11, allows the 
peptide to be cleaved with N-terminal protection, permitting a solution phase coupling 
reaction at the C-terminus of the peptide without the risk of polymerisation.  
 
Figure 4.12. Synthesis of decameric linker headgroups 18, 19 and 20. 
 
 
1% TFA 
DCM 
Chapter 4. Synthesis of multivalent ligands for SAP 
 
132 
 
4.2.5.2. Cleaving protected peptides 9, 10 and 11 from 2-Ctr resin using 1% TFA 
9, 10 and 11 required further post-cleavage modification; therefore they were cleaved by 
repeatedly treating the resin with 2ml 1% TFA in DCM to remove the peptide from the 
hyper-acid labile 2-Ctr resin without cleaving the protecting groups. After cleaving the 
peptide with a total volume of 20ml 1% v/v TFA/DCM, the solvent was pooled and 
separated from the crude peptide by rotary evaporation and then freeze-dried. For 
example, compound 9: M+1H ion: 893.5 m/z, r.a.: 100%, M+1H ion -Trityl protecting 
group fragmentation: 651.4 m/z, r.a.: 15%.  
 
4.2.5.3. Synthesis of 14 
hGlu was Fmoc-protected by dissolving the amino acid in water with 4 equiv. sodium 
bicarbonate. 1.2 equiv. Fmoc-succinimide (Fmoc-OSu) was dissolved in dioxane and 
added dropwise to the aqueous solution. After stirring overnight, the dioxane was 
removed by rotary evaporation to leave a turbid aqueous solution. Acidification of the 
aqueous solution with a couple of drops of concentrated HCl caused precipitation of a 
dense white solid. The precipitate was separated from the aqueous phase by vacuum 
filtration and dried on a dome freeze-dryer. For example: 0.1g (0.62mmol) hGlu and 
0.2g (2.38mmol) Sodium Bicarbonate were dissolved in 4ml water. 0.25g (0.74mmol) 
Fmoc-OSu in 5ml dioxane was added dropwise over two hours. Crude yield: 126mg 
(60.1%) Mass spectrum of crude Fmoc-hGlu-OH (12): M+1/2H ion (product flying as 
dimer on MS): 767.4 m/z, r.a.: 80%, M+1/2H +NH3: 784.4 m/z, r.a.: 35%, M+1H ion: 
384.4 m/z, r.a.: 100%, M+1H ion +NH3: 401.3 m/z, r.a.: 30%. Unidentified 
contaminating peak: 206.3 m/z, r.a.: 60%. Ammonia contamination was observed 
because the MS used is open access and used for characterisation of products purified 
under basic conditions, so occasional contamination is to be expected. 
 
1 equiv. of 12 was then reacted in solution with 2 equiv. of H-D-Pro-OtBu using 2 
equiv. benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate 
(BOP) as the coupling agent and 6 equiv. DIPEA (Figure 4.13). The reaction mixture 
was acidified with 200μl formic acid and purified by HPLC running an acetonitrile 
gradient from 40-100% over 40mins. The desired product, Fmoc-hGlu(dPro-OtBu)-
dPro-OtBu (13) was eluted after 25mins free from any remaining starting material and 
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was immediately freeze-dried. For example: 90mg (0.23mmol) 12 and 107mg 
(0.63mmol) H-D-proline-OtBu and 225mg (0.51mmol) BOP were dissolved in 2ml 
DMSO with 250μl (1.47mmol) DIPEA and stirred for 1 hour. Yield of 13: 73mg 
(44.9%). MS of 13: M+1H ion: 690.7 m/z r.a.: 100%. 
 
Figure 4.13. Decameric headgroup synthesis. 
 
Once freeze-dried, the Fmoc group was removed from 13 by dissolving the pure starting 
material in 2% piperidine, 2% 1,8-Diazabicycloundec-7-ene (DBU) in DMF and stirring 
for 2mins. After 2mins, MS analysis showed complete N-terminal deprotection of 13. 
100μl formic acid was added and the mixture immediately injected onto the HPLC 
running an acetonitrile gradient between 15-95% over 40mins, the desired product, 
hGlu(dPro-OtBu)-dPro-OtBu (14) was eluted after 18mins free from peptidyl impurities 
and placed on the freeze-dryer. For example: 73mg 13 was dissolved in 2ml 2% 
piperidine, 2% DBU DMF giving a purified yield of 35mg (49.4%) of 14. MS of 14: 
M+1H ion: 468.7 m/z r.a.: 100%, M+1/2H ion: 935.9 m/z, r.a.: 60%. 
 
4.2.5.4. Fragment condensation between decameric linkers (9, 10 and 11) and 14 
1 equiv. 14 was ligated to 1.2-2 equiv. of decameric linker 9, 10 or 11 by solution phase 
reaction in 10ml DCM with 1.2 equiv. BOP as the coupling agent and 3 equiv. DIPEA 
as the base (Figure 4.12). After mixing for 1 hour, a 10μl sample was taken and the 
DCM removed in a heating block at 100
o
C. The dried sample was treated with 2μl 
triisopropylsilane and 100μl TFA and placed in a heating block until all the acid had 
evaporated. The residue was dissolved in 200μl 50:50 acetonitrile:water and analysed 
by MS, which showed no detectable 14, indicating that the reaction was complete. The 
DCM was removed by rotary evaporation, redissolved in 3ml DMSO, acidified with 
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100μl formic acid and purified by HPLC running an acetonitrile gradient of 15-95% 
over 40mins. The desired products eluted after 34mins free from all peptidyl impurities. 
For example: 35mg (0.07mmol) 14 reacted with 75mg (0.08mmol) 9 with 37mg 
(0.08mmol) BOP and 36μl (0.21mmol) DIPEA in 7ml DCM gave the purified mass 
spectrum: M+1H ion: 1342.9 m/z, r.a.: 100%, M+1H ion -Trt fragmentation: 1100.9 
m/z, r.a.: 15%, unidentified contaminant peak: 691.4 m/z, r.a.: 15%. 
 
After freeze-drying the protected peptides were weighed, in total 45mg 15, 115mg 16 
and 170mg 17 was synthesised, as the products would not be isolated in solid form 
again before addition to the cyclic scaffold these values would serve as a basis for 
calculating expected yields of the multivalent products. The purified products were 
deprotected as in section 4.2.5 and then purified by HPLC using a gradient from 15 to 
45% acetonitrile over 40mins. The desired products eluted after 18mins (18) and 
21mins (19, 20). The purified products were identified using MS and then freeze-dried. 
MS of deprotected, purified products: 18: M+2H ion: 445.1 m/z r.a.: 100%; M+1H ion: 
888.5 m/z r.a.: 75%. 19: M+2H ion: 496.2 m/z, r.a.: 100%; M+1H ion: 990.9 m/z, r.a.: 
70%; M+2H ion + K
+
: 515.3 m/z, r.a: 15%. 20: M+2H ion: 540.2 m/z, r.a.: 100%; 
M+1H ion: 1078.8 m/z, r.a.: 40%; M+2H ion +Na
+
: 551.3 m/z, r.a.: 15%. 
 
4.2.6. Formation of multivalent ligands 
 
4.2.6.1. Preparation of 21, 22, 23, 24, 25 and 26 by thioether formation between 5 
and linker-headgroups 6, 7, 8, 18, 19 and 20 
5 and one of 6, 7, 8, 18, 19 or 20 linker-headgroups (LH) were taken in solvent directly 
from the HPLC and mixed together (Figure 4.14). The LH was targeted to be in a 
greater than 15-fold molar excess to central scaffold, i.e. a 3-fold excess of LH to each 
reaction site. Once mixed the pH of the solution was raised to between 7.5-8.0 with 
ammonium bicarbonate. The reaction was immediately frozen and placed under vacuum 
on a dome freeze-dryer to reduce the rate of LH dimerisation by disulphide bond 
formation, a process requiring an oxidant such as molecular oxygen. 
Chapter 4. Synthesis of multivalent ligands for SAP 
 
135 
 
Figure 4.14. Multivalent ligand assembly, thioether formation reaction between central scaffold 5 and 
linker headgroups 6, 7, 8, 18, 19 and 20. 
 
The sample was slowly dried under vacuum and consequently yielded a partially reacted 
mixture of S-nLH, where S is scaffold 5 substituted with n LH joined to the scaffold 
through thioether bonds. The desired multivalent product, S-5LH was the major 
constituent, with S-4LH and S-3LH as the only multivalent impurities detectable, an 
example of this is shown by the mass spectrum of 22 in Figure 4.20. MS analysis also 
showed the unreacted LH was not significantly dimerised. Therefore, the sample was 
redissolved in 50:50 acetonitrile/water, pH 7.5-8.0 and once again placed under vacuum 
as described above. This process was repeated until S-5HL was the only detectable 
multivalent species in the mixture or until there was no significant improvement in the 
ratio of S-5HL to S-(5-m)HL achieved by further reaction on the freeze-dryer, where m 
is the number of ligands missing from a multivalent scaffold. At this point the dried 
sample was purified by HPLC. 
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4.2.6.2. Purification of multivalent ligands and ligand-headgroups 
Adequate separation was achieved using a gradient of AcN from 5-45% over 40mins. 
Samples were dissolved in 3ml water or DMSO and acidified using 100μl formic acid 
prior to injection. Mass spectra of the final purified products: 21: M+3H ion: 1660.0 
m/z, r.a.: 20%, M+4H ion: 1245.3 m/z, r.a.: 100%, M+4H ion + K
+
: 1254.8 m/z, r.a.: 
15%, M+5H ion: 996.5 m/z, r.a.: 70%. 22: M+4H ion: 1373.1 m/z, r.a.: 25%, M+5H 
ion: 1098.7 m/z, r.a.: 100%, M+6H ion: 915.8 m/z, r.a.: 35%. 23: M+4H ion: 1483.2 
m/z, r.a.: 75%, M+5H ion: 1186.8 m/z, r.a.: 100%, M+6H ion: 989.2 m/z, r.a.: 50%. 24: 
M+4H ion: 1545.7 m/z, r.a.: 90%, M+4H ion +K+: 1555.3 m/z, r.a.: 10%, M+4H ion -
1x 18 + Cl: 1332.8 m/z, r.a.: 15%, M+5H ion: 1236.8 m/z, r.a.: 100%, M+5H ion -1x 18 
+ Cl: 1066.6 m/z, r.a.: 10%, M+6H ion: 1031.0 m/z, r.a.: 20%. 25: M+4H ion: 1673.7 
m/z, r.a.: 10%, M+5H ion: 1339.2 m/z, r.a.: 90%, M+6H ion: 1116.2 m/z, r.a.: 100%. 26: 
M+5H ion: 1427.2 m/z, r.a.: 30%, M+6H ion: 1189.6 m/z, r.a.: 100%, M+7H ion: 
1019.8 m/z, r.a.: 5%. Yield of final products: 21: 20mg, (49.5%). 22: 41mg, (72%). 23: 
43mg, (66%). 24: 24mg, (48%). 25: 21mg, (52%). 26: 32mg, (56%). Yields calculated 
based on initial mass of 4 activated with chloroacetic anhydride for reaction with LH. 
See appendix for purified mass spectra of products. 
 
4.2.6.3. Preparation of 21- 26 as chloride salts 
HPLC purification of peptides is generally performed with 0.1% TFA added to the 
mobile phase to improve peak resolution. Peptides are, therefore, present as 
trifluoroacetate salts after purification (Fields et al., 1993). Trifluoroacetate ions have 
the potential to bind to SAP in a calcium-dependent manner through their carboxyl 
group, so it is essential to exchange this counter ion with another counter ion, such as 
chloride. This was achieved by thrice redissolving the freeze-dried product in dilute HCl 
(0.1M) and freeze-drying the solution. No attempt was made to confirm the removal of 
trifluoroacetate ions from the purified multivalent ligands, but evidence exists in the 
literature that a single freeze-drying with dil. HCl is sufficient for complete exchange 
with chloride ions (Andrushchenko et al., 2007). 
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4.2.6.4. Packaging and storage of multivalent ligands 
Multivalent ligands dissolved in a small quantity of dilute HCl were aliquoted equally 
into 3 identical vials and a fourth containing 1mg and sealed under nitrogen. The 1mg 
vial was dispatched for amino acid analysis at the Protein and Nucleic Acid Chemistry 
Facility (University of Cambridge, UK) to determine the peptide content within the 1mg 
sample. The exact calculations were required for later determination of binding affinity 
to SAP by isothermal titration calorimetry discussed in Chapter 5. 
 
4.2.7. Ellman test for free thiol groups 
Ellman's reagent was used to test for free thiol groups in the purified products of the 
intramolecular and intermolecular thioether formation reactions. To prepare the solution 
for thiol detection, 4mg Ellman's reagent, dithio-nitrobenzoic acid, is dissolved in a 1ml 
solution of 0.1M sodium phosphate pH 8.0. 10μl of this solution is mixed with small 
quantity of the purified material of interest. The sample is incubated for 15 minutes at 
room temperature and the colour observed. If a free thiol is present the solution will turn 
a clear yellow colour, otherwise the solution will remain colourless. No colour change 
was observed for the products of the intramolecular and intermolecular thioether 
reactions (5, 21, 22, 23, 24, 25 and 26). However, a clear yellow colour was observed 
for the unreacted linkers 6, 7, 8, 18, 19 and 20.  
Figure 4.15. Reaction to test for free thiol groups using Ellman's reagent. Reduced thiol component 
responsible for the yellow colour observed for a positive result that indicates presence of a free thiol in 
the sample being analysed. 
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4.3. Results 
 
4.3.1. Final product yields 
Table 4.1 summarises the yields and percentage yields of the multivalent ligands 
calculated from the original syntheses of the central cyclic scaffold 4 through to their 
final ligation to the linker-headgroups (LH). The yields range between 21-32%, which is 
in line with yields reported by Zhang et al. (2004). Crucially, the quantity produced is 
large enough for a variety of different investigations of multivalent binding with SAP. 
 
Compound Number Yield (mg) Yield (%) 
21 20 21.7 
22 41 31.6 
23 43 29.0 
24 24 21.1 
25 21 22.8 
26 32 24.6 
 
Table 4.1. Yield of multivalent ligands calculated by weighing mass of chloride salt of 21-26 after freeze-
drying. 
 
4.3.2. Purity of 21-26 
HPLC purification of the multivalent ligands was sufficient to obtain all but 21 (85%) 
and 22 (81%) at greater than 90% purity as determined by LCMS (Table 4.2). The 
LCMS data from which the purity for each ligand was calculated can be found in the 
appendix (section A.1). 
 
Compound 
Number 
Purity Compound 
Number 
Purity 
21 85% 24 90% 
22 81% 25 91% 
23 96% 26 91% 
 
Table 4.2. Purity of multivalent ligands indicated by LCMS. 
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Inspection of the mass spectra for pentavalent ligands 21-23 shows minor peaks 
equivalent to -154 m/z of the molecular ion, which is likely to be the species reducing 
the overall purity of the ligands (see appendix section A.2). This corresponds to one 
multivalent arm missing Gly-Pro from the C-terminus, which may have occurred by 
diketopiperazine formation during synthesis (Figure 4.16). Another explanation for the 
missing residues is that that the coupling reaction did not proceed to completeness, but 
this can be discounted because there is no sign of the ligands missing just proline or just 
glycine; the pair of amino acids are missing simultaneously, indicating diketopiperazine 
(Gisin and Merrifield, 1972). 
 
Figure 4.16. Diketopiperazine formation between glycine and proline during SPPS under basic 
conditions. 
 
In this case, the ratio of 5 LH arms per scaffold has exacerbated the abundance of 
diketopiperazine afflicted arms (LH -GP) in the final molecule. If the abundance of LH 
-GP in the purified arms prior to ligation to 5 is just 2% then the we would expect 10% 
of final product to contain 1x LH-GP.  
 
No diketopiperazine formation was detected for the decavalent ligands because the 
synthetic strategy was different, the headgroup, 14, was synthesised by solution phase 
reaction and although the decavalent linkers 9, 10 and 11 were synthesised on the solid 
phase, the second amino acid was GABA, which has a backbone chain that is too long 
for diketopiperazine to form. 
 
4.3.3. Central scaffold cyclisation by thioether formation 
Disulphide bond formation was expected to be an issue in the formation of thioether 
bonds, but it was thought that the dimerisation reaction would not be significant in the 
case of the intramolecular cyclisation of 3 if the reactants were kept sufficiently dilute. 
This proved to be the case with no disulphide bond formation detectable by MS. The 
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mass spectrum of the cyclised material showed peaks for a M+3H ion at 514 m/z and an 
M+2H ion at 771 m/z (see appendix), which corresponds to a loss of 36 mass units from 
the uncyclised material (peaks: M+3H ion: 526 m/z, M+2H ion: 789 m/z) which is the 
mass change expected from the loss of HCl upon intramolecular thiol alkylation by an 
alkyl halide. Furthermore, an Ellman test of the purified material showed no colour 
change. These two experiments provide confidence that the desired reaction was 
successfully performed and product 4 had the correct structure post-cyclisation. 
 
4.3.4. Multivalent ligand synthesis by thioether formation 
The initial synthesis of 21 was attempted at room temperature open to the atmosphere to 
investigate if significant dimerisation of 6 did occur in air as expected. A mass spectrum 
was recorded at 2 hours after the reaction had started (Figure 4.18) with the original 
mass spectrum of 6 shown in Figure 4.17.  
 
 
Figure 4.17. Mass Spectrum of purified linker-headgroup 6 prior to reaction with central scaffold 5. 
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Figure 4.18. Mass Spectrum of reaction between 5 and 6 in air after 2 hours. Various partially reacted 
central scaffold units are visible with as many as 3 linker-headgroups attached. Some dimerisation of the 
linker-headgroups is visible, as is starting material 5. 
 
Figure 4.19. Mass spectrum of reaction of 5 with 6 in air after 7 hours. The most abundant peak 
corresponds to dimerisation of linker-headgroup compound group 6 by disulphide formation. This was 
due to performing the reaction in air. The desired product 21 is visible and the multivalent product 
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missing a single LH, no dehalogenation is seen from the unreacted site on the central scaffold. 
After 2 hours, the original peak for the monomeric ligand at 648.6 m/z had been 
replaced by another at 647.4 and a second peak corresponding to the mass of two 
headgroup molecules appeared at 1293.5 m/z indicating that significant dimerisation 
had occurred. However, there were clear signs of the desired reaction with S-1HL, S-
2HL and S-3HL all detectable by MS. It was also clear that no de-halogenation had 
occurred to the remaining chloroacetyl groups on the partially reacted multivalent 
ligands. Therefore, further 6 was added and the reaction left for a further 5 hours before 
another MS, which subsequently showed the desired product to be the principal 
multivalent species present (Figure 4.19). However, a very large peak on the MS for the 
dimerised product was seen and the spectrum had to be cropped at 650 m/z because the 
647 peak of the half charged ion of dimerised LH vastly exceeded the relative 
abundance of the detected multivalent product, making it difficult to assess the extent of 
the desired reaction. 
 
The product was then taken, freeze-dried and purified by HPLC. Anecdotally, the MS of 
the product after drying appeared to show greater progression of the reaction to the 
desired S-5HL product, suggesting that further thiol alkylation had occurred on the 
freeze-dryer. HPLC purification showed a very large peak for the dimerised 6 some 
remaining monomeric 6 and a range of peaks for S-nHL, of which the peak for S-5HL 
was the largest. These results gave confidence that the reaction was possible and would 
proceed without difficulty if ligand-headgroup dimerisation could be minimised. The 
anecdotal observations of the reaction occurring on the freeze-dryer provided an 
innovative solution to the dimerisation problem. 
 
A new reaction to synthesise product 22 was prepared by mixing 5 and linker-
headgroup 7 as before, but immediately after addition of base, the reaction was frozen at 
-20
o
C and placed in a dome freeze dryer at -44
o
C under vacuum. After drying, the 
sample was analysed by MS and showed conversion the majority of 5 to final 
multivalent product with some S-4HL and S6-3HL (Figure 4.20). A small sample was 
tested for free thiol groups using Ellman's reagent, which produced a yellow colour 
indicating not all the headgroup had dimerised. Therefore, the sample was immediately 
redissolved in 10ml 1:1 acetonitrile:water, the pH adjusted to 8.0 with sodium 
Chapter 4. Synthesis of multivalent ligands for SAP 
 
143 
 
bicarbonate and freeze-dried once more. The resulting mass spectrum of the second 
freeze-drying showed only the desired multivalent product (Figure 4.21). On this basis 
all other multivalent ligands were synthesised by repeated freeze-drying until no 
deficiency in the number of headgroups was detected. 
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Figure 4.20. Maximum entropy mass spectrum of reaction between 5 and 7 in air after drying on freeze-
dryer.  
 
Figure 4.21. Maximum entropy mass spectrum of reaction between partially formed 22 and 7 after 
second freeze-drying of reactants. 
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4.4. Discussion 
The main aim of this project was to synthesise multivalent ligands for SAP and although 
it was decided that peptides should constitute a major part of the structure, there were no 
additional constraints over the nature of the chemical linkages used to form the 
multivalent constructs. This permitted the use of thioether bonds, which have been 
shown to be applicable in both intramolecular cyclisation and intermolecular ligation 
reactions for constructing multivalent scaffolds. 
 
4.4.1. Forming thioether bonds during freeze-drying 
As far as this author is aware, this document constitutes the first case of thioether 
formation during freeze-drying the reaction mixture. This method provides the benefit 
of combining the reaction and sample desolvation steps. Furthermore, the concentration 
of the reactants actually increases as the reaction proceeds due to the shrinking volume 
of solvent, in contrast to conventional solution phase reactions where the concentration 
of reactants falls as they react in a constant volume of solvent. Naturally, the converse 
of this is that the reactants are expected to have greatly reduced freedom of movement 
in the solid phase. It is unclear whether the reaction is truly occurring in the solid phase 
or whether the sample reaches a stage where the oily nature of the reactants acts causes 
them to act as their own solvent when approaching dryness.  
 
A drawback of the freeze-drying method is that the entire process of solvation, freezing 
and drying must be repeated if the reaction is not complete and the reaction cannot be 
monitored while in process. Greater optimisation of the reaction conditions may 
improve the reaction efficiency and make the process quicker than performing the 
thioether reaction and freeze-drying steps separately. However, the maximum benefit of 
these reaction conditions may be attained by using them in conjunction with a normal 
room temperature reaction under nitrogen. Reactions do not pay attention to the 
working hours of the laboratory scientist and often require overnight to reach 
completeness. The solvent must then be removed the following day, which means the 
whole process takes much longer to complete. Using the reaction methodology 
presented here, a faster hybrid approach can be employed where the thioether reaction is 
started at room temperature and then continued overnight on a freeze-dryer yielding the 
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desired product in solid form ready for purification. Therefore, with further 
investigation it is possible that this method will add greater speed and flexibility in the 
synthesis of thioether containing compounds. 
 
4.4.2. Identification of multivalent ligands by mass spectrometry 
Mass Spectrometry (MS) is the standard method of sample identification in peptide 
synthesis. Electrospray Ionisation Mass Spectrometry (ESI-MS) was the principal 
technique used to characterise the multivalent ligands produced in this investigation, 
with additional qualitative analysis using Ninhydrin and Ellman's reagent to identify the 
presence of free primary amines and free thiol groups, respectively. Soft ionisation 
techniques, such as ESI, charge a peptide while minimising fragmentation, making it 
possible for the mass of the entire molecule to be analysed accurately.  
 
The final mass spectra of the purified multivalent ligands shows peaks corresponding to 
molecules carrying multiple charges, which is to be expected for relatively large 
peptides. Maximum entropy calculations can deconvolute multiply-charged peaks to 
show the molecular weight of the species that produced recorded spectrum (Ferrige et 
al., 1991). Maximum Entropy calculations were performed using the Micro Mass 
software with the results for each multivalent ligand detailed in Table 4.3 next to the 
predicted mass. The observed masses are in line with the predicted masses, with small 
variations caused by protonation of the sample in the MS. Furthermore, the mass 
difference between the individual components and the combined product masses are 
exactly as expected. The addition of five LH to the compound 5 resulted in a mass that 
is MW5 + 5(MWLH) – 5(MWHCl) where MWHCl is the molecular weight of HCl formed 
during the thiol alkylation. This calculation is evidence that the desired thioether bond 
has formed and the correct product has been synthesised. Further confidence of this 
conclusion is provided by the results of the Ellman's tests performed on the LH 
components prior to reaction with 5 and another test performed on the final products. 
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Ligand 
Expected 
Mass(g mol
-1
) 
Expected Mass 
Spectrum Ions (m/z) 
Observed 
Mass(g mol
-1
) 
Observed Mass 
Spectrum Ions (m/z) 
M+4H M+5H M+6H M+4H M+5H M+6H 
21 4973 1244 996 830 4980 1245 997 – 
22 5488 1373 1098 916 5492 1373 1099 916 
23 5928 1483 1186 989 5932 1483 1187 989 
24 6178 1545 1236 1031 6184 1546 1237 1031 
25 6693 1674 1339 1116 6695 1674 1339 1116 
26 7133 1783 1427 1188 7136 1784 1427 1189 
 
Table 4.3. Predicted and observed masses for multivalent ligands 21-26. Predicted figures were calculated 
based on the molecular weight of the constituent residues. The actual masses observed for final purified 
products were measured by maximum entropy mass spectrometry. The masses of the observed products 
are slightly higher than the calculated mass due to protonation during sample preparation. These 
variations are not considered significant. 
 
On the basis of these results, there is little doubt that multivalent ligands of the desired 
structure have been produced with sufficient quantity and quality for further 
investigation into their potential for binding with SAP. The results also demonstrate the 
versatility of the thioether linkage in the synthesis of multivalent ligands. In this 
investigation they were used for both intra- and intermolecular bond formation using 
standard, inexpensive and benign chemicals in reactions that proceeded with minimal 
side reactions when appropriate reaction conditions were applied. 
 
4.4.3. Avoiding diketopiperazine formation 
Diketopiperazine (DKP) formation has been shown to be an issue for the synthesis of 
pentavalent ligands 21, 22 and 23. The D-proline at the C-terminus will exacerbate DKP 
formation like no other standard amino acid. It was thought that the use of 2-chlorotrityl 
chloride resin would remedy the issue, but clearly the presence of 5 linkers on each 
central scaffold has magnified the influence of whatever small quantity of DKP had 
occurred. The issue can be easily overcome in future by simply placing GABA as the 
second amino acid rather than Gly and then placing Gly as the third amino acid. DKP 
requires the formation of a six-member heterocycle from the three backbone atoms of 
two amino acid residues, which requires two α-amino acids at the C-terminus.  
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Chapter 5. Analysis of binding between SAP and multivalent 
ligands 21-26 
 
5.1. Introduction 
The multivalent ligands synthesised in Chapter 4 were analysed for calcium-dependent 
binding to SAP by experiments designed to answer a logical series of questions 
regarding their interaction with the protein. Firstly, Ultraviolet-Visible spectroscopy was 
employed to determine whether the multivalent ligands bound at all to SAP. Secondly, 
mass spectrometry and x-ray crystallography were used to determine the mode of any 
observed binding, in particular whether the ligands bind through their carboxyl termini 
as seen for univalent D-proline in Chapter 2 and evaluate whether the decavalent 
ligands preserve the ability to cross-link two SAP pentamers in the non-covalent manner 
seen with CPHPC (Pepys et al., 2002). The final step, having determined if and how 
binding occurs, was to calculate the strength of any binding interaction using isothermal 
titration calorimetry (ITC).  
 
ITC requires accurate determination of sample quantities and purity (Wisemann et al., 
1989). Although the purity of the multivalent peptide ligands was calculated by LCMS 
in Chapter 4, the percentage peptide content of the sample remained undetermined. 
Amino acid analysis was selected as the appropriate technique for calculating peptide 
content because the multivalent ligands lack functional groups active in the UV/Vis 
spectrum necessary for standard absorbance measurements. 
 
5.2. Materials and Methods 
 
5.2.1. Peptide content analysis 
Purified, solid peptides still contain a considerable quantity of counter ions, water of 
crystallisation and other non-peptide impurities. Accurate measurements of peptide 
content are particularly important for ITC where assuming the weighed mass of a 
sample is 100% peptide will almost certainly lead to a gross underestimation of binding 
affinity. Protein concentrations are typically determined by measuring absorbance of 
UV light by aromatic side chains of Tyr and Trp residues at 280nm in a UV/Vis 
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spectrometer. The multivalent ligands do not contain aromatic groups, so an alternative 
strategy was required. In this investigation, amino acid analysis was employed to 
measure the total peptide content of purified multivalent ligand samples and LCMS data 
from Chapter 4 was used to measure the proportion of the desired product in the total 
peptide content.  
 
Amino acid analysis is typically employed for analysing amino acid contents of 
unknown polypeptides or for peptide sequencing by Edman degradation (Edman et al., 
1950). Amino acid analysis uses concentrated (6M) HCl heated at 100
o
C for 20 hours to 
first breakdown peptides into their individual amino acids. The amino acid mixture is 
separated by ion exchange chromatography and the eluate reacted with ninhydrin to 
facilitate peak detection. The elution time for each peak is compared to retention times 
for known amino acid standards to identify the amino acid constituents of the sample. It 
is possible to quantify the exact peptide content by comparing the observed peak area 
with the expected values based on the quantity of sample used (Spackman et al., 1958).  
 
Amino acid analysis was performed by Peter Sharratt at the Protein and Nucleic Acid 
Chemistry Facility (University of Cambridge, UK). In a typical experiment, 0.5-1.0mg 
accurately weighed peptide is dissolved in 1ml 10% acetic acid and mixed thoroughly. A 
norleucine internal standard is added to a 20μl aliquot of the solution and the mixture 
transferred to a pyrolysed tube. The tube is placed in a centrifugal evaporator and the 
mixture concentrated to dryness. Constant boiling hydrolysis is performed with gas 
phase hydrochloric acid in a hydrolysis vial at 115
o
C for 22 hours. After removing 
traces of acid, sodium citrate loading buffer, pH 2.2, is added to dissolve the residue. 
The resulting solution is filtered under centrifugation through a 0.2 micron filter. An 
aliquot of the filtrate is injected onto a Biochrom 30 amino acid analyser and 
chromatography performed on an ion exchange resin, utilising a sodium system, eluting 
with a series of buffers over the pH range 3.2 to 6.5. Peak detection is achieved by 
mixing the eluate with ninhydrin at 135
o
C and measuring the absorbance at 570 and 
440nm. Quantitation is performed using Chromeleon software and calibration curves for 
each amino acid of interest (correspondence with Peter Sharratt, University of 
Cambridge, UK; Spackman et al., 1958). In the analysis of the ligands 21-26, the 
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observed values of Gly, GABA, Lys and Pro were used to determine the peptide content 
of the samples.  
 
5.2.2. SAP ligand precipitation assay using Ultraviolet-Visible Spectroscopy 
As mentioned previously, SAP auto-aggregates in the presence of calcium unless there 
is an SAP binding ligand present (Pepys et al., 1997). This property can be exploited to 
rapidly screen ligands for binding to SAP. Typically, this is done by mixing microlitre 
drops of SAP stock solution with an excess of ligand at physiological pH, adding a 
small volume of 2mM calcium chloride solution and observing the drop under a 
microscope to look for precipitation, which denotes a lack of binding. Performing the 
analysis with larger volumes and looking for absorption of light by samples in a UV/Vis 
spectrometer provides a more precise method for analysing binding. Ligands are mixed 
with SAP and incubated in calcium-containing or calcium-free conditions and their 
absorption compared to a ligand-free, calcium-containing sample of SAP. 
 
A 2.0µM multivalent ligand solution was buffered to pH 8.0 with 90mM Tris. 5µl 
aliquots of the multivalent ligand solution were mixed with 5µl of 10.1 mg ml
-1
 (0.4µM) 
SAP in TN buffer (10mM Tris, pH 8.0, 140mM NaCl, 0.1% w/v NaN3) and 5µl of either 
600mM calcium chloride (calcium-containing assay) or 5µl TE buffer (10mM Tris, pH 
8.0, 140mM NaCl, 10mM EDTA, 0.1% w/v NaN3; calcium-free assay). After incubating 
for 3 hours at room temperature, the calcium-containing samples were diluted with TC 
buffer (2mM CaCl2, 10mM Tris pH 8.0, 140mM NaCl) and the calcium-free samples 
diluted with TE buffer to a final concentration of 1ml. The samples were mixed in a 
vortex for 1 minute and transferred to cuvettes.  
 
Absorption of 320nm wavelength UV light by samples was measured 5 minutes after 
dilution and then again 35 minutes after dilution. Measured absorption values were 
compared to ligand free samples containing 5µl 10.1mg ml
-1
 SAP in TN buffer and 
995µl TC buffer. 
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5.2.3. Mass spectrometry of SAP-multivalent ligand mixture 
Mass spectrometry (MS) of whole SAP-decavalent ligand complexes was performed by 
Idlir Liko at the University of Oxford, UK. Whole protein MS has a variety of uses in 
proteomics including analysing protein-ligand interactions (Aebersold and Mann, 
2003). The key aspects of calibration of equipment, sample preparation and analysis of 
results have been detailed extensively by Henández and Robinson (2007).  
 
5.2.3.1. MS sample preparation 
Samples were prepared by diluting 10.1mg ml
-1
 (81μM) SAP in 200mM ammonium 
acetate, pH 7.4 to a final concentration of 0.9μM. A two-fold excess of multivalent 
ligand (1.8μM) was added to the protein solution and incubated at room temperature. 
After 1 hour, 5mM calcium chloride was added and the samples biospun in 200mM 
ammonium acetate, pH 7.4, ready for MS analysis. MS was performed on a Waters 
QToF Mass Spectrometer with a 1.5kV capillary voltage, 60V cone voltage and a 
collision (SID) of 20V.  
 
5.2.4. Isothermal titration calorimetry of SAP with multivalent ligands 
Isothermal titration calorimetry (ITC) is a powerful technique that can be used to 
measure binding association constant Ka, enthalpy, ΔH, and stoichiometry, n, of ligand-
protein interactions (Wisemann et al., 1989). The calorimeter measures the heat change 
during a binding event and consists of two cells, a sample cell and a reference cell, 
made from a highly conductive material such as Hastelloy or gold (Pierce et al., 1999). 
The two cells are encased within an adiabatic jacket, preventing heat transfer with the 
outside environment. Heaters on both cells are used to raise the temperature to a specific 
value, typically 25
o
C, and the power applied to maintain the temperature is recorded as 
the reference baseline signal. The protein of interest is added to the sample cell in a 
buffer at a precise concentration prior to the start of the experiment. The ligand, 
prepared in identical buffer conditions is added periodically throughout the experiment 
using a syringe specially designed to rotate with a paddle-shaped needle to mix the cell 
constituents (Figure 5.1). 
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Figure 5.1. Typical design of calorimeter used in isothermal titration calorimetry. Adapted from Freyer 
and Lewis, 2008). 
 
As the protein is titrated with the ligand, a heat change occurs depending on whether the 
reaction is endo- or exothermic. Using an exothermic reaction as an example, the heat 
evolved increases the temperature of the sample cell relative to the reference cell. The 
calorimeter detects this temperature mismatch with thermopile/thermocouple circuits 
and reduces the power applied to the heating element on the sample cell until the two 
cells are returned to the same temperature (Freyer and Lewis, 2008). ITC records the 
time-dependent input of power required to maintain equal temperatures between the 
cells during a titration in units of μcal s-1. 
 
Plotting the μcal s-1 measurements for each injection gives a graph with peaks whose 
magnitude decreases during the titration as the binding sites of the protein become 
saturated with ligand (Figure 5.2). Integration of the area of each peak gives the total 
heat change of each injection, which can be plotted against the molar ratio of 
[L]total/[M]total, where [L]total and [M]total are the total concentration of ligand and free 
macromolecule in the sample cell. Fitting a sigmoidal curve to the data points by non-
linear least squares calculation gives a curve from which Ka and ΔH can be obtained and 
where the value on the x-axis at the midpoint of the curve is the stoichiometry, n, of the 
binding reaction (Figure 5.2). 
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Figure 5.2. Typical binding isotherm obtained from an ITC binding experiment. Top: raw heat change 
data recorded for each injection. Bottom: plot of heat evolved/taken in against the molar ratio of ligand to 
protein with a red line showing the sigmoidal line of best fit calculated by non-linear least squares 
(MicroCal ITC 200 User Manual, GE Life Sciences, Uppsala, Sweden, 2012). 
 
The shape of the curve in an ITC experiment is determined by the concentration of the 
macromolecule, [M], Ka and n. Modern ITC software can predict the curve recorded for 
a binding experiment if realistic estimates can be made of Ka and n, this can be used to 
optimise the protein concentration based on the expected binding affinity. The influence 
of [M], Ka and n on the expected binding curve can be expressed using the unitless c 
value in the relationship: 
 
𝑐 = 𝐾𝑎. [𝑀]. 𝑛 
 
c tends towards infinity as strength of binding increases, producing a curve that has an 
Equation 5.1. 
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instantaneous transition from unsaturated to complete saturation of all binding sites 
within a single injection as shown by Figure 5.3. This leads to a lack of data at the 
transition point making accurate Ka determination impossible, although ΔH and n can 
still be calculated accurately. Figure 5.3 shows the expected binding curve for a range of 
c values (Wisemann et al., 1989). Weak binding also prevents accurate determination 
because the curve's sigmoidal shape is lost. The most accurate ITC data is obtained 
when the c value is between 1-1000, this corresponds to Ka values in the range of 10
3
-
10
9
 M
-1
 (O'Brien et al., 2000). Larger Ka values would require the protein to be diluted 
to a point where the heat change upon addition of the ligand would be less than the 
detection limit of the apparatus (typically 0.1μcal s-1; Freyer and Lewis, 2008). 
Figure 5.3. Influence of c value (Eq. 5.1) on shape of sigmoidal curve (adapted from Wisemann et al., 
1989). As c value increases, the number of data points obtained on a curve decreases, making accurate 
determination of the binding constant from the gradient of the slope impossible. However, the enthalpy 
calculation becomes more accurate, as this is calculated from the heat change from the initial injections; 
as long as complete saturation of the binding sites does not occur in initial phase of the experiment. 
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From this point on binding affinities will be referred to in terms of the dissociation 
constant, Kd, which is the reciprocal of Ka. The reasons for this are: firstly, that all 
previous SAP ITC experiments report binding affinities in terms of Kd, following this 
convention will provide greater clarity of the results. Secondly, it can be shown 
mathematically that when half the binding sites of the protein are occupied, the 
dissociation constant is equal to [L], the concentration of unbound ligand in the sample 
cell (derivation found in appendix section A.4); this makes the Kd a convenient way to 
visualise how the binding constant actually relates to the reaction occurring in the 
sample. Simply put, the smaller the dissociation constant, the lower the concentration of 
unbound ligand at half-occupancy. 
 
5.2.4.1. ITC sample preparation 
Sample preparation for ITC requires precise buffer matching between the ligand and 
protein samples. The measured heat change in a binding reaction can be expressed as 
the following: 
 
∆𝐻 = ∆𝐻𝑏𝑖𝑛𝑑 + ∆𝐻𝑐𝑜𝑛𝑓 + ∆𝐻𝑖𝑜𝑛 
 
The observed enthalpy change (ΔH) is the sum of enthalpy contributions from binding, 
ΔHbind, conformation changes, ΔHconf, and ionisation ΔHion. Buffer mismatch introduces 
a systematic error by increasing the heat contribution from ionisation. This is a 
particular issue for Tris-Cl buffer, which has a relatively large heat of ionisation 
(O'Brien et al., 2001). Furthermore, during a binding assay, part of the heat change 
contribution is from by-products of the binding reactions, namely from dilution of the 
ligand upon injection into the sample cell and other non-specific effects (Blandamer, 
1998). These effects were removed by first performing a blank experiment to measure 
the background heat change from injecting each ligand into buffer and then using this 
data to subtract from the experimental data during data analysis. Equation 5.3 
demonstrates the calculation performed in the experimental data: 
 
∆𝑞𝑖 = ∆𝑞𝑎𝑝𝑝 − ∆𝑞𝑑𝑖𝑙 − ∆𝑞𝑛𝑠 = 𝑛[𝑀]𝑡𝑜𝑡 . 𝑉𝑐𝑒𝑙𝑙 . ∆𝐻𝑎𝑝𝑝. 𝑅 
Equation 5.2. 
Equation 5.3. 
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Subtracting background measurements of heat contributions from ligand dilution, Δqdil, 
and non-specific effects, Δqns, from raw heat change data for injection i. The heat 
change for the ith injection is equal to the macromolecule concentration, [M], which has 
n identical independent binding sites, in total cell volume, Vcell, where the enthalpy of 
binding is ΔHapp and R represents the degree of saturation of the macromolecule binding 
sites. 
 
Precise knowledge of reactant concentrations is also key for calculating accurate results 
from raw data in ITC. As previously mentioned, amino acid analysis was undertaken to 
establish exact peptide content of the multivalent ligand samples (Section 5.3.1), while 
the concentration of SAP stock solutions were measured using UV/Vis as detailed in the 
following section. 
 
5.2.4.2. ITC of SAP with multivalent ligands 22-26 
Auto-aggregation of SAP in the presence of physiological calcium concentration 
prevents ITC measurements under physiological conditions (Pepys et al., 1997). 
However, Kolstoe found that precipitation can be prevented using a concentration of 
calcium ions in excess of 200mM, most likely due to the high concentration of chloride 
ions coordinating calcium ions bound to SAP preventing binding by Glu167 by other 
SAP pentamers (Kolstoe thesis, 2005). Both SAP and the multivalent ligands were 
prepared in high calcium TC-like buffer containing 200mM CaCl2, 140mM NaCl, 
10mM Tris, pH 8.0, 0.01% w/v NaN3. SAP samples were prepared at a concentration of 
0.0096mM, the exact protein concentration of the initial stock solution was determined 
using by UV/Vis measurement at 280nm using an extinction coefficient of 1.71M
-1
 cm
-1
 
as determined by de Beers and Pepys (1982). The multivalent ligand samples were 
prepared for injection at a concentration of 0.080mM for pentavalent ligands 22 and 23, 
and between 0.032-0.040mM for decavalent ligands 24-26. The reference cell was filled 
with water and 0.01% w/v NaN3. All samples were degassed and spun down in a 
centrifuge prior to injection. 
 
ITC experiments were performed using a GE MicroCal 200 at 25
o
C with a reference 
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power of 6μcal s-1 and a mixing of 1000 rpm. 280μl water, 0.01% w/v NaN3 was 
injected into the reference cell and the same volume of SAP in high calcium TC buffer 
injected into the sample cell. The titration syringe was filled with 40μl multivalent 
ligand solution in high TC buffer. An initial 0.4μl dummy injection was performed to 
counteract diffusion of ligand from the injector tip during equilibration. Subsequently, 
the ligand was injected into the sample cell in 1μl volumes for the pentavalent ligands 
and 2μl for decavalent ligands at a rate of 2 times the injection volume per second, 
injections were separated by 120 seconds. Analysis of results was conducted with 
Origin software using a single binding site model (version 7.20, MicroCal, GE Life 
Sciences, Uppsala, Sweden). 
 
5.2.4.3. ITC of SAP with 21 
Multivalent ligand 21 was analysed by ITC as part of a proof of concept study prior to 
synthesis of 22-26. ITC of this ligand was performed on a TA instruments NanoITC. 
The preparation of samples for 21 was the same as for those analysed on the MicroCal 
apparatus, but the protein and ligand quantities were adjusted due to lower sensitivity of 
the calorimeter and the larger sample cell of the NanoITC. 1ml 0.008mM SAP in high 
calcium TC buffer was added to the sample cell, into which 0.16mM ligand 21 in 
identical buffer was injected using 8μl injection volumes separated by 200s after an 
initial 4μl injection. The results were analysed using NanoAnalyze (version 2.2.3, TA 
instruments, New Castle, Delaware). 
 
5.2.5. X-ray crystallography of SAP with multivalent ligands 23 and 24 
 
5.2.5.1. Crystallisation 
Separate crystal screens were prepared to co-crystallise each of the five multivalent 
ligands with SAP by hanging-drop vapour diffusion at room temperature, but SAP 
crystals were only obtained in screens containing ligands 23 and 24. Crystals were 
cryoprotected by sequential 5 minute immersions in microlitre drops of crystallisation 
cocktail containing steadily increasing concentrations of glycerol, up to a final 
concentration of 20% v/v glycerol (Garman, 1999). Crystals were then harvested in a 
nylon loop, flash cooled in liquid nitrogen and stored at 100K prior to data collection. 
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5.2.5.2. Data collection 
Data sets for crystals of both multivalent ligands in complex with SAP were collected at 
100K on beamline I03 at Diamond Light Source (Didcot, UK). SAP-23: 1500 images 
were collected with an oscillation angle of 0.2
o
 from a single crystal using 50% 
transmission of the x-ray beam and an exposure time of 0.04s. SAP-24: 2400 images 
were collected with a 0.15
o
 oscillation angle from a single crystal using 20% 
transmission of the x-ray beam with an exposure time of 0.05s. 
 
5.2.5.3. Data processing, molecular replacement and structure refinement 
Data for the SAP-23 crystal was processed using XDS and XScale as part of the Xia2 
automatic data processing 3daii run (Kabsch, 2010), merged with Aimless (Evans, 
2006), scaled using Scala. For SAP-24 data processing was completed using Mosflm 
(Powell, 1999). Molecular replacement for both datasets was completed using Phaser 
with PDB file 1SAC used as the search model (McCoy et al., 2007; www.pdb.org/rcsb), 
followed by a single round of rigid body refinement in Refmac (Murshudov et al. 
1997). Model building was undertaken in Coot (Emsley and Cowtan, 2004). Subsequent 
rounds of restrained refinement for SAP-24 were completed using Refmac applying 
global NCS restraints. Coordinate files for fractions of ligand 24 were generated using 
the Prodrg server (Schüttelkopf and Van Aalten, 2004) with geometric restraints 
calculated with Phenix.elbow (Afonine et al. 2012). 
 
5.3. Results 
 
5.3.1. Peptide content analysis 
Peptide content analysis was performed on all multivalent ligands to give accurate 
quantities for use in subsequent experiments, in particular isothermal titration 
calorimetry, where exact quantities are needed to determine meaningful binding 
constants and reaction stoichiometry. The results of the amino acid analysis are 
summarised in Table 5.1, the average peptide content ranged between 46.0% for 21 and 
78.5% for 22. Peptide content analysis was not performed prior to ITC of ligand 21 as it 
was synthesised as part of a preliminary proof of concept study preceding synthesis of 
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ligands 22-26. 
 Peptide Content (%) 
Multivalent Ligand Run 1 Run 2 Average 
21 49.0 43.0 46.0 
22 77.0 78.0 77.5 
23 61.0 62.0 61.5 
24 57.0 58.0 57.5 
25 68.0 65.0 66.5 
26 68.0 64.0 66.0 
 
Table 5.1. Peptide content of multivalent ligand samples as determined by amino acid analysis. 
 
5.3.2. UV-Vis spectroscopy SAP precipitation assay 
The auto-aggregation of SAP is caused by the side chain carboxyl group of Glu167 on 
the A-face of each subunit coordinating the double calcium binding site on the B-face of 
another pentamer (Emsley et al., 1994). Aggregation is completely inhibited by the 
presence of a SAP binding ligand such as N-acetyl D-proline (Pepys et al., 1997). Using 
UV/Vis spectrometry to measure absorption, this property can be exploited to rapidly 
screen compounds for calcium-dependent binding to SAP. If the potential ligand does 
not bind to SAP, precipitation will occur leading to a rise in absorption, otherwise the 
absorption should remain at the baseline level determined from samples containing SAP 
and ligand, but calcium-free. The measured absorption value is also compared to an 
aggregated SAP sample (ligand-free SAP in TC buffer). 
 
Around 50µg SAP is incubated with a 5-fold excess of multivalent ligand either in the 
presence or absence of calcium. During incubation 200mM CaCl2 is used to because the 
high concentration of calcium prevents SAP precipitation. The incubated samples are 
then diluted to give a final 1ml volume and physiological calcium concentration. 
 
Tables 5.2 and 5.3 show that no significant precipitation was observed for any of the 
calcium containing solutions indicating that all the multivalent ligands bind to SAP with 
sufficient affinity to prevent auto-aggregation. A small increase in absorption was 
observed for 26 indicating that some precipitation had occurred. However, Run 1 of the 
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calcium free sample for 26 showed a similar rise above the baseline level suggesting 
that the increase may not have been due to SAP precipitation. Furthermore, the signal is 
still some 8-fold smaller than the absorption of auto-aggregated SAP in the ligand free, 
TC buffer samples. These results were taken as evidence of binding and that further 
analysis of their binding to SAP was warranted. 
 
 Absorption at 320nm 
Ligand Buffer Run 1 Run 2 Run 3 Average 
Water Blank None 0.000 0.000 0.000 0.000 
Ligand Free SAP TC 0.137 0.120 0.192 0.150 
S6-5H3 TC -0.002 -0.003 0.000 -0.002 
TE 0.000 -0.001 0.000 0.000 
S6-5H5 TC 0.003 0.001 0.003 0.002 
TE -0.003 0.000 0.000 -0.001 
S6-5H110 TC 0.003 0.002 0.007 0.004 
TE -0.003 0.000 0.000 -0.001 
S6-5H310 
 
TC 0.001 -0.002 -0.001 -0.001 
TE 0.003 0.003 -0.003 0.001 
S6-5H510 
 
TC 0.001 0.015 0.020 0.012 
TE 0.017 -0.002 0.001 0.005 
 
Table 5.2. UV-Vis SAP precipitation assay with multivalent ligands 5 minutes after sample preparation. 
UV-Vis spectroscopy measurements were made of samples of SAP mixed with the multivalent ligands in 
TC and TE buffer absorption at 320nm wavelength and 5 minutes after sample preparation. Multivalent 
ligand free samples of SAP in TE and TC buffer were used as control measurements. 
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 Absorption at 320nm 
Ligand Buffer Run 1 Run 2 Run 3 Average 
Water Blank None 0.000 0.000 0.000 0.000 
Ligand-free SAP TC N/A N/A N/A N/A 
S6-5H3 TC -0.001 -0.002 0.000 -0.003 
TE -0.001 0.000 0.000 -0.001 
S6-5H5 TC 0.001 0.000 0.000 0.000 
TE -0.004 -0.002 -0.006 -0.004 
S6-5H110 TC 0.002 0.007 0.002 0.004 
TE -0.003 0.000 0.000 -0.001 
S6-5H310 
 
TC 0.001 -0.002 0.000 0.000 
TE 0.003 0.001 -0.003 0.000 
S6-5H510 
 
TC -0.001 0.016 0.020 0.012 
TE 0.018 -0.003 0.002 0.006 
 
Table 5.3. UV-Vis SAP precipitation assay with multivalent ligands 35 minutes after sample preparation. 
UV-Vis spectroscopy measurements were made of samples of SAP mixed with the multivalent ligands in 
TC and TE buffer absorption at 320nm wavelength. The ligand-free SAP samples were not retested as 
agglutination of precipitated SAP gave poor reproducibility of results. 
 
5.3.3. Mass Spectrometry of SAP with decavalent ligands 
Mass spectrometry was performed for each of the decavalent ligands to investigate 
whether the SAP decamer forming capability of the bivalent CPHPC headgroup was 
retained in the decavalent structures. Samples of SAP were prepared at 0.9μM and 
incubated with the multivalent ligands at physiological pH prior to the addition of 
5.0mM calcium ions. The results pictured in Figure 5.4 show the pentamer/decamer 
distribution in the absence/presence of the ligand. It is clear from the results that a far 
greater proportion of decameric SAP was detected in the samples containing the 
decavalent ligands when compared to the ligand-free sample.  
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Figure 5.4. Whole Protein Mass Spectrometry results of SAP in complex with multivalent ligands a) 24, 
b) 25, c) 26 and d) SAP multivalent ligand free. 
 
Close inspection of the spectra is hampered by the noisy baseline, but it is possible to 
see some pentameric SAP present in sample ligand 26 (Figure 5.4c). A similar ratio of 
pentameric/decameric SAP may be present in spectra of ligand 24 (Figure 5.4a) and 
ligand 25 (Figure 5.4b), but it is not discernible because of the poor signal-to-noise 
ratio. 
 
The total mass of the protein complexes detected by each experiment varies 
considerably from the expected mass. Table 5.4 shows the expected mass of each 
complex and the observed mass. The deviations of the observed values from the 
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predicted masses are detailed in Table 5.7. The implications and possible reasons for 
this are discussed in section 5.4.3. 
 
Complex 
Ligand 
Mass 
Predicted 
Pentameric Complex 
Mass 
Predicted 
Decameric Complex 
Mass 
Observed Mass of 
Decameric Species 
SAP-24 6184 133497 (±5.5) 260809 (±11) 254526 (±58) 
SAP-25 6699 134012 (±5.5) 261324 (±11) 252856 (±58) 
SAP-26 7149 134462 (±5.5) 261774 (±11) 262584 (±19) 
SAP N/A 127313 (±5.5) 254625 (±11) 246684 (±32) 
 
Table 5.4. Comparison of predicted masses for SAP-decameric ligand complexes versus masses of 
complexes observed in this study. Predicted mass of SAP obtained from Tennent and Pepys (1994). 
 
5.3.4. ITC of SAP with multivalent ligands 
Multivalent ligand 21 was synthesised before ligands 22-26 to validate the ligand 
design's ability to bind to SAP. Therefore, ITC analysis was performed separately from 
22-26 and on a different calorimeter to the other multivalent ligands. The ITC of SAP 
titrated with ligand 21 was performed before the amino acid analysis and therefore 
before the exact peptide content of the sample was known. Instead it was assumed to be 
70% of the dry peptide mass, but subsequent peptide content analysis suggests it may 
have been significantly lower. It is not possible to recalculate the binding affinity 
retrospectively with the accurate figure for peptide content because the samples were 
freeze-dried into sealed vials for amino acid analysis, therefore they may not have 
contained the same quantity of water as the unsealed vials used to transport 21 for the 
initial ITC study. The total yield of 21 was exhausted by the time the second ITC runs 
were performed on the 5 larger ligands and resynthesis was not considered necessary 
after other multivalent ligands showed significantly stronger binding affinities with SAP 
that ligand 21 was unlikely to surpass. Therefore, the 1.0µM binding affinity reported 
for 21 with SAP was interpreted as evidence of binding rather than a precise 
measurement. 
 
The dissociation constant of 21 was calculated to be almost 20 times stronger than 
univalent N-acetyl-D-proline (Kolstoe thesis, 2005). This result provided evidence that 
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the chosen ligand design offered significant promise. 21 was intended to be the smallest 
pentavalent ligand and it was expected that synthesising larger multivalent ligands 
would improve binding by ensuring that all SAP binding sites could be occupied by a 
single ligand simultaneously. 
 
The results obtained from the ITC experiments are listed in Table 5.5, with the results 
averaged from three identical runs for each ligand (values for all runs can be found in 
appendix section A.5). All binding isotherms showed an exothermic binding process 
with negative entropy values indicating a reduction of disorder, both of which were 
expected. The entropy values were significantly more negative for the decavalent 
ligands, indicating a greater reduction in disorder and potentially pointing to decamer 
formation, although this cannot be confirmed by ITC alone.  
 
The strongest binding affinities were recorded for the decavalent ligands, which had 
dissociation constants approximately two orders of magnitude smaller than the 
corresponding pentavalent ligand. The strongest binding affinity was observed for 
ligand 25 with a Kd of around 250ρM. It is crucial to note that this binding affinity is 
considered too strong for accurate determination by ITC, which is demonstrated by the 
high standard deviation of ±200ρM (Table 5.5). Figure 5.5 shows a typical isotherm for 
ligand 25 binding to SAP; few points are observed on the transition of the curve making 
it difficult to accurately determine the dissociation constant. Using the observed Ka and 
n values with a protein concentration of 0.0096mM gives a C value of over 15000, 
which is much greater than the desired range of 1-1000 (O'brien et al., 2001). The 
strongest binding affinities for both the pentavalent and decavalent ligands were 
recorded for those containing the PEG3 linker, suggesting that this size is the best 
balance of size and flexibility for the chosen ligand design. 
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Figure 5.5. Typical results of ITC binding experiment between SAP and multivalent ligand 25. Top: raw 
heat change in μcal s-1 per injection. Bottom: Plot of integrated heat change against molar ratio of 
[L]total/[M]total with sigmoidal line of best fit calculated by non-linear least-squares regression. See 
appendix section A.6 for binding curves of SAP titrated with multivalent ligands 21-24 and 26. 
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Ligand Ka (M
-1
) Kd (M) n ΔH (cal mol
-1
) ΔS (cal mol-1) 
22 3.46E7 
(±6.48E6) 
2.89E-8 
(±5.60E-9) 
0.741 -2.32E4 
(±241) 
-43.7 
23 2.70E7 
(±6.52E6) 
3.65E-8 
(±9.29E-9) 
0.679 -2.61E4 
(±403) 
-53.3 
24 6.96E8 
(±2.29E8) 
1.44E-9 
(±4.74E-10) 
0.390 -6.01E4 
(±572) 
-161 
25 3.93E9 
(±3.12E9) 
2.54E-10 
(±2.02E-10) 
0.412 -5.17E4 
(±572) 
-130 
26 1.46E9 
(7.54E8) 
6.85E-10 
(±3.54E-10) 
0.312 -4.50E4 
(±488) 
-109 
 
Table 5.5. ITC results of multivalent ligands 22-26 binding to SAP. 
 
5.3.5. X-ray crystallography of SAP in complex with multivalent ligands 
Crystals of SAP were obtained for screens using microlitre drops of 10mg ml
-1
 protein 
and a two-fold molar excess of ligands 23 and 24 mixed with equal volumes of a 
crystallisation cocktail containing 100mM cadmium chloride, 14-28% PEG 4000 and 
100mM sodium acetate, pH 4.6. In both cases, the drops appeared cloudy within 10 
minutes of sealing the wells suggesting some amorphous precipitation. The drops 
remained cloudy throughout, but crystals began appearing within 1 week growing to a 
maximum size in excess of 1mm x 0.4mm x 0.4mm in 4 weeks. 
 
5.3.5.1. X-ray crystallography of SAP-23 
The SAP-23 dataset was processed in spacegroup P212121 with unit cell dimensions a = 
58.54Å, b = 115.64Å, c = 190.10Å, α = β = γ = 90o. The results of merging and scaling 
gave a dataset with resolution limit of 2.1Å with outer shell statistics, I/σ(I) of 4.5, 
completeness 96.6% and R-meas 54.3%. 
 
Molecular replacement was performed on the scaled data using Phaser and PDB file 
1SAC as the model to search for a single pentamer in the asymmetric unit as indicated 
by Matthews (Matthews, 1968) from the CCP4 program suite. Phaser achieved a 
molecular replacement solution for the dataset with a log-likelihood of 11095 and 
translation function Z-score of 9.0, indicating a certain solution. The positioning of the 
model in the PDB file output by Phaser was refined using a single round of rigid body 
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refinement in Refmac, which gave an initial R-work of 33.29% with an R-free of 
32.51%.  
 
The electron density map output by Refmac was viewed in Coot to look for evidence of 
ligand binding to SAP. The density of the calcium binding site showed two strong 
spheres of density in calcium binding loop, it was inferred from the crystallisation 
conditions that these were cadmium ions. Therefore, 10 cadmium ions were built into 
the model and the structure refined in Refmac. A small Y-shaped portion of electron 
difference density was observed adjacent to the cadmium binding site in the area where 
ligands for SAP are observed (Figure 5.6). The electron density was identified as either 
water or acetate ions, from the ammonium acetate buffer used in the crystallisation 
cocktail. This indicated that ligand 23 was not occupying the calcium-binding sites of 
SAP and could not be detected elsewhere within the asymmetric unit. 
 
Figure 5.6. Model of the metal-binding site of SAP-23 constructed from the SAP-23 crystal data. The Y-
shaped difference electron density map (grey mesh, 1.5σ) adjacent to the binding site was identified as 
being too small to be the expected multivalent ligand, instead it was most likely to be an acetate ion. Two 
cadmium ions (limon yellow spheres) were identified from the crystallisation conditions bound in the 
calcium-binding site of SAP. Model colours: cartoon representation: β-sheet (yellow ribbon), loop regions 
(green ribbon); ball and stick representation: carbon (green), oxygen (red), nitrogen (blue). 
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The model was subjected to a round of restrained refinement in Refmac to improve the 
calculated phases and rule out the possibility that the shape of the binding site electron 
density in the initial map was due to phase error. Subsequent observation of the newly 
calculated map in Coot showed no improvement in the electron density at the ligand 
binding site. Therefore, no further effort was made to refine the structure. 
 
5.3.5.2. X-ray crystallography of SAP-24 
The data was processed using Mosflm in monoclinic spacegroup C2 with unit cell 
dimensions a = 169.28Å, b = 95.45Å, c = 88.18Å, α = 90.00o, β = 120.29o and γ = 
90.00
o
. Monoclinic C-centred unit cell can also be processed in body-centred space 
group, I2. The generally accepted convention for selecting between C2 and I2 is to 
select the system that gives the shortest vectors on the ac plane with b as the unique axis 
and the β angle non-acute (Mighell, 2002). The CCP4 program Pointless indicated I2 
was the preferred space group for the data with unit cell dimensions a = 88.18Å, b = 
95.45Å, c = 146.20Å, α = γ = 90.00o and β = 91.10o and Reindex was used to apply the 
transformation from C2 to I2. The data was scaled and merged using Scala to a 
resolution of 2.02Å, which gave an I/σ(I) of 2.2, R-meas of 88.0% and 100.0% 
completeness in the outer shell. 
 
   Unit Cell Dimensions 
Solution Spacegroup Penalty a (Å) b (Å) c (Å) α (o) β (o) γ (o) 
1 P1 0 88.1 94.9 97.2 119.2 116.0 90 
2 P1 1 88.1 94.9 97.3 60.7 64.0 90 
3 C2 3 169.5 95.0 88.2 90.0 120.2 90 
4 I222 25 87.9 94.8 146.8 90.0 90.0 90 
4AVV* C2 N/A 154.4 108.6 120.3 90.0 138.5 90 
 
Table 5.6. Mosflm unit cell determination results for SAP-24 and unit cell dimensions of PDB file 4AVV. 
*Data taken from www.rcsb.org on 28/05/2014. Chosen spacegroup and unit cell dimensions of SAP-24 
dataset highlighted in blue. 
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The program Matthews predicted one SAP pentamer in the asymmetric unit, which were 
searched for using molecular replacement program Phaser with PDB file 1SAC as the 
search model. Phaser obtained a solution with a LLG of 8440 and TFZ of 8.2, indicating 
a certain MR result. The molecular replacement solution output by Phaser was initially 
refined using the rigid body refinement function in Phenix, giving initial R-free of 
37.20% and R-work 36.90%. Phenix was then used for all subsequent rounds of 
restrained refinement applying NCS restraints. The molecular graphics package, Coot 
was used for model building yielding a final model with R-work, 20.43% and R-free of 
23.91%.  
 
A single pentamer was found in the asymmetric unit arranged B-face to B-face with 
continuous difference electron density visible between the pentamer and a neighbouring 
pentamer related by the two-fold rotation axis (Figure 5.7). A total of 10 cadmium ions 
were built into the calcium-binding sites of SAP. In addition, a further 25 cadmium ions 
were built into areas of strong electron density highlighted by Coot's unmodelled blob 
validation function, some of which were built with reduced occupancy to highlight the 
ambiguity in their identity. Five CPHPC-N headgroups of ligand 24 were built into the 
structure straddling the gap between opposing binding sites in the same manner as 
observed for CPHPC in PDB file 4AVV. However, there was insufficient continuous 
electron density to build the entire ligand with adequate certainty, so only the terminal 
four residues, N-Gly-hGlu(D-Pro)-D-Pro-OH (Gly-N-CPHPC) of each arm of the 
multivalent ligand were built (Figure 5.7).  
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Figure 5.7. Left: Fo-Fc difference electron density map (green mesh) drawn at 1.5σ prior to model 
building. SAP protomers from two symmetry-related pentamers can be seen in cartoon representation at 
the top and bottom of the image arranged B-face to B-face. The electron density map shows a continuous 
region of density not accounted for by the model; further spherical density near the surface of the 
protomers indicates the presence of metal ions in the calcium binding site of SAP. Right: 2Fo-Fc electron 
density map (grey mesh, 1.5σ) after model building. Two cadmium ions (cream spheres) and multivalent 
headgroup Gly-N-CPHPC can be seen tracing the electron density, with well-defined electron density in 
the chain linking the two D-proline termini indicating a preferred conformation. No further electron 
density is visible at the N-terminus of the Gly preventing model building and suggesting greater ligand 
flexibility. Model colours: SAP cartoon representation: β-sheet (yellow ribbon), α-helical-like regions (red 
ribbon), loop regions (green ribbon). Ligand atom colours: carbon (turquoise), nitrogen (blue), oxygen 
(red). 
 
In addition to the ligands and metal ions built into the model, 5 N-acetyl glucosamine 
(NAG) units were placed in covalent bonding distance to the amide side chain of Asn32, 
identified as a glycosylation site by Tennent and Pepys (1994). The resolution of the 
structure also allowed 390 waters and 4 acetate molecules to be built into the electron 
density.  
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Space Group I2 
Unit Cell Dimensions a = 88.18Å, b = 95.45Å, c = 146.20Å,  α = 
γ = 90.00o and β = 91.10o Resolution Range 80.04 – 2.02Å
No. of Reflections 481 261 
No. of Unique Reflections 79 403 
Multiplicity 6.1 (6.1) 
Completeness (%) 100.0 (100.0) 
Rmeas 0.123 (0.880) 
(I)/σ(I) 9.1 (2.2) 
Refinement  
Molecular Replacement Model 1SAC 
No. of Residues 1020 
No. of Solvent Molecules 390 (Water),  25 (Cd), 4 (ACY) 
No. of Ligand Molecules 5 (Gly-N-CPHPC), 10 (Cd), 5 (NAG) 
Rmsd Bonds 0.01Å 
Rmsd Angles  1.25
o
 
Residues in Favoured Regions (%) 97.80% 
Residues in Disallowed Regions (%) 0.00% 
Average B-factor 40.24 
Protein 39.75 
Ligand 49.42 
Solvent 44.86 
R-factor (%) 20.43 
R-free (%) 23.91 
 
Table 5.7. Processing and refinement statistics for SAP-24 crystal structure. Figures in parenthesis denote 
results for the highest resolution shell (2.13-2.02 Å). 
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5.4. Discussion 
 
5.4.1. Amino acid analysis 
Accurate peptide content analysis proved to be essential as the values were significantly 
below 100% and varied widely from the 70% assumption that was made for ligand 21 
prior to ITC analysis (Table 5.1). This data shows the importance of accurate 
quantitation of peptide content prior to use in assays that require accurate knowledge of 
ligand concentration, such as ITC. The figures are considered to be in an acceptable 
range, although the 46% for ligand 21 is lower than anticipated. The possible 
explanation for the lower content is that it was the first ligand to be synthesised and as 
such the synthetic strategy was still being developed, this could have led to an increase 
in low molecular weight organic impurities in the final product. 
 
5.4.2. Ultraviolet/Visible absorption SAP precipitation assay 
The UV/Vis SAP precipitation assay quickly identified binding of all six multivalent 
ligands to SAP. The lack of precipitation observed for all samples indicated that they all 
bound with sufficient affinity to prevent auto-aggregation; there is little more that can be 
concluded from this assay, but it provided confirmation that further study was 
warranted. Such an assay should be employed as the first step in all SAP ligand binding 
investigations. 
 
5.4.3. Mass spectrometry of SAP-multivalent ligand complexes 
From the outset of the investigation, there was considered to be a low probability of 
producing crystals of SAP in complex with the multivalent ligands within the time-
frame of the investigation. The large size of the ligands was expected to complicate SAP 
crystal packing, meaning conditions that had previously produced x-ray diffraction-
quality crystals of SAP in complex with univalent ligands were unlikely to be successful 
with the much larger multivalent ligands. Therefore, mass spectrometry was identified 
as a suitable alternative strategy to investigate the effect of the decavalent ligands on the 
distribution of pentameric/decameric SAP in the presence of calcium. In reality, 
crystallisation of SAP with decameric ligand 24 occurred rapidly and produced suitable 
crystals for x-ray diffraction. So the mass spectrometry results serve to validate the x-
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ray diffraction results for SAP-24 and provide insight into the nature of the interaction 
of SAP with ligands 25 and 26, which have not been crystallised as of yet. 
 
The addition of decavalent ligands to a solution of SAP at physiological pH results in a 
shift from mostly pentameric SAP to the decameric form being the only species present 
in detectable quantities (Figure 5.4). However, the observed masses of the complexes, 
as calculated by maximum entropy, vary from the expected value, calculated by 
summing the molecular weight of SAP measured by Tennent and Pepys (1994) and the 
molecular weight of the ligands measured by mass spectrometry in Chapter 4. Table 5.8 
shows the deviation of the measured masses from the expected values given by two 
measurements of the mass of SAP: firstly the mass of SAP calculated by Tennent and 
Pepys (1994) and secondly from the mass of the pentraxin observed in the ligand-free 
SAP decamer (Figure 5.4d). 
 
Complex Complex 
Mass 
Predicted 
from 
Literature 
Data 
Complex 
Mass 
Predicted 
from 
Observed 
Data 
Mass 
Observed 
by MS 
Deviation 
from 
Literature 
Prediction 
Deviation 
from 
Observed 
Prediction 
SAP-24 260809 (±11) 252868 (±32) 254526 
(±58) 
-6283 +1658 
SAP-25 261324 (±11) 253383 (±32) 252856 
(±58) 
-8468 -527 
SAP-26 261774 (±11) 253833 (±32) 262584 
(±19) 
+810 +8751 
Ligand-free 
SAP 
254625 (±11) 246684 (±32) 246684 
(±32) 
-7941 N/A 
 
Table 5.8. Deviation of masses of SAP-decavalent ligand complexes from the expected values. The 
literature value for mass of an SAP decamer containing two pentamers and a single multivalent ligand 
was calculated using the mass of SAP from Tennent and Pepys, 1994. The predicted value calculated by 
adding the mass of the ligand measured by MS in Chapter 4 and the observed ligand-free mass of 
decameric SAP (Figure 5.4d). All figures are in units of Daltons (Da). 
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Table 5.8 shows two different calculated values for the SAP-ligand complexes. The first 
are calculated using the ligand molecular weights measured in Chapter 4 and the 
reported mass of SAP from Tennent and Pepys (1994). The second are the values 
calculated using the ligand molecular weights from Chapter 4 and the observed mass of 
the ligand free decamer from Figure 5.4d. Each of the observed masses of the SAP-
ligand decamers (Figure 5.4a-c) differs significantly from one of the calculated values, 
in some cases the difference is almost 8000Da. Furthermore, the value for the ligand-
free decameric complex is less than would be expected based on the mass of the 
pentameric SAP detected in the same experiment (Figure 5.4d). The observed mass for 
pentameric SAP deviates by only around 700Da from the expected literature value. This 
suggests that deviation in the decamer mass may be the result of an error in the 
maximum entropy calculation of the decameric complex. However, the exact cause of 
the deviations is difficult to pinpoint from this study. Van Dongen and Heck investigated 
the use of ESI-MS to study non-covalent proteins interactions, using the example of 
Apo-Concanavalin A binding with selected carbohydrates ligands (2000). They 
concluded that a number of factors affected the quality of results and that each new non-
covalent interaction study necessitates a period of equipment and sample optimisation to 
produce highly precise data.  
 
The quantity of multivalent ligands produced and the availability of protein for this 
investigation simply did not allow for the period of optimisation suggested by Van 
Dongen and Heck (2000). This does not invalidate the results, but it does add some 
uncertainty as to the nature of the protein-ligand interaction and the identity of the 
complexes detected by MS. The variability in the recorded mass means it is not possible 
to infer whether the decameric complexes contain the multivalent ligands or whether 
they induce complex formation without involvement in the final arrangement. However, 
with unequivocal x-ray diffraction data showing non-covalent cross-linking of two SAP 
pentamers by ligand 24, it highly likely that the increased proportion of SAP decamers 
observed by mass spectrometry is due to the presence of the same SAP-multivalent 
ligand complexes observed by x-ray crystallography. 
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Like so much early stage research the mass spectrometry data presented in this study 
offers tantalising results that require optimisation to increase precision. The decavalent 
ligands have been shown to induce decamer formation in SAP by mass spectrometry, 
which is an early indication that the non-covalent cross-linking ability of CPHPC has 
been preserved in the decavalent N-CPHPC headgroups synthesised in this 
investigation. Although the reliability of these results is questionable when viewed in 
isolation, when taken in combination with the reaction stoichiometry calculated by ITC 
and the decameric SAP-24 complex observed by x-ray diffraction, these results add an 
acceptable level of confidence that all the decavalent ligands are non-covalently cross-
linking SAP pentamers in the same manner as bivalent ligand CPHPC, but with 
potentially stronger binding affinities. 
 
5.4.3.1. Optimising mass spectrometry for SAP-decavalent ligand complexes 
Any future mass spectrometry of SAP-multivalent ligand complexes should try to 
achieve sharper peaks for the desired product and a greater signal-to-noise ratio. At least 
part of the mass variability and poor baseline may be the result of the ligands being 
present as chloride salts. Chloride ions suppress ionisation and can lead to excessive 
adduct formation during mass spectrometry experiments (Henández and Robinson, 
2007). Adduct formation will result in peak widening and this makes deconvolution of 
the mass more difficult. In future analysis it would be best to perform the buffer 
exchange with a higher concentration of ammonium acetate to improve the precision of 
the mass determination. A buffer concentration of 1M may be appropriate, as this has 
been shown to improve peak resolution and reduce noise at the low mass range (Verkerk 
and Kebarle, 2005). Acetate ions do have the potential to bind to SAP, so higher 
concentrations could prevent complex formation between SAP and multivalent species. 
This would need to be carefully monitored, but given the strong binding avidity of the 
multivalent ligands to SAP it would be hoped that acetate would not disrupt complex 
formation. 
 
It is also conceivable that the mass may have varied due to fragmentation. These 
fragments may be hidden by or even contributing to the noisy baseline in the loss mass 
range. If fragmentation is occurring due to harsh ionisation conditions then a lower cone 
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voltage should increase the observed mass of the complex. 
 
5.4.3.2. Mass spectrometry of pentavalent ligands 21-23 in complex with SAP 
No effort was made to perform mass spectrometry with SAP and the pentavalent ligands 
21-23. The potential for 21-23 to form decameric complexes with SAP was considered 
low. This was based on the fact that once a single headgroup has bound to a pentamer, 
the probability of the other headgroups coordinating the other calcium-binding sites on 
the same pentamer is more likely than binding another incoming pentamer. ITC 
observations offered further evidence that decamers do not form between SAP and 21-
23. The stoichiometry of the binding is roughly double that observed for the decameric 
ligands and much closer to ITC observations of univalent ligand binding to SAP made 
by Kolstoe (Kolstoe thesis, 2005). Furthermore, the entropy of the observed ITC 
binding for pentavalent ligands is significantly less negative than that of the decavalent 
ligands, indicating a more disordered system, which suggests 21-23 form pentameric 
complexes with SAP rather than decamers. For these reasons, mass spectrometry of the 
pentameric ligands with SAP was not considered an appropriate use of the limited 
protein stock available. 
 
5.4.4. Isothermal titration calorimetry 
The initial ITC investigation between SAP and 21 showed an estimated binding affinity 
20-fold greater than univalent N-acetyl-D-proline (NADPro; Pepys et al., 2002). 21 
may not have been capable of binding to all SAP binding sites on a single pentamer 
simultaneously because it had the shortest PEG chain in the linkers used to bridge the 
central scaffold to the headgroups and therefore should have the smallest radius of all 
the pentavalent ligands. If 21 can only partially occupy the binding sites of an SAP 
pentamer then there would be a significant penalty to the binding affinity from the high 
flexibility of the ligand. The increased affinity over univalent NADPro provided 
confidence that the methodology and ligand structure had the potential to produce 
ligands with significantly tighter binding avidity if they had a larger effective radius to 
enabling coordination of all five SAP binding sites simultaneously.  
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The fact that the exact peptide content of the ligand had not been determined prior to the 
ITC reduces the precision of the result. However, larger multivalent ligands were shown 
to have significantly stronger binding affinities with SAP, so an exact measurement was 
deemed unlikely to significantly alter the results of the study.  
 
5.4.4.1. Isothermal titration calorimetry of ligands 22-26 
The second ITC investigation utilised a different calorimeter that was vastly more 
efficient with the protein stock available, but still provided heat changes well in excess 
of the detection limit of 0.1μcal s-1 (MicroCal ITC 200, User Manual, GE Life Sciences, 
Uppsala, Sweden). The ITC results show the decavalent ligands to be around 100-fold 
tighter binders to SAP than their pentavalent counterparts (Table 5.5). The values 
calculated for the dissociation constant are beyond the accurate measurable limit of the 
apparatus, which is a promising result, but will require a different binding assay to 
measure accurately (see section 5.4.4.3).  
 
5.4.4.2. Stoichiometry deviation from expected values 
The stoichiometry, n, of the binding is below the expected values of 1 for the 
pentavalent ligands and 0.5 for the decavalent ligands (Table 5.5). In ITC, calculated 
stoichiometry is known to vary when the sample purity is less than 99% (Giancola and 
Pagano, 2012). The purity of the peptide content of the multivalent ligands was found to 
be between 85-96% in Chapter 4 as determined by LCMS (Table 4.2). This will have 
increased the error in the calculation of reaction stoichiometry. As this is the first 
reported case of synthesis and design of multivalent ligands for SAP, it is inevitable that 
the quality of the products is lower than compounds produced by established 
methodologies, such as commercial products obtained from chemical suppliers. The 
protein concentration may also have deviated from the expected value, SAP auto-
aggregation in the sample cell prior to addition of the ligand may have been the cause of 
the error. Aggregated SAP would not be available for binding and therefore saturation 
would be reached at an artificially lower concentration of protein, resulting in a lower 
stoichiometry value. It was observed that the reference power began to vary slightly 
from the specified 6μcal s-1 value between runs, which can be symptomatic of a dirty 
sample cell (MicroCal ITC 200, User Manual, GE Life Sciences, Uppsala, Sweden). 
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This may indicate that some SAP had precipitated and coated the sample cell. However, 
no precipitation was observed in the solution removed from the ITC at the end of any 
titration. 
 
It is worth noting that Kolstoe found an n value of 0.78 for univalent ligand 
phosphoethanolamine, PE, and 0.36 for bivalent ligand, CPHPC (Kolstoe thesis, 2005). 
X-ray diffraction has shown PE to interact with a single subunit of SAP in a 1:1 binding 
stoichiometry (Mikolajek et al., 2011) and CPHPC is known to interact with two 
subunits from different SAP pentamers in a 1:2 ratio (Pepys et al., 2002). Therefore, the 
n values for the multivalent ligands are not too dissimilar to values observed in other 
SAP ITC experiments. It is realistic to conclude from the calculated stoichiometry that 
the pentavalent ligands bind a single SAP pentamer in a 1:1 ratio and the decavalent 
ligands interact with two SAP pentamers in a 1:2 ratio. This inference is in agreement 
with the decameric complex of SAP-24 observed by x-ray diffraction. 
 
5.4.4.3. Binding cooperativity  
The reason for synthesising multiple D-proline headgroups into a single molecule was 
to take advantage of the vastly increased avidity from cooperative binding (Boas and 
Heegaard, 2004). Cooperative binding is the increase in binding activity achieved in a 
multivalent species over the corresponding univalent components working 
independently. The binding affinity enhancement can be attributed one of two effects: 
the additive effect or the cluster effect. Additive binding is the binding efficiency 
increase achieved by having a higher number of binding entities per molecule in a 
multivalent ligand than in a univalent ligand. The cluster effect, also known as the 
dendritic effect, is observed when synergies of simultaneous binding of multiple ligands 
results in a larger increase in binding activity than would be expected by a solely 
additive process. Cooperative binding can be positive and enhance the affinity of each 
binding event resulting in an equilibrium constant greater than the additive equilibrium 
constant. Alternatively, the binding can be negatively cooperative, the affinity of 
binding is less than expected for a purely an additive cooperative process. 
 
In multivalent ITC experiments, a sigmoidal curve is indicative of a cooperative binding 
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process (Schön and Freire, 1989). Sigmoidal curves were observed for all ITC 
experiments of multivalent ligands 21-26 binding to SAP. The sharp transition from 
unsaturation to saturation of SAP binding sites makes the sigmoidal shape appear 
almost like a step transition, showing that the cooperative effect has greatly increased 
the affinity of NADPro binding to SAP. 
 
In Biochemistry, the extent of cooperativity in a multivalent binding process can be 
determined using the α-value, which is calculated by Equation 5.4 (Mammen et al., 
1998). 
 
𝛼 =
log𝐾𝑚𝑢𝑙𝑡𝑖
log⁡(𝐾𝑢𝑛𝑖)𝑛
 
 
In Equation 5.4, Kmulti is the association constant of the multivalent process, Kuni, the 
association constant for the univalent binding and n the number of binding events in the 
multivalent process. Theoretically, if a process is positively cooperative then α >1, 
additive: α =1 or negatively: α <1 cooperative. However, very few processes are 
determined to be positively cooperative by this measure (Ercolani and Sciaffino, 2011). 
So the α-value is more instructive for comparing the relative cooperativity of different 
multivalent binding events. In this case, for comparing cooperativity of SAP binding to 
bivalent ligand CPHPC and penta- and decavalent ligands 21-26. 
 
The α-values for the multivalent ligands were calculated using the dissociation constant 
of 15μM for univalent N-acetyl-D-proline reported by Pepys et al. (2002); the 
reciprocal of the dissociation constant being the association constant. The α-values for 
all the multivalent ligands are less than 1, indicating negative cooperative binding 
(Table 5.9). The Log Ka calculated for NADPro was multiplied by an n value of 5 to 
calculate the α-value for pentavalent ligands 21-23 and an n value of 10 was used for 
calculating the α-value for decavalent ligands 24-26. 
 
 
 
Equation 5.4. 
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Ligand Log Ka α 
N-acetyl-D-proline 
(NADPro) 
4.82 1.00 
21 6.00 0.25 
22 7.54 0.31 
23 7.43 0.31 
24 8.80 0.18 
25 9.59 0.20 
26 9.16 0.19 
CPHPC 8 0.83 
 
Table 5.9. The α-values for the binding constants of the multivalent ligands binding to SAP as measured 
by ITC. Ligands 21-23 are compared to the additive binding constant predicted for 5 NADPro, while 24-
26 are compared to the additive constant predicted for 10 NADPro binding to SAP. 
 
The complex structure of the ligands means that there is significant freedom of 
movement and many different conformations in which they can exist. Binding to a 
macromolecule will significantly reduce the freedom of movement, thus greatly 
increasing the negativity of the entropy term. The Van't Hoff equation shows how a 
more negative entropy term weakens the equilibrium constant for a binding process 
(Equation 5.5).  
 
ln𝐾 = −
∆𝐻
𝑅𝑇
+
𝑇∆𝑆
𝑅
 
         
The greater structural complexity of multivalent ligands over univalent NADPro 
slightly reduces the binding affinity for the multivalent process and that is why the 
values of α are less than 1. This result is not unexpected, as the vast majority of 
interactions measured by this ratio appear to be negatively cooperative (Ercolani and 
Sciaffino, 2011). Performing the same calculation for bivalent ligand CPHPC (log (Kbi / 
log (Kuni)
2
), based on the dissociation constant of 10nM gives a value for α of 0.83, 
which shows the binding of CPHPC to SAP to be more cooperative than the multivalent 
ligands in this study, even though it has a weaker binding affinity. The higher α-value 
for CPHPC reflects the fact that the palindromic structure of the molecule allows a 
mode of binding that is impossible for univalent NADPro, namely non-covalent 
Equation 5.5. 
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decamerisation of two pentamers. The decameric complex of SAP-5(CPHPC)-SAP can 
be visualised as each pentamer bound to a pseudo pentavalent ligand that presents five 
NADPro headgroups in perfect geometry for binding. Furthermore, the five points of 
non-covalent attachment decrease them likelihood of the decamer disassociating, so any 
headgroups that do unbind from the calcium-binding site are likely to quickly rebind as 
they are kept in close proximity to the binding site by the decameric arrangement. In 
contrast, a univalent ligand, such as NADPro, is more likely to dissociate from the 
binding site of SAP and not rebind as there is nothing prevent it diffusing into the 
surrounding solvent. Pentavalent ligands 21-23 overcome this issue by binding to SAP 
at five identical sites, if any one headgroup dissociates it is kept in close proximity to 
the binding site by the remaining bound ligands to which it is covalently tethered. The 
lower dissociation constant is therefore derived from the fact that the probability of all 
five ligands dissociating is significantly lower than a single univalent NADPro 
dissociating.  
 
The dissociation constant measured for the decavalent ligands was slightly smaller than 
observed for CPHPC. The reason for this is the same reason the pentavalent ligands 
bind more strongly than univalent NADPro. The probability of ten decavalent 
headgroups dissociating is less than the probability of the two headgroups in CPHPC 
dissociating diffusing out of the decameric complex. The short tether linking the two 
NADPro in CPHPC and the mechanism which uses another SAP pentamer as a pseudo-
scaffold is clearly a highly efficient binding mechanism and although the affinity is 
slightly improved by tethering five CPHPC together it does not result in the same 
increase in affinity over CPHPC that CPHPC has over NADPro.  
 
5.4.4.4. Accurate determination of the dissociation constant 
Decavalent ligands 25 and 26 have been estimated to bind to SAP with a sub-nanomolar 
dissociation constant, which is considered to be beyond measurable range of the ITC. 
Therefore, an alternative method of measuring the dissociation constant should be 
sought. Typically in this situation a competition assay would be employed (Sigurskjold, 
2000), where a weak binding ligand is bound to SAP and then replaced upon addition of 
the stronger binding multivalent ligand. The energy required to break the interaction of 
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the weak binding ligand reduces the measured affinity of the stronger binding process, 
ideally bringing the dissociation constant into the measurable micromolar-nanomolar 
range. However, this methodology is not appropriate for this investigation because the 
weak binding ligand would need to have a dissociation constant in the high micromolar 
range, perhaps around 100μM. The only known ligands for SAP that have this affinity 
are univalent or bivalent. It would be impossible to determine if all five univalent 
ligands had been displaced by the multivalent ligand in a competition assay. Therefore, 
it would necessitate the availability of a weak binding multivalent ligand for SAP for 
the analysis to be a fair and interpretable competition assay and no such ligand is 
known. 
 
An alternative strategy to calorimetry would be a fluorescence assay. This method 
requires prior knowledge of the binding stoichiometry to calculate the dissociation 
constant from the concentration of unbound ligand as ligand is slowly added to a known 
concentration of protein. From the ITC and crystallography experiments is known with 
reasonable confidence to be 1:1 for SAP with pentavalent ligands and 2:1 with 
decavalent ligands. From this method it will be possible to produce a Scatchard plot 
which shows the dissociation constant from the gradient (Voet, 1995) and the Hill 
equation to determine the extent of cooperative binding. 
 
Often fluorescence assays require one of the reactants to be labelled with a dye whose 
fluorescence changes upon binding (Siegel and Linstad, 2010). This may not be 
necessary because the binding of NADPro headgroups to SAP involves close packing of 
the pyrrolidine ring against two tyrosine side chains. This packing may quench the 
natural UV fluorescence of the phenol side chains sufficiently to be used to 
quantitatively assess the extent of binding. This should be investigated prior to any 
modification of either SAP or the multivalent ligands.  
 
If however a fluorescent dye is required, then the C-terminal carboxyl of the multivalent 
ligand could be used as currently this is only used to link the peptide to the solid phase 
during synthesis. The most common fluorescent dyes utilise amine or thiol functional 
groups for attachment to a polypeptide. Post-cleavage modification of the C-terminus of 
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the central scaffold of the multivalent ligands with diaminoethane would be a simple 
way to place a free amine on the molecule. This would require a slightly different 
protecting group strategy, but it could easily be achieved without significantly changing 
the synthetic strategy. 
 
5.4.5. X-ray crystallography 
The crystal structure of SAP co-crystallised with 24 provides conclusive evidence of the 
ligand's capability to induce decamer formation by non-covalent cross-linking of two 
SAP pentamers in the same manner as observed for CPHPC (Figure 5.8; Kolstoe et al., 
2014). In contrast, it has not been possible to crystallise SAP in complex with 
multivalent ligand 23, despite obtaining crystals from SAP-23 crystal screens in the 
same conditions as those used to crystallise SAP with 24.  
 
Addition of divalent cations to crystallisation cocktails is a recognised method for 
bridging non-covalent interactions between protein molecules (McPherson, 1982; 
McPherson, 1990); cadmium ions are particularly known for improving crystallisation 
in this manner (Trakhanov et al., 2008). While this has been shown to be beneficial to 
the diffraction-quality of crystals produced for decameric SAP (Kolstoe et al., 2014), it 
may have been detrimental in the preparation of SAP-23 crystals. Multiple contacts 
between pentamers bridged by cadmium ions created smaller channels between 
pentamers leaving insufficient space for ligand 23. In place of the desired ligand, acetate 
ions from the ammonium acetate buffer can be seen completing the coordination 
spheres of the metal ions in the calcium-binding site of SAP (Figure 5.6). 
 
5.4.5.2. SAP-24 complex structure analysis 
Both pentamers in the SAP-24 complex displayed the characteristic features of hSAP 
described by Emsley et al. (1994) and detailed in Chapters 1 and 2 (Figure 5.8). A 
continuous area of difference density was visible running between calcium-binding sites 
from each pair of opposing protomers (Figure 5.7). This was identified as the N-CPHPC 
headgroup from multivalent ligand 24. The continuous nature of the density indicated 
that N-CPHPC interacts with two protomers from opposing pentamers simultaneously. 
Therefore, the non-covalent, cross-linking binding mechanism of CPHPC has been 
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preserved in the modified N-CPHPC headgroup used in the decavalent ligands.  
 
Figure 5.8. Cartoon representation for the SAP-24 crystal structure viewed top down (left) and side on 
(right) generated with Pymol. 2 SAP pentamers are non-covalently cross-linked by 24 forming a B-face to 
B-face decamer. Only the 5 N-CPHPC headgroups of 24 could be built into the electron density. Model 
colours: cartoon: α-helix (red ribbon), β-sheet (yellow ribbon), loop regions (green ribbon); ball and stick 
representation: carbon (turquoise), nitrogen (blue), oxygen (red) and cadmium (limon yellow spheres). 
 
Once the N-CPHPC headgroup had been built into the map, further electron density was 
visible protruding adjacent to the N-terminus of N-CPHPC. This was determined to be 
the Gly residue used to ligate the headgroup to the rest of the multivalent ligand. No 
further electron density for the ligand could be conclusively identified. This implies that 
the central cyclic core and polyethylene glycol linkers have some freedom of movement 
and no one particular conformation dominates in the time frame of the experiment. 
Furthermore, it leaves a large portion of the ligand undetermined, Figure 5.9 shows the 
complete structure of ligand 24. Only the terminal four residues of each arm have been 
located in the electron density map for the SAP-24 crystal structure.  
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Figure 5.9. Structure of ligand 24. Image drawn with Marvin Sketch (ChemAxon, Budapest, Hungary). 
 
The lack of electron density means it is difficult to determine the binding stoichiometry. 
When there is not continuous electron density linking all the headgroups together it is 
difficult to conclude that all the headgroups belong to a single molecule of 24. 
Conceivably, it would be possible for multiple ligand molecules to bridge contacts 
between multiple decamers forming a non-covalent polymer of SAP decamers. 
However, from the electron density that has been modelled, all Gly residues are 
arranged with their N-termini pointing towards the central pore of the complex, so the 
implication is that the headgroups belong to a single multivalent ligand molecule. 
Similar disorder in the central scaffold was observed by Kitov et al. (2000) in the crystal 
structure of their STARFISH ligand in complex with Shiga-like toxin 1. Kitov et al. 
produced a graphic plotting the position they expected the ligand to occupy in the 
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complex Figure 5.10) and a similar situation is expected for the SAP-24 structure is 
presented here (Figure 5.11).  
 
Figure 5.10. Ball and stick model of STARFISH Shiga-like toxin inhibitor binding to SLT-1 (cartoon 
representation) developed by Kitov et al., 2000. The authors were unable to reliably build the entire 
structure of the inhibitor in their crystal structure due to its flexibility. Therefore, they proposed a possible 
arrangement for the central core of the ligand (magenta dotted line). It is likely that ligand 24 is similarly 
arranged in the crystal structure of SAP-24. 
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Figure 5.11. View of the A-face of a single SAP pentamer in the crystal structure of SAP-24 with a 
proposed position for the central core and polyethylene glycol linkers of ligand 24 (purple chain). As no 
defined conformation for the ligand could be discerned beyond the Gly-N-CPHPC headgroups, the 
proposed position should be taken as only a possible conformation that illustrates the relative size of the 
ligand to the protein. Model colours: cartoon: α-helix (red ribbon), β-sheet (yellow ribbon), loop regions 
(green ribbon); ball and stick representation: carbon (turquoise), nitrogen (blue), oxygen (red) and 
cadmium (limon yellow spheres). 
 
The D-proline termini of the headgroup can be seen coordinating the cadmium ions in 
the calcium-binding site of SAP through their carboxyl groups in the same manner as 
seen for D-proline in Chapter 2 and as for CPHPC described by Kolstoe et al. (2014). 
The pyrrolidine rings of D-proline fit into SAP's hydrophobic pocket formed by Leu62, 
Tyr64 and Tyr74 (Figure 5.12). 
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Figure 5.12. Calcium-binding site of SAP in SAP-24 crystal structure. Left: the cadmium ions are 
coordinated by the side chains of multiple SAP residues and water molecules (red dashed lines). The 
coordination spheres are completed by the carboxyl of a single D-proline from the N-CPHPC headgroup 
of 24. Right: the fit of the coordinated cadmium ions, water and N-CPHPC within the 2Fo-Fc electron 
density map (grey mesh, 1.5σ). Clear evidence can be seen in the electron density map for the trans 
arrangement of the peptide bond between the C-terminal D-proline and hGlu. Image generated in Pymol. 
 
One of the key considerations in the design of the multivalent ligands for SAP was the 
length of the linker used to separate the headgroup from the central cyclic core. The 
linkers needed to be long enough to allow the headgroups to reach all five binding sites 
of SAP simultaneously without imposing a strained conformation on the headgroup. 
The NADPro ligand from the NADPro-SAP complex was superimposed on the SAP-24 
crystal structure to assess the fit of the D-proline headgroups within binding site of SAP 
(Figure 5.13). The position of NADPro and the D-proline termini of 24 show very close 
correlation in the position of the carboxyl and pyrrolidine functional groups. However, 
the orientation of the peptide bond at the N-terminus of D-proline is different. In 
NADPro-SAP, all acetyl groups of the ligand molecules were built with a cis 
conformation, in the SAP-24 structure there is clear evidence that the peptide bond 
adopts the trans conformation. This appears to have been due to the geometric 
constraints imposed on hGlu by the chiral α-carbon. Therefore, the design of the 
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headgroups has not conserved the weak hydrogen bond between the carbonyl oxygen of 
the peptide bond and the amide side chain of Gln148 identified in Chapter 2. Although 
this may have been beneficial, the binding affinities measured by ITC suggest that the 
loss of this bond has not been detrimental to the overall binding mechanism. This 
emphasises the fact that the coordination of the metal ions and packing of the 
pyrrolidine ring into the hydrophobic pocket are the key interactions for small molecule 
binding to SAP and these feature have been retained in ligand 24 despite its more 
complex structure. 
 
Figure 5.13. Comparison of D-proline position for N-CPHPC (turquoise carbons) and NADPro (yellow 
carbons) when bound in the calcium-binding site of SAP. There are significant similarities in the position 
of the two D-proline-based ligands. The key difference is in the arrangement of the peptide bond between 
the N-terminus of D-proline and the next functional group. NADPro favours a cis conformation while the 
position of the alkyl chain in N-CPHPC imposes a trans conformation. The pyrrolidine ring of NADPro 
penetrates slightly deeper into the hydrophobic pocket of SAP, this could be a sign of strain in the N-
CPHPC headgroup, which the D-proline from adopting the ideal bonding conformation. Model colours: 
SAP carbons (green), N-CPHPC carbons (turquoise), NADPro carbons (yellow), oxygen (red), nitrogen 
(blue), water (red spheres), cadmium ions (limon yellow). Figure generated in Pymol. 
 
The multivalent ligand is not the only species bridging a non-covalent interaction 
between each pentamer in the SAP-24 crystal structure. Two cadmium ions coordinated 
by multiple water molecules bridge the space between carboxyl groups of Glu14 on 
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opposing protomers (Figure 5.14). A number of other cadmium sites have been 
identified with varying degrees of confidence. Coot's unmodelled blob feature 
highlights difference density in the electron density map that is too large to be a water 
molecule. Some areas of the electron density map showed roughly spherical density that 
was determined to be cadmium ions. However, the average B-factor for these ions was 
76.72, significantly more than the average value of 33.76 determined for the overall 
structure by the CCP4 program, Baverage. Therefore, some cadmium ions were built 
with partial occupancy. It may be that another metal ion was responsible for the peak in 
the electron density map, such as sodium. However, it has not been possible to 
definitively identify the ion from the electron density, so the reduced occupancy can be 
viewed as an expression of doubt in both the position and identity of the ion. 
 
Figure 5.14. The electron density map (right panel, grey mesh, 2Fo-Fc map drawn at 1.5σ) shows a 
number of cadmium ions coordinated by multiple water molecules and the carboxyl side chain of Glu14. 
The combination of water molecules and cadmium ions appear to form a bridge between Glu14 residues 
on opposing SAP protomers. Left: red dashed lines show the coordination of cadmium ions (limon 
yellow) by oxygens from water (red spheres) and carboxyl side chains of Glu14 (red; not to scale). Image 
generated with Pymol. 
 
Different length alkyl chain linkers in bivalent ligands affect decamer geometry in terms 
of pentamer separation and relative displacement or “roll” of pentamers when viewed 
top-down. The pentamer roll for SAP-24 was measured in Pymol to be 17
o
, which is 
significantly more than the 5
o
 measured for SAP-CPHPC (Figure 5.15). Additionally, 
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inspection of Figure 5.15 shows that the roll was anti-clockwise for the uppermost 
pentamer in SAP-24 and clockwise for SAP-CPHPC. The pentamers are also 1.6Å 
closer in SAP-24 when the distance between identical residues from opposing 
pentamers is normalised for the increased pentamer roll. 
 
Figure 5.15. Roll of pentamers in SAP-24 and SAP-CPHPC (PDB file: 4AVV; Kolstoe et al., 2014). 
Distances and pentamer roll measured in Pymol. Pentamer roll determined using position of α-carbon of 
residue 53, which sits close to the middle of each protomer.  
 
The smaller pentamer separation and increased pentamer roll is likely to be due to the 
nature of the ligands bridging the gap between the two pentamers in the decamer. 
Therefore, the multivalent headgroup may have played some part in the arrangement. 
The hydrated cadmium complexes may also have contributed to the relative 
displacement (Figure 5.14). The strong density observed for the alkyl chain between the 
D-proline termini in the N-CPHPC ligand suggests a defined conformation. This is in 
contrast to previous reports of SAP-CPHPC where the electron density for the alkyl 
chain is less clear and the conformation often indeterminable (Kolstoe et al., 2014). By 
occupying a single defined conformation, the ligand is likely to be forming a more rigid 
complex with SAP, which may display greater stability because the thermal motion of 
the complex is less, reducing the probability that the complex will dissociate. The 
multivalent ligand will have a greater reduction in conformational entropy by adopting a 
defined conformation, but considering the disorder observed for the rest of the 
multivalent ligand, it is unlikely that this greatly influenced the stability of the SAP-24 
complex in terms of entropy. 
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5.4.6. Cooperative binding of multivalent ligands with SAP 
The multivalent ligands have been shown to participate in cooperative binding with 
SAP by UV/Vis spectroscopy, isothermal titration calorimetry and x-ray 
crystallography. Mass spectrometry and x-ray crystallography have provided evidence 
that decavalent ligands can be synthesised with greatly increased mass and complexity 
than the bivalent ligand upon which they are based and still maintain the non-covalent 
cross-linking ability of CPHPC (Pepys et al., 2002). X-ray crystallography of the SAP-
24 complex has shown multivalent ligands to bind to SAP through their carboxyl 
termini, preserving the binding mechanism of the univalent ligand upon which they are 
based. Finally, ligands were shown by ITC to have binding affinities almost 6 x 10
5
 
times stronger than univalent N-acetyl-D-proline. Furthermore, ligands 25 and 26 may 
have tighter binding affinities for SAP than CPHPC, which is the strongest known small 
molecule ligand for SAP reported in the literature (Pepys et al., 2002).  
 
There are clear areas for improvement in the synthesis, sample preparation and analysis 
of these multivalent ligands. In particular, the purity of the multivalent ligands needs to 
be increased. This can be addressed through minor changes to the structure of the 
ligands and improved synthesis and purification protocols, which will be discussed in 
the next chapter. The attained purity of the multivalent ligands has not been sufficient to 
provide reliable data on binding stoichiometry by ITC, but the results are in agreement 
with previous ITC measurements of N-acetyl-D-proline and CPHPC recorded by 
Kolstoe (Kolstoe thesis, 2005). Therefore, conclusions about stoichiometry from the 
ITC data have still been possible and reinforced by the decameric complex observed in 
the SAP-24 crystal structure. Overall these data have provided the first recorded 
example of synthesis of multivalent ligands for SAP. This is the first time multivalent 
structures designed for other proteins (Zhang et al., 2004) have been applied to SAP, so 
it is to be expected that the synthetic strategy and methods of analysis need optimisation 
and suggestions for doing so will be introduced in the next Chapter. 
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Chapter 6. Conclusions 
 
Despite long-standing evidence of the pentraxins homo-pentameric structure suggesting 
that subunits cooperate in binding multiple ligands simultaneously (Osmand et al., 
1977), this work comprises the first reported synthesis and characterisation of 
multivalent ligands binding simultaneously to all five binding sites of Serum Amyloid P 
component (SAP). The fact that multivalent scaffolds displaying sub-nanomolar binding 
affinities for SAP have been constructed using only commercially available building 
blocks, solid phase peptide synthesis (SPPS) and basic side chain modifications 
demonstrates the strength of peptide-based architectures.  
 
The idea for multivalent ligands targeting the pentraxins was first seriously considered 
after bivalent SAP ligands were discovered during a search of a Roche compound 
library (Pepys et al., 2002). The D-enantiomer of Captopril was one of the initial hit 
compounds and with some serendipity it was discovered that dimerising the ligand by 
disulphide formation produced a bivalent compound with significantly enhanced 
binding affinity for SAP. CPHPC was the result of optimising the functional groups of 
the bivalent D-Captopril hit compound. CPHPC is clearly a very promising therapeutic; 
it has a simple structure, is not metabolised in vivo and binds to SAP with a low 
nanomolar dissociation constant (Gillmore et al., 2010). However, CPHPC is incapable 
of removing SAP from the surface of amyloid fibrils (Tennent et al., 1995). 
Development of an anti-SAP antibody is an alternative strategy that only requires 
removal of circulating SAP and relies on its persistence in all forms of amyloid (Bodin 
et al., 2010). Antibodies are of course notoriously expensive to produce (Samaranayake 
et al., 2009), so finding a molecule that can compete with amyloid deposits for bound 
SAP offers the potential for a single drug treatment to stimulate removal of all forms of 
amyloid. 
 
It has not been possible to measure the exact binding affinity with SAP for some of the 
decavalent ligands synthesised because their projected binding affinity is beyond the 
measurable limit of isothermal titration calorimetry. Pursuing a method that can 
accurately measure the concentration of unbound ligand should be the next logical step. 
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If accurate determination confirms the sub-nanomolar binding affinity recorded in 
Chapter 5, then there is a realistic probability that the decavalent ligands will be able to 
competitively inhibit SAP binding to amyloid deposits. 
 
Competitive inhibition experiments would be relatively straightforward. Amyloid fibres 
could be prepared in vitro (Reviewed by Nilsson, 2004). After SAP has been incubated 
with the fibres, any unbound SAP would be washed from the fibres and a solution 
containing the decavalent ligand added. After a suitable period of time the multivalent 
ligand solution could be separated from the fibres and analysed by gel filtration. If SAP 
has been removed from the fibres then it will be present as a decameric complex 
producing a peak that can be quantified by using a series of reference SAP-decavalent 
ligand samples of known concentration. 
 
A number of recommendations can be made to improve the structure of the multivalent 
ligands for future investigations based on observations made during synthesis and 
analysis. Diketopiperazine (DKP) formation is an issue with the pentavalent ligands in 
their current form. DKP is a recognised problem in solid phase peptide synthesis (SPPS; 
Barany and Merrifield, 1977). Occurrence of DKP is sequence specific, with peptides 
containing C-terminal proline particularly susceptible. DKP formation requires two α-
amino acids at the C-terminus of the peptide. Therefore, the observed DKP can be 
entirely eliminated from future syntheses of pentavalent ligands by swapping the 
penultimate amino acid glycine with its neighbouring γ-aminobutyric acid (Figure 6.1).  
 
Figure 6.1. The proposed structure of linker-headgroups for synthesising pentavalent ligands not 
susceptible to diketopiperazine formation. 
 
Research of the literature uncovered a potential structural change for the decavalent 
ligands that may increase the binding affinity by reducing steric hindrance caused by the 
position of the amino group used to ligate the modified CPHPC headgroup to the 
multivalent scaffold. Dimerised D-Captopril presented as an SAP ligand by Pepys et al. 
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(2002), showed a much weaker affinity for SAP than CPHPC (Figure 6.2). The removal 
of a methyl group and a disulphide bond are the structural differences that facilitated 
tighter binding with SAP. It is not clear whether the improved affinity derives from the 
loss of the hydrophobic methyl groups, or the fact that CPHPC has greater 
conformational freedom by eliminating two chiral centres and the disulphide bond. In 
the decavalent ligands, the headgroup is bound to the multivalent scaffold by replacing 
the hexanoyl chain of CPHPC with homo-glutamic acid (hGlu). The amino group is 
attached to the α-carbon, in a similar position to the methyl groups of dimerised D-
Captopril. This could potentially be reducing the binding affinity of the ligands by 
bringing the attached PEG-linker chain into close contact with the surface of SAP. 
Using β-homoglutamic acid would move the chain further from the surface of SAP, 
potentially permitting tighter binding. 
 
Figure 6.2. Bivalent ligands for SAP. a) Dimerised D-Captopril. b) CPHPC. c) Amino-CPHPC used as 
the headgroup in decavalent ligands 24-26 for SAP, d) proposed structure of headgroup for decameric 
SAP. Shifting the amino group towards the centre of the molecule could potentially reduce steric 
hindrance by the attached linker in a multivalent ligand, which may increase the binding affinity. 
 
Application of the multivalent construct presented in this investigation could also be 
applied to other pentraxins. Multivalent ligands, beyond bivalency, are yet to be 
considered for C-reactive Protein (CRP), despite an ongoing drug development program 
based around bis-phosphocholine compounds to target CRP mediated ischemic injury in 
cardiovascular disease (Pepys et al., 2006). Phosphocholine-based bivalent ligands are 
promising lead compounds, but they have shown themselves to be difficult to synthesise 
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in significant quantities at acceptable purity. bis-phosphocholine ligands bind to CRP 
through the same pharmacological mechanism as CPHPC binding to SAP. The binding 
of a univalent phosphocholine compound to CRP has a dissociation constant (Kd) of 
2μM (Kolstoe thesis, 2005). When two phosphocholine residues are linked by a 
heptanoyl chain the dissociation constant drops to around ~150nM. In this investigation, 
linking five N-acetyl D-proline ligands into a single pentavalent compound reduced the 
dissociation constant from 15μM to around 40nM. This dramatic increase in binding 
affinity shows that univalent ligands with only modest binding affinities can be 
transformed into very strong binding species by combining them into a single 
multivalent ligand. If this methodology were applied to CRP, it could allow the use of 
univalent ligands that bind more weakly than phosphocholine, but which has superior 
qualities in terms of ease of synthesis, purification and sample handling. 
 
The library of small molecules known to bind to CRP is much smaller than for SAP, 
with phosphocholine and phosphoethanolamine probably the best characterised ligands 
for CRP. Phosphoethanolamine binds to CRP with a dissociation constant of 
approximately 40μM. But phosphoethanolamine does not have the positively charged 
choline group that contributes to difficulties in synthesis of bis-phosphocholine 
compounds. The synthesis of multivalent phosphoethanolamine compounds is in theory 
not too complex and could be based on the method used to synthesise bis-
phosphocholine complexes (Pepys et al., 2006). Theoretically, linking five 
phosphoethanolamine compounds into a single pentavalent entity should result in a 
greatly increased binding affinity, not too dissimilar to that of bis-phosphocholine. And 
if a decavalent ligand involving bis-phosphoethanolamine headgroups could be 
synthesised then it would be expected that the affinity would exceed that of the bis-
phosphocholine ligands. Furthermore, as the headgroups would make up only a small 
proportion of the multivalent ligand, their properties should not significantly influence 
ligand solubility or purifiability.  
 
The obvious objection to using decavalent ligands based on phosphoethanolamine to 
target CRP is that they would also target SAP. However, evidence of sustained depletion 
of circulating SAP from amyloidosis patients has shown no ill effect (Gillmore et al., 
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2010). Only temporary depletion of CRP would be needed to prevent ischemic injury 
during cardiac events, so the expected inability of bis-phosphoethanolamine compounds 
to differentiate between human pentraxins would probably not be too detrimental. 
 
This study has also presented some evidence that multivalent ligands can be used to 
solve difficult crystallographic problems and their use is not limited to studying binding 
mechanisms or developing therapeutics. Structural biology plays a crucial role in 
evolving understanding of natural multivalent processes. It is likely that x-ray 
crystallography will remain a central tool in investigations of multivalent processes and 
tools that aid the crystallisation processes will always be a benefit to these 
investigations. 
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Appendix 
 
A.1. Liquid chromatography mass spectrometry analysis of purified multivalent 
ligands 21-26 
 
A.1.1. Compound 21 
 
 
Figure A.1. Structure of compound 21. 
 
 
Figure A.2. UV-Visible spectrum after liquid chromatography of compound 21 at 280nm. 
 
Peak Number Retention Time (mins) Area (%) 
1 4.96 14.83 
2 5.01 85.17 
 
Table A.1. Purity calculation from peak area of LC trace for purified compound 21. 
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Figure A.3. Mass spectrometry detector total ion count recorded during LCMS of purified 21. 
 
 
Figure A.4. Mass spectrum of peak detected at 5.18 mins. 
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A.1.2. Compound 22 
 
 
Figure A.5. Structure of compound 22. 
 
 
 
Figure A.6. UV-Vis spectrum after liquid chromatography of compound 22. 
 
Peak Number Retention Time (mins) Area (%) 
1 5.17 6.71 
2 5.21 12.03 
3 5.25 81.27 
 
Table A.2. Purity calculation from peak area of LC trace for purified compound 22. 
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Figure A.7. Mass spectrometry detector total ion count recorded during LCMS of purified 22. 
 
 
Figure A.8. Mass spectrum of peak detected at 5.43 mins. 
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A.1.3. Compound 23 
 
 
Figure A.9. Structure of compound 23. 
 
 
 
Figure A.10. UV-Vis spectrum after liquid chromatography of compound 23. 
 
Peak Number Retention Time (mins) Area (%) 
1 5.36 3.89 
2 5.45 91.11 
 
Table A.3. Purity calculation from peak area of LC trace for purified compound 23. 
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Figure A.11. Mass spectrometry detector total ion count recorded during LCMS of purified 23. 
 
 
Figure A.12. Mass spectrum of peak detected at 5.62 mins. 
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A.1.4. Compound 24 
 
 
Figure A.13. Structure of compound 24. 
 
 
 
Figure A.14. UV-Vis spectrum after liquid chromatography of compound 24. 
 
 
Peak Number Retention Time (mins) Area (%) 
1 5.34 9.81 
2 5.43 90.19 
 
Table A.4. Purity calculation from peak area of LC trace for purified compound 24. 
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Figure A.15. Mass spectrometry detector total ion count recorded during LCMS of purified 24. 
 
 
Figure A.16. Mass spectrum of peak detected at 5.34 mins. 
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A.1.5. Compound 25 
 
 
Figure A.17. Structure of compound 25. 
 
 
Figure A.18. UV-Vis spectrum after liquid chromatography of compound 25. 
 
Peak Number Retention Time (mins) Area (%) 
1 5.51 4.85 
2 5.53 4.32 
3 5.58 90.83 
 
Table A.5. Purity calculation from peak area of LC trace for purified compound 25 
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Figure A.19. Mass spectrometry detector total ion count recorded during LCMS of purified 25. 
 
 
Figure A.20. Mass spectrum of peak detected at 5.80 mins. 
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A.1.6. Compound 26 
 
 
Figure A.21. Structure of compound 26. 
 
 
Figure A.22. UV-Vis spectrum after liquid chromatography of compound 26. 
 
 
Peak Number Retention Time (mins) Area (%) 
1 5.61 3.07 
2 5.68 6.38 
3 5.72 90.55 
 
Table A.6. Purity calculation from peak area of LC trace for purified compound 26. 
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Figure A.23. Mass spectrometry detector total ion count recorded during LCMS of purified 26. 
 
 
Figure A.24. Mass spectrum of peak detected at 5.91 mins. 
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A.2. Mass spectrometry of purified multivalent ligands 
 
 
Figure A.25. Mass spectrum of compound 21. 
 
 
Figure A.26. Mass spectrum of compound 22. 
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Figure A.27. Mass spectrum of compound 23. 
 
 
Figure A.28. Mass spectrum of compound 24. 
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Figure A.29. Mass spectrum of compound 25. 
 
 
Figure A.30. Mass spectrum of compound 26. 
 
 
 
 
 
 
Appendix 
 
232 
 
A.3. Mass spectrometry of purified central scaffold prior to cyclisation (compound 
3) and after cyclisation by intramolecular thioether substitution (compound 4) 
 
 
Figure A.31. Uncyclised compound 3 prior to intramolecular thioether substitution reaction. 
 
 
Figure A.32. Cyclic compound 4 after intramolecular thioether substitution reaction and purification. 
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A.4. Derivation of the dissociation constant, Kd, when half macromolecule, M, 
binding sites are occupied by ligand, L.  
 
The dissociation of constant of the binding event [L] + [M] = [ML] is equal to: 
 
𝐾𝑑 =
[𝑀][𝐿]
[𝑀𝐿]
 
 
𝐾𝑑 =  
1
𝐾𝑎
 
 
Where Ka is the association constant. If Fb is the fraction of bound macromolecule, then: 
 
𝐹𝑏 =
[𝑀𝐿]
[𝑀] + [𝐿]
=  
𝐾[𝑀][𝐿]
[𝑀] + 𝐾[𝑀][𝐿]
=  
𝐾[𝐿]
1 + 𝐾[𝐿]
 
 
Therefore, the fraction of unbound macromolecule is: 
 
1 − 𝐹𝑏 = 1 −
𝐾𝑎[𝐿]
1 + 𝐾𝑎[𝐿]
=
1
1 + 𝐾𝑎[𝐿]
 
 
Combining the two previous equations gives: 
  
𝐹𝑏
1 − 𝐹𝑏
= 𝐾𝑎[𝐿] 
 
And when Fb = 0.5: 
 
𝐾𝑎 =
1
[𝐿]
 
 
As Kd is the reciprocal of Ka, then: 
 
1
𝐾𝑎
= 𝐾𝑑 = [𝐿] 
 
 
Derivation adapted from Privalov, 2012. 
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A.5. Isothermal titration calorimetry results for all runs of multivalent ligands 
binding with SAP 
 
Ligand Run Ka (M
-1
) Kd (M) n ΔH 
(cal mol
-1
) 
ΔS 
(cal mol
-1
) 
22 1 2.37E7 
(±3.54E6) 
4.22E-8 
(±6.30E-9) 
0.751 -2.29E4 
(±216) 
-43.3 
2 1.87E7 
(±2.24E6) 
5.35E-8 
(±6.41E-9) 
0.746 -2.33E4 
(±207) 
-44.9 
3 6.15E7 
(±1.80E7) 
1.40E-8 
(±4.10E-9) 
0.727 -2.35E4 
(±301) 
-43.0 
23 1 1.35E7 
(±2.37E6) 
7.40E-8 
(±1.30E-8) 
0.597 -2.54E4 
(±436) 
-52.6 
2 2.96E7 
(±4.36E6) 
3.38E-8 
(±4.98E-9) 
0.745 -2.70E4 
(±231) 
-55.3 
3 3.79E7 
(±1.42E7) 
2.64E-8 
(±9.89E-9) 
0.695 -2.58E4 
(±542) 
-51.9 
24 1 6.28E8 
(±1.81E8) 
1.59E-9 
(±4.58E-10) 
0.389 -6.10E4 
(±535) 
-164 
2 1.00E9 
(±3.44E8) 
1.00E-10 
(±3.44E-11) 
0.402 -5.91E4 
(±459) 
-157 
3 4.59E8 
(±1.63E8) 
2.18E-9 
(±7.74E-10) 
0.360 -6.03E4 
(±721) 
-163 
25 1 5.31E9 
(±4.28E9) 
1.88E-10 
(±1.51E-10) 
0.414 -5.57E4 
(±539) 
-142 
2 1.52E9 
(±8.29E8) 
6.58E-10 
(±3.59E-10) 
0.410 -6.08E4 
(±701) 
-163 
3 4.93E9 
(±5.08E9) 
2.03E-10 
(±2.09E-10) 
0.413 -5.59E4 
(±597) 
-146 
26 1 1.76E9 
(±8.61E8) 
5.68E-10 
(±2.78E-10) 
0.264 -4.33E4 
(±362) 
-103 
2 1.82E9 
(±8.97E8) 
5.49E-10 
(±2.71E-10) 
0.346 -4.49E4 
(±562) 
-108 
3 7.94E8 
(±4.50E8) 
1.26E-9 
(±7.14E-10) 
0.325 -4.68E4 
(±539) 
-116 
 
Table A.7. Isothermal titration calorimetry results for all runs of multivalent ligands 22-26 binding with 
SAP in the presence of calcium ions. 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
235 
 
A.6. Isothermal titration calorimetry binding curves for multivalent ligands 22-26 
with SAP 
 
Figure A.33. ITC binding curve recorded for ligand 22 with SAP. 
 
Figure A.34. ITC binding curve recorded for ligand 23 with SAP. 
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Figure A.35. ITC binding curve recorded for ligand 24 with SAP. 
 
Figure A.36. ITC binding curve recorded for ligand 25 with SAP. 
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Figure A.37. ITC binding curve recorded for ligand 26 with SAP. 
